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SUMMARY
The evaluation of the level of oestrogen receptor protein in the soluble 
fraction of mammary tumour tissue has been shown to provide an index of 
response by breast cancer patients to hormonally-based therapeutic regimes. 
This method, although giving a better indication than physical or clinical 
features, is not completely reliable, since some tumours do not respond 
favourably to endocrine manipulation despite containing receptor. It has 
been of interest, thus, to expand the study of receptor availability as an 
index of hormonal stimulation by examining the integrity of the hormonal 
mechanism of action as a whole.
In the present study, nuclear as well as cytoplasmic receptor levels have 
been considered on the basis that entry of receptor into the nucleus and 
subsequent binding to acceptor sites on chromatin are essential pre­
requisites of long-term hormonal stimulation. The presence of receptor 
within the nucleus should thus indicate that the cell’s translocation 
mechanism had survived malignant transformation, and give further evidence 
of a hormonal component in tissue growth. A defect in translocation would 
be a major point of blockage in the endocrine system, although further steps 
may also be sensitive to damage.
Using this approach, oestrogen receptor levels have been measured in 1000 
mammary tumour biopsies representing both primary and advanced lesions from 
women of all ages. Using the criterion that only samples containing 
receptor at both cellular levels are truly hormone-dependent, 33% of tumours 
were identified as potentially responsive to hormone therapy.
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Two abnormal situations were discovered where receptor was present in one 
cellular fraction only. These represented only a small percentage of cases, 
and appeared to indicate tumour autonomy. Good, but not perfect, continuity 
was noted in receptor status estimated in primary and secondary or early and 
late secondary biopsies from the same patient.
Receptor content was examined in relation to several variables. Absolute 
level of both cytosol and nuclear receptor was seen to increase with patient 
age, but this effect seemed to be menopausally - rather than age - related. 
Menopause also appeared to influence slightly the distribution of receptors 
within the cell. Most dramatically, the situation where receptors were 
present in the nucleus alone was detected in only postmenopausal tissue. No 
correlation between tissue receptor status and nodal involvement, histological 
grade, lactalbumin content, plasma steroid levels or plasma receptor content 
was noted.
Follow-up data were collected concerning a number of patients who had 
received hormonal manipulation as the sole form of treatment at some time 
subsequent to assessment of receptor status in a tumour biopsy. In 70% of 
cases where hormonal-dependence was indicated by receptor presence in both 
soluble and pellet fractions, the patient experienced benefit for at least 
six months. Only 10% of those patients whose biopsies had contained no 
detectable receptor responded to any form of hormone therapy, and this was 
presumably by some indirect pathway. In cases where receptor presence was 
limited to one fraction, only a small percentage responded. Overall, in 
85% of cases the response to hormonal therapy was correctly predicted from 
receptor status of the biopsy.
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Further follow-up data revealed that the presence of receptor at both 
cellular levels indicated a much improved prognosis over complete absence.
The disease free interval in cases where receptor had been detected in only 
one fraction was similar for either fraction and tended towards the pattern 
displayed by receptor-negative tumours. A comparison was made between the 
influence of receptor and nodal status on prognosis. Receptor-positive 
lesions with no nodal infiltration indicated the best prognosis, receptor- 
negative biopsies displaying nodal involvement giving the worst. In cases 
of no receptor, but some nodal involvement,.or no nodal infiltration, but 
detectable receptor levels, very similar prognosis was noted initially, with 
nodal status becoming predominant with time.
In the course of designing this assay system, the instability at low 
temperatures of the hormone/receptor complex from both fractions became 
apparent. Dissociation of the hormone was accelerated at higher temperatures, 
but was appreciable at 4°C over a period of 18 hours. This shows that 
exchange of added for endogenous steroid can occur at low as well as elevated 
temperatures, and that this assay system measures both filled and unfilled 
sites. Thus, it is not possible to distinguish between filled and empty sites 
by this method.
The abnormality of receptors found only in the soluble fraction has been 
investigated. Preliminary results showed that these receptors could not be 
induced to translocate into nuclei of a hormone-responsive tissue. This 
suggests that the defect lies with the receptor rather than cellular functioning 
in these cases.
Receptors were studied in other human tissue types; notably colonic carcinoma.
- xiii -
Specific binding was not detected, despite the fact that tentative evidence 
of hormonal response does exist.
An in vitro approach to the study of hormonal dependence was attempted.
The isolation procedures and subsequent growth requirements for epithelial 
cells from mammary tumour biopsies were studied. The most successful method 
involved the use of a confluent monolayer of non-dividing cells (feeder 
layer) onto which collagenase-digested tissue was innoculated. In the 
majority of cases, this enhanced the development of epithelial colonies, 
while inhibiting stromal cell attachment and growth.
Preliminary studies were carried out on the effects of hormones using this 
system. Initial results suggested that growth on a feeder layer might be 
a marker of malignancy. However, subsequent findings that "normal" mammary 
epithelial colonies developed on feeder layer challenged the validity of this 
marker, and emphasised the requirement for further methods of characterizing 
cells cultured in this manner.
PART
The Interaction of Steroid Hormones with Normal 
and Neoplastic Tissue
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1. INTRODUCTION
1.1 CONTROL MECHANISMS
The elucidation of the control mechanisms which regulate the human body 
has proved much more difficult than the study of those found in a 
unicellular bacterium. This is due mainly to the fact that the more 
complex system is controlled by a compilation of extracellular as well 
as intracellular interactions. Despite this fact, it has been possible 
to find two general control systems regulating the human body - the 
central nervous system and the endocrine system. In the case of the 
nervous system, effects on even the most distant parts of the body are 
achieved instantaneously by a series of electrical impulses emanating 
from the brain. The endocrine system acts more slowly, however, utilising, 
instead of electrical, chemical messages in the form of hormones which are 
synthesised in and released from one organ to act on another organ(s). It
may be many hours before the external effects of hormonal stimulation are 
evident.
The organs which synthesise hormones are known as endocrine glands. From 
these, the hormone is released into the bloodstream and carried on a 
transport protein(s) to other parts of the body. Although a hormone may 
come into contact with a number of organs throughout the body, it will 
only affect specific ones which are known as target organs for that hormone. 
These are parts of the body which respond to a given hormone in some 
physiological manner, whether it be by synthesis of some special substance 
or by an overall growth and division of cells. Target organs may be
- z -
sensitive to just one hormone or a combination of many and, in the same 
way, one hormone may have one target organ or a selection of them 
throughout the body.
Although it was in 1849 that Berthold produced the first demonstration of 
the ability of one gland to effect the functioning of the whole body 
(Malkinson, 1975), it was not until 1905 that the term "hormone" was first 
introduced by Starling. He used the word in reference to secretin, the 
existence of which he had demonstrated three years previously (Bayliss & 
Starling, 1902). The word "hormone" he derived from a Greek word meaning 
"I excite" or "arouse". At the time of its introduction, there was much 
controversy over the exact literal meaning of the Greek word, but, although 
attempts were made to introduce a different term, the use of "hormone" was 
adopted (Wright, 1978). In 1914, Starling further defined a hormone as 
"any substance normally produced in the cells of some part of the body, and 
carried by the bloodstream to distant parts, which it affects for the good 
of the organism as a whole". This definition has been challenged by 
Huxley in 1935 and more recently by Robison et al.,(1971) as being too 
generalised, but can still be used to describe hormones as a whole.
Since the pioneering work with hormones by Berthold, much investigation has 
been carried out into the exact location of the endocrine glands and the 
nature and effects of the hormones produced by each one. Different methods 
of classifying hormones have emerged from these studies, using the type of 
response, structure or mechanism of action as the criteria for classification, 
Robison et al.,(1971) considered the type of response evoked by the hormone, 
and found two classes - rapidly-acting ones, such as glucagon or luteinizing
— J —
hormone, and slow-acting onces, including insulin and all steroid 
hormones. Insulin can, of course, also invoke some rapid responses.
If, instead, structure is taken into account, three classes emerge - 
peptides, steroids and amino acid derivatives. The last type of classifi­
cation, by mechanism of action, yields two groups. One group, containing 
steroid and thyroid hormones, exerts its actions by actually entering the 
target cell. The other group, including peptide hormones and catecholamines, 
was initially thought to act exclusively via a second messenger within the 
cell, the hormones never actually entering the cells themselves. However, 
there is now evidence that some of these hormones do enter the cell at a 
later stage, perhaps along with their cell surface receptors, but the 
reason for their entry is not yet understood (Kolata, 1978) although it 
may simply be to give controlled degradation of the hormone.
It is clear that there exists a wide variety of properties which must be 
considered when undertaking a study of hormones. Since the subject of this 
thesis relates directly to steroid hormones, the different aspects of these 
will be considered in more detail.
1.2 STEROID HORMONES
1.2.1 STRUCTURE AND NOMENCLATURE
1.2.1.1 General Structure
In contrast to peptide hormones, whose structures include a wide range of 
numbers of amino acids (from three in the case of thyrotropin releasing 
hormone to almost two hundred in the case of growth hormone and even to
dimers such as LH and FSH, which contain, in excess of two hundred amino
- 4 -
acids), and thus vary tremendously in size, steroid hormones are derived all 
from a single parent compound, cholesterol. Cholesterol is synthesised 
mainly in the liver and intestine, which together account for about 60% of 
the daily yield. It is synthesised also in glands which produce steroid 
hormones, such as the adrenal cortex, ovaries and testis. Other tissues, 
such as brain,do contribute to the body’s pool of cholesterol, but only 
to a very limited extent (Ramsey & Nicholas, 1972). Some cholesterol is 
taken into the body in the diet, and the overall level at any one time is 
a function of the level of absorption in the diet, the amount of de novo 
synthesis and the excretion of either cholesterol itself or any one of its 
metabolic products. In order to be converted to steroids, cholesterol 
is modified in a series of dehydrogenation reactions to give hormones of 
different carbon atom content. The skeletons formed contain 21 carbon 
atoms (progestins, glucocorticoids, mineralocorticoids), 19 carbon atoms 
(androgens) or 18 carbon atoms (oestrogens) {see Figure 1). All have a 
common ring structure of three six-membered rings and one five-membered 
ring. In addition, there may be a number of different substituents at 
different positions on this skeleton. Steroids found in nature may have 
such substituents as double bonds, hydroxyl groups or ketone groups, either 
alone or in combination. The aldehyde group is another possible substituent, 
but this is not so common, the only notable example being that of aldosterone. 
An unsaturated A ring is common in biologically active steroids.
1.2,1.2 Nomenclature
Early studies to isolate steroid hormones from different tissues of the 
body and metabolites from urine proceeded from the early 1930’s onwards in 
a number of different laboratories. As a consequence of this, each
Figure 1 - Formation of Steroid Skeletons from Cholesterol
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compound isolated became known by merely a trivial name. This proved 
quite acceptable as long as the number of steroids identified was limited. 
However, it became clear that not only was there a large number of steroid 
hormones, but also that they each had a number of metabolic products which
must be named, A system for nomenclature of steroids was required,
therefore, to avoid confusion. The rules for such a system were first 
discussed and published in 1950 and 1951. Since then, these rules have 
been revised, and nomenclature is now governed by the International 
Union of Pure and Applied Chemistry (lUPAC) and the International Union of 
Biochemistry (lUB) in their "Revised Tentative Rules for Steroid Nomenclature" 
(lUPAC-IUB, 1969), and amendments (lUPAC-IUB, 1971).
A summary of the system for numbering carbon atoms and lettering rings is 
shown in Figure 2. The basic skeleton, with 17 carbon atoms and no 
substitutions, is known as gonane. When the gonane molecule has a 
methyl group substituted at carbon 13, it is then known as oestrane. For
all substitutions, groups which lie below the plane of the paper are
designated a, while groups lying above the plane of the paper are known as 
B. When there are substitutions at C20, groups lying to the left of the 
carbon atom are a, and groups to the right B. The nature of the 
substituent on the molecule is denoted by either a prefix or a suffix, 
which is particular for that specific type of substitution. For example, 
alcohols are denoted by the prefix "hydroxy-" or the suffix "-ol". When 
the prefix "nor-" is used, followed by a number, this means that a methyl 
group has been eliminated from the usual formula of that compound, the 
number indicating which carbon atom has been lost.
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Some steroids are still commonly known by the trivial names they were 
given when they were first isolated. A list of the trivial names which 
are referred to in this thesis along with their correct systematic names 
can be found on page iv.
1.2.2 MECHANISM OF ACTION
Steroid hormones are synthesised by various different endocrine glands 
throughout the body and excreted into the bloodstream in which they are 
transported by protein molecules, such as sex steroid binding globulin 
and albumin, which bind the steroids with varying degrees of affinity 
(Daughaday & Mariz,1960, Westphal, 1970). Uptake of hormone into cells, 
however, is dependent on the concentration of free hormone. The 
equilibrium between free and carrier-bound hormone is always strongly in 
favour of the bound form.
Entry into cells most likely occurs by passive diffusion, although a 
facilitated entry process has been postulated (Milgrom et al.J.973,
Gorski & Gannon, 1976). If the cell into which the steroid passes is 
not part of a target tissue for that particular hormone, it will quickly 
pass out again (Jensen & Jacobson, 1960). If, on the other hand, the 
cell penetrated by the hormone is in a target tissue, its exit is delayed 
by the presence of receptor molecules to which it is tightly and 
specifically bound. The possession of these receptors is one of the 
definitive properties of a target tissue (Folca et al., 1961, Clark & 
Gorski 1969, Jensen & De Sombre, 1972, Higgins et al., 1973). Receptors 
are found experimentally in the cell cytoplasm, where they may occur
•M  ^  -M
free or loosely bound to the cytoplasmic membrane (Wittliff, 1975).
Their synthesis has been shown to be promoted by the presence of high 
•levels of circulating hormone (Sarff & Gorski, 1971, Clark et al., 1977).
Most work on the action of steroid hormones has been carried out using,, 
as a model,the interaction of oestradiol-173 with the immature rat uterus 
(Jensen et al., 1974). A scheme for the mechanism of action of steroid 
hormones in general with target tissue cells was worked out using this 
system and was published independently in 1968 by Jensen et al. and 
Gorski et al., a preliminary report having been made by Shyamala &
Gorski the previous year. It is a two step mechanism, as summarised in
Figure 3.
The hormone enters the cell and.is bound to a receptor molecule. The 
receptor has been shown to be proteinaceous in nature by its sensitivity 
to proteolytic enzymes, but not nucleases (Toft et al., 1967). After 
binding the hormone, the receptor is modified in some fashion during a 
step referred to as "activation". This is thought to involve the 
addition of a further polypeptide subunit of molecular weight of the order 
of 50,000 (Notides & Nielsen, 1974, Leake, 1976). The heat-dependent
nature of the "activation" step has been demonstrated by the fact that
warming the system causes the conversion even in the absence of nuclei 
(Jensen et al., 1974). The actual site of this transformation is 
unknown, but a matter of current debate (Linkie & Siiteri, 1978,
Sheridan et al., 1979).
Once activation has occurred the receptor/hormone complex is free to 
bind the specific "acceptor" sites on the chromatin. The specificity
Figure 3 - Mechanism of Action of Steroid Hormones
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of these sites is thought to be due to their 3D conformation as, if 
chromatin is removed from its natural environment, the destruction of 
configuration causes loss of this property.
After the receptor/hormone complex has become bound to the acceptor 
sites, the various effects of the hormone’s presence are seen. These 
effects vary according to the particular hormone, but generally involve 
first of all transcriptional activation, leading to an increased synthesis 
of RNA (Spelsberg, 1976), specifically mRNA, which is then transported into 
the cytoplasm, where protein synthesis occurs on cytoplasmic ribosomes 
(O’Malley & Means, 1974). Not all mRNA species may be synthesised at 
the same time, however, as was demonstrated by Palmiter et al., (1976) 
in chick oviduct, suggesting some intermediate step between binding to 
chromatin and transcriptional activity. The type of protein synthesised 
varies from cell to cell depending on the kind of response elicited.
These events occur quite quickly after stimulation by the steroid. Cellular 
growth and division is seen much later. The specific actions of 
oestrogens on target tissues will be discussed in detail in a later section.
Once the hormone/receptor complex has been bound to the acceptor sites 
for a specific length of time, it is then released. The hormone is 
released in the same form as it had when it entered the cell, not being 
metabolised in any way during this process (Puca & Bresciani, 1968). The
receptor appears to be recycled in some fashion, and total receptor 
content of the cytoplasm after oestrogen stimulation is due to a mixture 
of recycling and de novo synthesis (Neithercut, 1977).
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Although this mode of action was elucidated specifically for the action 
of oestradiol-173, it has been shown to hold true for many other steroid 
hormones and also for 1,25-dihydroxy vitamin (Gorski & Gannon, 1976).
In the case of androgens, testosterone is metabolised within the target 
cell before binding to the receptor.
1.2.3 OESTROGENS
1,2.3.1 Synthesis
In Man, oestrogens may arise from a number of different sources. In 
the case of the premenopausal female, the main source is the ovaries, 
with the ovulating one contributing more than the inactive one during 
each cycle. The adrenal cortex also produces a small amount of oestrone, 
but this is not really a significant percentage of the circulating level. 
Another major source, predominantly for postmenopausal females is the 
conversion of androgens to oestrogens, (England et al., 1974) the main 
pathway being the transformation of androstenedione to oestrone (Gower & 
Fotherby, 1975). There is also a pathway for the conversion of testosterone 
to oestradiol, which leads to approximately 50% of the male oestrogen 
production. Another contribution in the male comes from the testes where 
a direct secretion of oestrogens has been demonstrated (Longcope et al., 
1972), In the pregnant female, an additional source is the foetoplacental 
unit, which produces large amounts of oestrogens, predominantly oestriol 
(De Hertogh & Thomas, 1975).
The pathway for synthesis of oestrogens, where no conversion of androgens 
is involved, is that shown in Figure 1. Oestrogens are all 18-carbon atom
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molecules with substituents at various positions in the ring structures.
The three main natural oestrogens are shown in Figure 4, along with the 
very potent synthetic oestrogen diethylstilboestrol,which has wide medical 
applications. All the oestrogens have a conjugated A ring, and the 
overall structure is very important for binding to receptor molecules 
within the cell,as will be described later,
1.2.3.2 Action of Oestrogens
All studies on the action of oestrogens and the discovery of the identities 
of their target tissues have been greatly facilitated by the synthesis of 
a tritium-labelled form. Prior to this, carbon-14-labelled oestrogens 
were the only available tools and, to give a measureable activity at the 
end of the experiment, it was necessary to administer doses of hormone 
well in excess of the physiological level. Tritiated-hexoestrol was the 
first such oestrogen to be developed, and this was used in sheep, goats 
and humans to trace the relevant target organs (Glascock & Hoekstra, 1959, 
Folca et al., 1961). Jensen & Jacobson (1960) then synthesised tritiated- 
oestradiol, using either carrier-free tritium gas or 10% tritium in hydrogen. 
They used this form in studies on the fate of oestrogens in various 
different tissues of the body, in this way identifying the uterus, vagina 
and anterior pituitary as target tissues. Other target organs later 
identified using tritium-labelled-oestradiol, were the hypothalamus 
(Eisenfeld & Axelrod, 1966) and the mammary gland (Sander, 1968).
The mechanism of action of oestrogens has been accepted generally as that 
detailed earlier and summarised in Figure 3, although doubts are now being
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cast upon its accuracy. The sequence of events following the binding 
of the hormone/receptor complex to the acceptor sites on the chromatin 
has been investigated extensively, and a clear timetable of steroidal 
stimulation has emerged similar to that summarised by Spelsberg (1974) 
for progesterone action on the chick oviduct.
I
The first indication of oestrogenic stimulation in the rat uterus is a 
rise in RNA polymerase B (or II) activity 15 minutes after hormone 
administration, followed 15-45 minutes later by a similar rise in RNA 
polymerase A (or I) activity Classer et al ., 1972) .The rise in RNA poly­
merase A activity has been demonstrated to be dependent on the presence 
of RNA polymerase B by Borthwick & Smellie (1975) in studies using a - 
amanitin, a specific inhibitor of the latter enzyme. Cycloheximide was 
effective in the inhibition of increased RNA polymerase A activity also, 
indicating a requirement of some protein synthesis, presumably as a con­
sequence of the RNA polymerase B activity.
Other "early" events following oestrogen administration are a rise in the 
levels of specific mRNAs, phospholipid and glycogen after 1-2 hours and 
then later in total RNA, DNA and protein. The effect of the hormone has 
been reported to be an increase in the number of initiation sites available 
for transcription on the chromatin (Tsai et al., 1975). The RNA synthesis 
is not a general effect, with mRNA and tRNA being synthesised earlier than 
rRNA (Billing et al., 1969a, 1969b, Jensen & De Sombre, 1972). Noteboom 
& Gorski (1963) and Gorski (1964) found that puromycin inhibited the rise 
in total RNA levels and concluded that protein synthesis must be a pre­
requisite for this effect. This was suggested also by Ui & Mueller (1963).
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However, these findings should be treated with caution, as side effects 
of inhibitors could be misleading in these circumstances. Conclusions 
reached by Hamilton (1968) about the specificity of RNA produced in the 
cell should also be approached cautiously. He extracted RNA from an 
oestradiol-stimulated organ and found that it caused growth in a non­
stimulated uterus, but the RNA extracted may have been contaminated with 
oestradiol. The variation in the length of time required for the 
stimulation of RNA synthesis is reflected in the timetable of the appearance 
of different proteins (Palmiter et al., 1976). Some mRNA is stimulated 
as early as 15-30 minutes after steroid administration and protein synthesis 
is detected at times from 30 minutes up to 48 hours.
In the rat uterus, oestradiol was found to give another "early" effect.
This was the synthesis of a protein known as oestrogen specific uterine 
protein or induced protein (I.P.), first noted by Notides & Gorski (1966).
It was found to be produced 30-40 minutes after oestradiol stimulation 
(Jensen & De Sombre, 1972), having been totally undetectable before steroid 
administration (Bamea & Gorski, 1970) within the sensitivity of the assay 
conditions described, I.P. synthesis is blocked by actinomycin D, but 
not by protein synthesis inhibitors (De Angelo & Gorski, 1970), showing 
that its synthesis must be one of the earliest events triggered off by 
oestrogen stimulation. Characterization has shown it to be an acidic 
polypeptide (Mayol & Thayer, 1970), with a molecular weight of approximately 
45,000 (lacobelli,et al.,1978) J.P,has also been discovered in vitro 
(Katzenellenbogen & Gorski, 1972), showing that an intact vascular or 
nervous system is not necessary for oestrogenic stimulation of uterine 
cells. Recent evidence proves that I.P. has enolase activity (Kaye et al., 
1979, Kaye, 1980).
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"Late" responses to oestrogen administration include a sustained high 
activity of RNA polymerase A, and a second rise in RNA polymerase B 
activity about four hours after the first response. This new peak is 
then sustained. Other•effects are a general growth and division of cells. 
Clark & Peck (1976) reported that the hormone/receptor complex must remain 
in the nucleus for at least 4-6 .hours in order to elicit these "late" 
responses and hence true uterine growth, as a shorter period than this 
represents failure to fully activate the specific acceptor sites on 
chromatin.
Oestradiol-176 is the active oestrogen in the human female, and can fulfil 
the requirement to retain the presence of the receptor in the nucleus.
The other natural oestrogens in the body do not do this in the normal course 
of events. Oestrone was reported as being retained in neither the uterus 
nor vagina, and any activity it had was attributed to a conversion to 
oestradiol-176 (Williams-Ashman & Reddi, 1971). However, Ruh et al.,
(1973) reported that oestrone itself can cause I.P. synthesis, but much 
higher levels are required than for oestradiol, and some conversion to 
oestradiol does occur (about 20%). This is probably due to the lower 
affinity of the oestrogen receptor for oestrone, as determined by Lovgren 
et al. , (1978), which may be responsible also for the actions of oestriol. 
Oestriol was, at one time, thought to be an inhibitor of oestradiol-176 
action in the rat uterus (Brecher & Wotiz, 1967). The fact that it is 
a pregnancy hormone was thought to account for its different actions 
(Hisaw, 1959) . It was found that it did not act like oestradiol in 
stimulating later events such as the second rise in RNA polymerase B 
activity after 4 hours (Hardin et al., 1976). However, Clark et al.;(1977)
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demonstrated by the use of implanted oestriol pellets, which would keep 
plasma levels high (as found during pregnancy), that oestriol is a potent 
oestrogen under these conditions, though not if injected as a single dose. 
These studies, along with some carried out using derivatives of oestriol 
(Lan & Katzenellenbogen, 1976), confirmed the idea that retention of the 
hormone/receptor complex in the nucleus is important for long term 
responses to the hormone.
Before the discovery that oestriol was not an oestrogen antagonist in 
high levels, it was thought that it could counteract oestradiol, thus 
preventing the growth of some breast tumours. This view was supported 
by the fact that women of oriental origin, who have a low incidence of 
breast cancer, had a high ratio of oestriol to oestradiol plus oestrone 
(the oestriol ratio). This ratio was low in Caucasian women, who 
exhibit a high incidence of the disease (Dickinson et al., 1974). It 
was then realised that this ratio may change throughout life, and, thus, 
would have to be measured early in life to predict the likelihood of 
developing breast cancer (Henderson et al., 1975). Pike et al., (1977) 
found daughters of breast cancer patients had high levels of oestriol, 
although they were at high risk of developing the condition. In addition, 
the overall correlation between oestriol ratio values and the incidence of 
breast cancer was found to be very poor (Cole et al., 1978). Combined 
with the discovery of the true nature of oestriol, this led to the abolition 
of the use of this discriminant in determining the likelihood of developing 
breast cancer.
— 19 —
1.2.4 OESTROGEN RECEPTORS
1.2.4.1 Properties
Oestrogen receptors are proteins of molecular weight around 80,000 
found in oestrogen target tissues. Their protein nature has been 
demonstrated using purification by chromatography (King, 1968) and by 
their sensitivity to pronase but not nuclease (Toft et al., 1967,
Korenman, 1968). They have a pH optimum of 7, and binding is destroyed 
by a pH of 6 and below or 9 and above (Master et al., 1970). They are 
also heat-labile (McGuire & De La Garza, 1973b), prolonged exposure 
to temperatures above 30°C causing reduction in, and eventually abolish­
ment of binding. It has also been shown that sulphydryl groups play an 
important part in the interaction between the receptor and the oestrogen 
(Jensen et al., 1967, Muldoon, 1971), even if only indirectly by ensuring 
the maintenance of the correct conformation of the receptor. Since the 
receptors are proteinaceous, the usual precautions must be taken in 
handling. Storage, especially, must be carefully controlled, as freezing 
and thawing destroys the receptor conformation (King et al., 1978) , 
However, lyophilization has been shown to be a successful form of storage 
for receptors from many different types of tissue (Koenders et al.,1978). 
The amount of oestrogen receptor present in the cell has been found to 
depend on the level of oestrogens in the circulation (Sarff & Gorski,
1971) and also on prolactin concentration (Asselin & Labrie, 1978). The 
role of oestrogens in controlling their own receptors is demonstrated by 
the variation in uterine receptor levels during the rat oœtrous cycle, 
although reports on the time of peak cytoplasmic receptor content vary. 
Feherty et al., (1970) found that levels were highest at pro-oestrous,
-which was contradicted by the finding of Lee & Jacobson (1971) that 
the level was lowest on this day. Kielhorn & Hughes (1977) reported 
that the peak was found at di-oestrous, and levels were declining by 
pro-oestrous. White et al., (1978), in contrast to all of these reports 
could find no variation at all throughout the cycle. The latest report, 
by Fishman & Fishman (1979), places the peak at pro-oestrous and oestrous.
It is clear that there is a variation, but the exact peak of receptor
levels has not yet been agreed. A variation in receptor levels found 
in human endometrium during the menstrual cycle has been detected (Soutter
et al., 1979), with a peak at day 9.
1.2.4.2 Cytoplasmic Binding
Two distinct types of binding entity have been reported in the cytoplasmic 
fraction of the cell (McGuire & Julian, 1971). These display high and
low affinity binding. Low affinity sites have a dissociation constant
-5
of the order of 10 M, while high affinity sites display a value of
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10 M - the usual circulating level of oestradiol in the bloodstream.
It is the high affinity receptor which mediates the cellular activity of 
oestradiol (King, 1975, Feherty et al., 1971). Low affinity sites may 
represent contamination of the cytoplasmic preparation with plasma binding 
proteins. More recently, there have been reports of two different 
binding sites in the cytosol which have much closer affinities (Eriksson, 
1978, Smith et al., 1979), the dissociation constants differing by only 
one power of ten. Another source of heterogeneity of the cytosol receptor 
has been reported by Fishman & Fishman (1979), who find that only some of 
these receptors will bind the antioestrogen tamoxifen, the remainder being 
insensitive to the drug. This again suggests two separate populations of
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receptor within the cytoplasm.
The size of the cytoplasmic receptor has been investigated in sucrose 
density centrifugation studies, using bovine serum albumin as a marker. 
First reports stated that the receptor had a sedimentation coefficient of 
9.5S (Toft & Gorski, 1966, Jensen et al,, 1967, Jensen et al., 1968). Later 
reports indicated a value of 9S (Clark & Gorski, 1969, Shyamala & Gorski, 
1969, Steggles & King, 1969), but the finally agreed value was 8-9S 
(McGuire & Julian, 1971, Shyamala & Nandi, 1972, Jensen et al., 1974).
There were also reports of a 48 receptor (Steggles & King, 1969, McGuire & 
De La Garza, 1973a). This was found when using a high salt environment 
(0.4M KCl), but Stancel et al., (1973) recognised that this was not the 
true cellular environment and so the real form of the receptor in vivo 
could not be determined using this system. There are also suggestions 
that the 48 form is, in fact, alpha-fetoprotein - a major high affinity 
oestrogen binding protein in rat. The levels of this protein decline as 
the rat matures, but it is still evident at 20 days (Labarbera & Linkie,
1978). It is thought to combine with albumin to give the 48 binding 
protein and thus the 48 species measured at low ionic strength may be due 
completely to serum contamination of alpha-fetoprotein (Uriel et al.,1976). 
Muldoon (1978) has proposed that there are, in fact, two forms of the 
cytoplasmic receptor - 48 and 88, the 88 form being important to conserve 
oestrogenic action when oestrogen levels fall, and so being necessary to 
ensure tissue responsiveness. A 58 form of receptor was also isolated 
by Muldoon (1971), and this was presumed to represent the 48 receptor in 
its activated form, with the additional polypeptide added at the time of 
transformation (Notides & Nielsen, 1974, Spelsberg, 1974) prior to or
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concurrent with translocation. Linkie & Siiteri(1978) propose that the 
conversion of AS to 5S receptor occurs within the nucleus. Translocation 
from cytoplasmic to nuclear compartments may not, in fact, be a real event, 
and pretransformed receptor is probably evenly distributed throughout the 
soluble fraction of the cell.
The oestrogen receptor displays great specificity for oestrogenic compounds. 
It will not interact with non-oestrogenic compounds such as oestradiol-17a, 
but will bind some non-steroidal compounds, such as diethyl stilboestrol 
or hexoestrol, if they have oestrogenic or anti-oestrogenic properties 
(Puca & Bresciani, 1968). This has been demonstrated by the fact that 
only oestrogenic and anti-oestrogenic compounds will interfere with the 
binding to receptor of oestradiol-176 (Puca & Bresciani, 1969). Of the 
natural oestrogens, oestriol binds to approximately one-fifth of the 
level of oestradiol-176, while oestrone binds to around one quarter. The 
synthetic oestrogen diethylstilboestrol, however, binds with double the 
affinity of oestradiol-176 (Korenman, 1968).
Investigations into the specificity of the receptor have yielded some 
information on the type of configuration necessary for binding to occur. 
This, in turn, has led to the discovery of how the receptor binds the 
hormone. HHhnel and Twaddle (1974) examined the binding of a number of 
different steroids to the receptor. They concluded that, for binding 
to take place, the steroid must have an aromatic A ring, a phenolic 
hydroxyl group at carbon atom 3 and an oxygen function in ring D (see 
Figure2for nomenclature). This was confirmed by the findings of 
Poortman et al., (1975). The actual process by which binding of 
oestradiol-176 to the receptor takes place was then elucidated by
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Powell-Jones et al., (1975) as an initial attachment of the phenolic 
hydroxyl group at carbon atom 3 to a highly specific site which facilitates 
attraction of a 6-hydroxyl group at carbon atom 17 to a less specific site.
1.2.4,3 Nuclear Binding
The accepted mechanism of action of steroid hormones of Jensen et al.,(1968) 
and Gorski et al., (1968) states that once the oestrogen has become bound 
to the receptor, the complex as a whole travels into the nucleus in a 
"translocation" step. It is not yet clear how the complex gains entry 
to the nucleus, or indeed why (or whether) the receptor should stay in 
the cytoplasm until bound to a steroid. Gorski and Gannon (1976) suggested 
that this may indicate that the receptor is bound to something in the cyto­
plasm from which it is released upon binding a hormone. Another explanation 
is that it may be too big to enter the nucleus on its own and the hormone 
somehow changes its shape to allow it entry. King et al., (1976) reported 
that receptors may be active on their own, but require the binding of 
steroid to increase their efficiency. This could be by providing a key 
to the nucleus. More recently, there have been several reports of unoccupied 
receptors occurring in the nuclei of human breast tumour cells, where they 
are thought to be inactive, although this cannot be stated with certainty 
(Garola & McGuire, 1977a, Panko & MacLeod, 1978, Kato et al., 1978,
Thorsen, 1979). Unoccupied nuclear oestrogen receptors have also been 
identified in a cell line (MCP 7) derived from a pleural effusion of a 
breast cancer patient (Zava et al., 1977, Horwitz & McGuire, 1978). These 
receptors, even though uncharged, were thought to be stimulating cellular 
growth in some fashion (Zava et al., 1977). Clearly, this is an area of 
great significance, which is not yet fully understood, and is involved in
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the question of whether the hormone acts to carry the receptor to the 
nucleus or vice versa.
Early experiments on nuclear binding of oestrogens seemed to indicate 
that the hormone was bound directly to a chromatin protein (Maurer & 
Chalkley, 1967). However, a separate receptor was then recognised and 
identified as the cytoplasmic receptor (Gorski et al., 1968). More 
recently, Greene et al., (1977) have purified receptor and prepared 
antibodies to it. Using these, they have been able to confirm the 
similarity between the cytoplasmic and nuclear forms of the receptor in 
the same cells as well as compare receptors from different species.
The idea of the cytoplasmic receptor being modified to allow entry into 
the nucleus evolved with the models of steroid hormone action of 1968.
When the disappearance of cytoplasmic receptor was found to correlate 
with the appearance of oestradiol in the nucleus (Shyamala & Gorski,
1969), this destroyed any ideas of the hormone binding directly to nuclear 
DNA or protein. Translocation of the hormone/receptor complex from the 
cytoplasm to the nucleus was found to occur rapidly after oestradiol 
administration (Williams & Gorski, 1971, Anderson et al., 1974). The 
level of nuclear receptors can be maintained at a maximum for 24 hours 
by a second administration of hormone, if given within 3 hours after the 
first dose, but otherwise the level will decline (Anderson et al., 1974). 
Temperature has been reported to be important, both in causing translocation 
to occur (Williams & Gorski, 1971) and in promoting binding of the hormone/ 
receptor complex to the acceptor sites on chromatin (McGuire et al.,1972). 
Linkie & Siiteri (1978) reported that the type of receptor present in the
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nucleus depended on temperature. If translocation occurred at 4°C, a 
4S form was obtained, but at 37^C, the nuclear receptor was in the 5S 
form. Heterogeneity of nuclear sites was also proposed by Tseng & Gurpide
(1978) while studying the interaction of the oestrogen oestetrol with 
human endometrium. They found that some sites bound this oestrogen more 
easily than others, and, further, suggested that thé sites which bound it 
more slowly are the biologically active ones. Eriksson (1978) also 
found two types of binding within the nucleus, one which had translocated 
from the cytoplasm and another one, always present in the nucleus, which 
served to deal with the processing of the hormone/receptor complex upon 
translocation. Based on their own findings, Linkie & Siiteri proposed a 
revised mechanism of action of oestradiol in which the steroid enters the 
cell, binds to a 48 receptor, which is converted to 58 once inside the 
nucleus, and it is this complex which binds to acceptor sites within the 
nucleus.
The mechanism by which the hormone/receptor complex binds to the acceptor 
sites on the chromatin is not yet fully understood. It was suggested that 
the receptor may have a site for binding hormone and another which interacts 
with chromatin (Milgrom et al., 1973). The same group also proposed an 
enzymatic conversion of the receptor within the nucleus, which allowed it 
to bind to acceptor sites, but it is still not clear how binding is 
achieved, or the nature of that binding. The actual site of binding on 
the chromatin is not yet certain either, but it has been shown to involve 
the non-histone proteins, specifically fraction APg (Spelsberg et al.,
1972) in chick oviduct (O’Malley et al.. 1972) and human mammary tissue 
(Charreau & Baldi, 1977). In fact, it probably involves both the DNA
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and the non-histone proteins in active roles (King & Gordon, 1972).
Spelsberg (1974) suggests two sites on the receptor, one to recognise DNA 
and one to bind acceptor. Yamamoto & Alberts (1975) found that, although 
the hormone/receptor complex does bind to DNA, the binding is non-specific. 
They also suggested that many specific sites could exist at different loci 
on the chromatin. The exact nature and specificity of these sites still 
remains a mystery (Yamamoto & Alberts, 1976). The study of acceptor sites 
in vitro is probably hindered by the inability to isolate chromatin while 
retaining its 3D structure (Higgins et al., 1973). It may be that it is 
this conformation which holds the solution to the question of how the 
specificity of acceptor sites arises (Leake, 1976).
1.3 THE SIGNIFICANCE OF OESTROGEN RECEPTOR LEVELS IN BREAST CANCER
1.3.1 THE MAMMARY GLAND
The growth and differentiation of the normal mammary gland are controlled 
by a number of different hormones, both polypeptide and steroid in nature. 
The plasma level of each of these hormones is determined by the functioning 
of the hypothalamic-pituitary axis. The regulation of growth within the 
breast, then, depends not only on circulating levels of hormone, but also 
on the integrity of this system. In addition to this, the mammary gland 
has been shown to have the capacity to synthesise its own oestradiol 
(Adams & Li, 1975). The differentiation of the mammary gland is controlled 
by this hormonal milieu, the function of some of the individual hormones 
being unclear as yet (Wittliff et al., 1978), whilst the roles of others 
have been elucidated (Topper, 1970). Insulin controls the formation of 
secretory cells, hydrocortisone the formation of secretory proteins and
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prolactin causes RNA synthesis in epithelial cells. There is a 
synergistic effect of hormones, in that one hormone can be active in the 
synthesis or activity of another. Examples of such interplay are the 
stimulation of progesterone receptor levels (Horwitz et al.,1975a) and 
prolactin release (McGuire et al., 1976a) both by oestrogens. The 
overall functioning of the gland, for example lactogenesis (Denamur, 
1971), is controlled by the combined effects of a number of different 
hormones. The role of sex steroids is clearly seen by the changes in 
morphology which are evident at puberty, during pregnancy and at the time 
of the menopause.
Despite this potential for sensitivity to oestrogens, the normal, non-
lactating mammary gland contains very little measurable oestrogen receptor
as the proportion of epithelial tissue is very small. It does have a
very low level of receptors, since it has been reported to take up and 
3
retain H-oestradiol, making it an oestrogen target organ (Puca & 
Bresciani, 1969, Block et al., 1975, Sander, 1968). The gland must, 
therefore, contain machinery to switch on the synthesis of oestrogen 
receptors when they are required. When a breast cell undergoes malignant 
transformation, two things can happen. Firstly, there may be a loss of 
the ability to form oestrogen receptor molecules, in which case the tissue 
is no longer recognised as target tissue for oestrogens, and endocrine 
control is no longer present (McGuire et al., 1977a). Secondly, the 
machinery for receptor synthesis may be "switched on" and amplified by 
the transformation, in which case the tissue will become very sensitive 
to endocrine control (Deshpande et al., 1967, Folca et al., 1961,
Wittliff et al., 1972, Jensen, 1975). Oestrogen receptors have been 
found in some cases of benign breast lesions (Feherty et al., 1971), but
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the levels are not as high as those found in malignant tissue, where 
excessive levels of synthesis have been activated (Sakai & Saez, 1976).
The activation of receptor synthesis is not confined to female breast 
cancer, as binding has been detected also in male cases (Leclerq et al.,
1975). It has been pointed out that one-third of male tumours are 
hormone-associated (mainly cancer of the prostate), while the figure for 
females is one-half (Miller, 1978).
The possible stimulation of oestrogen receptor synthesis at the time of 
transformation is not the only biochemical alteration which occurs in the 
breast. Enzymes responsible for hormone metabolism also appear to be 
effected. Follow et al., (1977) observed that 17g-hydroxy-steroid 
dehydrogenase levels fell dramatically in human malignant mammary tissue, 
thus diminishing the amount of oestradiol converted to oestrone. This 
increases the exposure of the tissue to oestradiol. Brooks et al., (1978) 
using MCE7 cells, found that conversion of oestradiol to oestrone was 
increased rather than decreased. However, King et al., (1965) had found, 
like Follow, that oestrone was converted to oestradiol at a much greater 
rate in rat mammary tumour tissue than in normal tissue from the same source 
and so the former tissue was exposed to greater amounts of oestradiol.
King also found the tumour tissue more active in metabolising testosterone, 
in keeping with the more recent discovery by Deshpande et al., (1977) 
that tumour tissue has a specific receptor for 5a-dihydrotesteosterone.
Yet another change in enzymic activity was observed with A^-^0-reductase 
(Abul-Hajj, 1979), This form of the enzyme was found in tumours which 
had little or no oestrogen receptor content. The A*^-5a-reductase, however, 
was found associated with tumours containing a significant level of oestrogen
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receptor. As the Sa-reductase produces metabolites which interact 
with oestrogen receptors, they may act to stimulate growth of the tumour. 
Another example of this kind of self-preservation mechanism is the ability 
of tumour cells to cause angiogenesis - a function unknown in normal cells 
(Maiorana & Gullino, 1978). The binding of glucocorticoids, which play 
an active role in lactation (Shyamala, 1973) does not appear, however, to 
be effected by the change to malignancy, although the binding protein is 
very similar to the oestrogen receptor (Gardner & Wittliff, 1973). Binding 
properties were found to be the same in both malignant and normal breast 
tissue, although the quantitative result might prove to be different 
(Goral & Wittliff, 1975).
1.3.2 HORMONAL INVOLVEMENT IN BREAST CANCER
The study of hormonal mechanisms in breast cancer has been greatly assisted 
by two model systems. One is the hormone-dependent rat mammary tumour 
induced by 7,12-dimethylbenz-a-anthracene (DMBA), an aromatic hydrocarbon 
administered via the gastro-intestinal tract. This tumour was first 
developed by Geyer et al., (1953), and later found to be capable of 
exhibiting hormone-dependence (Huggins et al., 1959, 1961, Young et al., 
1963), This is not found in every case, however, with about 30% being 
autonomous. The other system is the MCE7 cell line, derived from a 
pleural effusion of a patient with hormone-dependent breast cancer 
(Soule et al., 1973), This line has been shown to contain oestrogen, 
progesterone, androgen and glucocorticoid receptors (Horwitz et al., 1975b), 
and cellular growth is sensitive to hormonal control.
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1.3.2,1 Treatment in Cases of Breast Cancer
Treatment for breast cancer falls into three areas - radiotherapy, 
chemotherapy and hormone therapy. Each of these has associated with it 
considerable side effects, the worst being experienced with chemotherapy. 
This involves the prescription of cytotoxic drugs, which act to kill 
dividing cells. The cells in a mammary tumour do not divide very 
rapidly, and so exposure to these drugs must be maintained over an extended 
period of time. Intestinal cells divide rapidly and so are vulnerable to 
these drugs, which is why one of the worst side effects is considerable 
nausea, caused by the extended periods of treatment.
Hormonal therapy can take one of two general forms - either ablative or 
additive. Ablative therapy means removal of an endocrine gland, thus 
causing hormone deprival. Additive therapy involves either the adminis­
tration of pharmacological doses of hormones, or the use of antihormones, 
both of which interfere in some way with the normal functioning of oestrogen 
actions within the breast. Usually, a tumour will respond much more 
successfully to one form than another (Huggins, 1965) and even within one 
general type, there may be variation in response to different treatments. 
Within ablative procedures, the success of a particular operation appears 
to depend on the hormonal status of the patient. Oophorectomy is most 
successful for premenopausal or menopausal women, while hypophysectomy 
and adrenalectomy are more suited to postmenopausal patients,with 
adrenalectomy the more traumatic operation (Binder et al., 1977). In 
addition to this, "chemical adrenalectomy" can now be achieved by the 
use of aminoglutethimide, which is thought to act by blocking the synthesis
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of steroids at the conversion of cholesterol to pregnenolone, with an 
effect on aromatisation also. This can be used in cases suitable for 
adrenalectomy, the chemical method having much less trauma associated 
with it.
The mechanism by which additive therapy operates is not absolutely clear, 
but it is presumed to act by a feedback mechanism (down regulation), 
which lowers levels of oestrogen receptors. Large doses of oestrogens, 
progestins, androgens or glucocorticoids are used to good effect (McGuire 
et al., 1976b) . The action of glucocorticoids in causing regression of 
breast tumours has been postulated to be by a dual effect (Osborne 
et al., 1979). One proposed aspect of action is a direct inhibition of 
breast cancer cell proliferation, the other being an opposition of the 
stimulatory effect of insulin. The efficacy of progesterone in suppressing 
oestrogen action was noted over thirty years ago in guinea pig (Lipschütz 
et al., 1939, Lipschütz & Maass, 1944). Investigations on DMBA-induced 
mammary tumours in the rat revealed that progesterone, when given in 
incremental doses along with increasing doses of oestradiol-176 gave 
increased tumour regression over the oestrogen alone (McCormick & Moon,
1973), . Progesterone alone, however, hastened tumour appearance in this
system. Progesterone can influence other hormones of the mammary gland, 
such as prolactin (Djicane & Durand, 1977), so the effect of progesterone 
on human breast tumour growth could occur by an indirect pathway. High 
doses of androgens, also, are successful in causing regression of breast 
tumours. It was not known why this was so, but there have recently been 
reports of androgens binding to oestrogen receptors, a step which might be 
involved in their action (Garcia & Rochefort, 1977, Zava & McGuire, 1978, 
Garcia & Rochefort, 1978, 1979). In addition, androgen receptors have
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been isolated from breast tumour cells (Lippman et al., 1975, King et al.,
1976). It is not clear which receptor, if either, is involved in the 
tumour regression caused by androgen administration.
The other form of additive therapy is the use of antihormones such as the 
antioestrogens nafoxidine, clomiphene and tamoxifen. Antioestrogens act 
to inhibit the ability of oestrogens to produce their full effect. The 
way in which the effect is brought about has been keenly studied, not 
only because antioestrogens have been found to be most effective in 
causing regression of breast tumours, but also because this might lead to 
further elucidation of the mechanism involved in the target cell response 
to oestrogens. Clark et al.,(1973) demonstrated two potential useful 
facts in studies on the interaction of nafoxidine hydrochloride (1-{2- 
(P-{3,4-dihydro-6-methoxy-2-phenyl-l-naphthyl}phenoxy)ethyl}-pyrrolidine, 
hydrochloride, also known as Upjohn 11,100A) with rat uterus. The first 
observation was that the antioestrogen bound to the oestrogen receptor 
and caused translocation into the nucleus, but there was no replenishment 
of cytoplasmic receptor. The other interesting finding of their studies 
was that the receptor complex, once translocated, resided in the nucleus 
for at least 67 hours, and possibly as long as 19 days. These two 
factors, in combination with competition for oestrogen receptor sites 
(Clark et al., 1974) were thought to constitute the reason for the anti- 
oestrogenic action of nafoxidine. The lack of cytoplasmic receptor 
replenishment was noted also by Katzenellenbogen & Ferguson (1975), who 
suggested also that there was uptake of oestradiol into the nucleus 
during the time that nuclear retention of receptor was sustained, but 
that this was not due to translocation of cytoplasmic receptor. However, 
Nicholson et al., (1976) and Koseki et al., (1977) both noted while
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studying the action of tamoxifen (1-{4-B-dimethyl amino ethoxyphenyl} 1,2- 
diphenylbut-l-ene) on mammary tumours, that replenishment of cytoplasmic 
receptors did in fact occur using doses of tamoxifen equivalent to those 
known to cause regression of tumours in humans. Nicholson (1979) 
suggested that the lack of cytoplasmic receptor replenishment,noted when 
using higher doses of the drug,could be due to a blocking of some specific 
genetic response. He also postulated that receptor replenishment might 
not be non-existent, but merely repressed to a very low level.
Horwitzet al,, (1978 showed that high doses of tamoxifen, but not 
nafoxidine, could be oestrogenic rather than antioestrogenic, and so it 
is important that the dose used is regulated with care. Tamoxifen has 
been shown to have different effects in various tissues, and, in fact, 
is oestrogenic rather than anti-oestrogenic in the mouse (Terenius,
1971). Bichon & Bayard (1979) have demonstrated oestrogenic actions of 
the drug in the rat liver also, but the high doses administered may have 
led to this finding.
Koseki et al., (1977) postulated that it is the disappearance of the 
oestrogen receptor from the nucleus rather than its reappearance in the 
cytosol which is the important factor in oestrogenic response, and that 
this "processing" of the nuclear receptor may be important in antioestrogenic 
actions. Horwitz & McGuire (1978) used MCE7 cells to demonstrate the 
same fact. Progesterone receptor stimulation by oestrogens was found to 
require "processing" of the hormone/receptor complex within the nucleus 
rather than merely translocation. Progesterone receptor synthesis is not 
stimulated by antioestrogens, demonstrating a repression of late oestrogenic
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responses. A rapid increase in RNA polymerase B activity does occur 
with tamoxifen treatment (Nicholson et al., 1977), so early responses 
are not effected. This has been confirmed in studies on the effects 
of tamoxifen on DNA synthesis in the immature rat uterus (Cowan & Leake,
1979). Master et al., (1977) hypothesised that the reason for this might 
be an alteration of the oestrogen receptor by tamoxifen, causing inactiva­
tion.
A completely different mode of action for tumour regression caused by 
antioestrogens was proposed by Jordan & Dowse (1976). They suggested 
that tamoxifen inhibited the oestrogen-stimulated synthesis of prolactin, 
and caused tumour growth to cease by this indirect pathway. This seems 
unlikely, however, as even some patients who had previously undergone 
hypophysectomy have been found to respond to tamoxifen treatment (Moseson 
et al., 1978), The anti-tumour effect of tamoxifen has been demonstrated 
to occur through binding to oestrogen receptor rather than by altering 
the secretion of pituitary hormones (Tanaka et al., 1978). It has also 
been suggested that antioestrogens dissociate more quickly than oestrogens 
from the receptor, and thus do not elicit a full oestrogenic effect 
(Bouton & Raynaud, 1978). This theory, that rapidly-dissociating compounds 
are necessarily antioestrogenic, has been disproved by Nicholson et al.,
(1979) and Rochefort et al., (1979), who compared the actions of oestradiol, 
tamoxifen and its more active metabolite with their binding properties.
They conclude that binding characteristics cannot be used to predict agonistic 
or antagonistic properties.
Although the way in which antioestrogens act is not yet fully understood, 
it appears that they do interact with the usual machinery for steroid
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hormone action, but that the blockage of oestradiol action lies beyond 
the translocation step. They have proved to be an innovation in 
hormonal therapy of breast cancer, as they represent an additive form 
which does not have the usual extreme side effects or possible upsurge 
of tumour growth associated with other additive regimes (Moseson et al.,
1978). However, they can, themselves, have some side effects (Kiang & 
Kennedy, 1977a).
More advances in the treatment of breast cancer are necessary as it is 
surprising how little the mean survival rate has changed since the early 
breakthrough by Beatson in 1896 with hormonal treatments (Baum, 1976, 
Bulbrook, 1977a). Some tumours do not appear to respond particularly 
well to any one form of therapy, and it has been suggested that, since 
this may be due to cellular heterogeneity, combined cytotoxic and endocrine 
therapy should be considered (Nenci, 1978).
1.3.2.2 Rationale Behind Hormonal Therapy in Breast Cancer
The first demonstration that breast tumours might be sensitive to endocrine 
manipulation came in 1896, when George Beatson induced regression of 
inoperable and advanced lesions in two young women by oophorectomy. 
Following this, hormonal therapies of various types were often used in 
cases of breast cancer, but not all patients benefitted from the treatment. 
Huggins & Bergenstal (1952) reported that adrenalectomy caused regression 
of far advanced cases of mammary tumours, but not in every patient.
Luft et al., (1958) favoured the use of hypophysectomy, as this eliminated 
pituitary hormone involvement as well, but again there was no method of 
predicting which patients would benefit from the operation. As
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Pearson & Ray (I960) reported, the only guide to whether a response
would be found with hormonal therapy was a previous response to another form
of endocrine manipulation, and even this did not give complete certainty.
All the forms of hormone therapy used involved ablative procedures, which 
could prove highly traumatic for patients already weakened by illness, 
and were not without side effects. Baker et al., (1960) called for some 
method by which the likelihood of response could be predicted, and, on this 
basis, the form of therapy selected. In addition to the possible dangers 
of ineffective hormonal manipulation, there is also the consideration that 
its administration represents a delay in instituting some other therapy 
such as chemotherapy or radiotherapy, either of which might be of real 
benefit to the patient.
The discovery that organs responsive to oestrogens had the capacity to 
3retain H-hexoestrol, when this was injected into rats (Glascock & Hoekstra, 
1959, Jensen & Jacobson, 1960), prompted Polca et al., (1961) to administer 
the labelled hormone to breast cancer patients about to undergo adrenal­
ectomy. They found that response was seen in patients whose tumours con­
centrated large amounts of label. This phenomenon was also noted by 
other workers (McGuire et al,, 1976b). However, the correlation between 
the uptake of steroid and response to hormone therapy was not strong enough 
to merit the adoption of this method on a routine basis.
Bulbrook et al., (1960) suggested another approach, involving the measure­
ment of urinary steroid metabolites in breast cancer patients. The ratio 
of 11-deoxy, 17-oxosteroids to 17-hydroxy corticosteroids was used in an 
equation to find what they termed a "discriminant" (Bulbrook et al., 1962a, 
1962b, Hayward & Bulbrook, 1968). A positive discriminant was found to
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give a good prediction of response to adrenalectomy or hypophysectomy 
(60%). Ahlquist et al.» (1968), however, found that no such correlation 
existed when these measurements were carried out, and so doubt fell on 
the method (Zumoff et al., 1975). Another line of approach was to measure 
serum levels of hormone. Oestradiol was measured, but found to be 
similar in all cases, whether the serum came from a healthy control or a 
breast cancer patient (Skinner, 1974, Thijssen et al., 1975). Progesterone 
levels, on the other hand, were found to be elevated in women with breast 
disease (Smethurst et al., 1976, England et al., 1975).
1.3.2.3 The Oestrogen Receptor Hypothesis
From the studies on the uptake of labelled oestrogen into tumours sensitive
to hormonal manipulation, and the discovery of the role of oestrogen
receptors in introducing the hormone into the target cell, came the concept
that the presence of oestrogen receptor in a breast tumour could implicate
hormonal involvement in the growth and development of that tumour. Jensen
et al., (1971) suggested that hormone-dependent tumours could be identified
by their content of oestrogen receptors. Feherty et al., (1971) measured
3 . .receptors by labelling them with H-oestradiol in a cytoplasmic preparation
of a breast tumour. They found that almost 60% of tumours contained
cytoplasmic receptors. Maass et al., (1972) used the method of incubating
3
tumour slices with H-oestradiol, and correlated results with subsequent 
response to hormone therapy, Engelsman et al., (1973) studied the response 
of patients to hormone therapy in relation to receptor levels. 80% of 
receptor-containing tumours regressed on hormone therapy, although this 
percentage may be artificially high due to the small number of patients 
involved. Only 10% of receptor-deficient tumours responded. Similar
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studies carried out using various methods to measure cytoplasmic levels 
of oestrogen receptors revealed a somewhat lower success rate for receptor- 
positive biopsies. This was the subject of a workshop held by the Breast 
Cancer Task Force (McGuire et al., 1975a). Updated results such as those 
of De Sombre et al., (1978) and Byar et al., (1979) confirm success rates 
found in this workshop, 40-60% of receptor-positive tumours regressing on 
hormonal treatment,
1.3.2.4 "False-Negatives" and "False-Positives"
Although the measurement of cytoplasmic receptors had cut down the number 
of patients receiving unnecessary hormone therapy, a significant number 
of receptor-containing tumours still did not respond to this type of 
treatment. Patients whose tumours lack receptors, however, have very 
little chance of response to hormone therapy (Jensen, 1975). Due to 
these findings, it was decided that it was more reliable to state that 
no receptor signified no chance of response, as the presence of receptor 
could in no way guarantee a favourable response (Maass et al., 1975, King, 
1975, McGuire et al., 1975b, Lippman, 1976). More recently, Roberts et al.,
(1978), having considered overall response rates to hormone therapy, in 
relation to oestrogen receptor levels, reported that, although oestrogen 
receptor-containing tumours are 4 to 5 times more likely to respond to 
hormonal manipulation than tumours containing no receptor, it is not worth 
carrying out surgery for the sole purpose of receptor determination.
Routine biopsy of breast tumours for oestrogen receptor assay had been 
suggested by Jensen (1975) on the basis that oestrogen receptor level is 
thought to be maintained in the transition from primary to secondary 
disease (King, 1975, Jensen et al., 1977, Block et al., 1978). A 
measurement of receptor content in primary tumour tissue would thus enable
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immediate treatment of secondary disease, whether a local metastasis or 
one of the common, and surgically inaccessible, distant métastasés of 
bone or lung (Haagensen, 1974). The fact that receptor content is 
maintained during the change from primary to secondary disease might also 
be useful in cases of a second tumour arising, the source of which is 
uncertain. Kiang & Kennedy (1977b) suggest that, if the lesion were a 
secondary of a receptor-containing primary tumour, this could be identified, 
This method is not very accurate, as another primary might have the same 
hormonal status.
The fact that very few receptor-deficient tumours respond to hormone 
therapy, while a much larger percentage of receptor-containing tumours 
fail on hormone therapy is somewhat strange, since there are as many 
reasons for "false-negative" results as for "false-positives". "False-
negative" results could stem from a truly receptor-deficient tumour 
responding to hormonal therapy by some indirect pathway, such as 
inhibition by tamoxifen of prostaglandin synthetase (Tisdale, 1977).
There also exist many steps in the assay of receptors where they could be 
destroyed by incautious handling, as they are extremely thermolabile and 
unstable. The source of the tumour sample might also lead to an invalid 
result if it originated from a non-raalignant piece of tissue, or a piece 
of tumour containing no receptor, while the majority of the rest of the 
tumour did contain receptors. The effect of endogenous oestrogens has 
also been proposed to have a masking effect on receptors in premenopausal 
patients. The percentage of premenopausal patients whose tumours contain 
cytoplasmic oestrogen receptor is significantly lower than that of post­
menopausal patients (Wittliff et al., 1972). This has been attributed to
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endogenous oestrogens filling the receptor sites and making them 
unavailable for measurement (Braunsberg et al., 1974, Sakai & Saez, 1976). 
Mobbs & Johnson (1976) suggested that the stage of the menstrual cycle 
should be taken into account when measuring receptors in order to counter­
act this effect.
Since the incidence of "false-positive" results is so high, it is important 
to realise all the possible causes of these, and try to find methods of 
circumventing them. Their occurrence makes the whole concept of the assay 
of oestrogen receptors somewhat less than perfect. All the reasons for 
false-positive results are not yet understood, but several possibilities 
exist. The first one is that only one part of the mechanism of action of 
oestradiol is being taken into consideration when cytoplasmic oestrogen 
receptor levels are measured. If there is a defect in the mechanism for 
transferring the hormone/receptor complex into the nucleus, then, no matter 
how many receptors are found in the cytoplasm, oestradiol will not be 
influencing the growth of the cell (Maass et al., 1975). The obvious 
solution here is to rule out this possibility by the assay of nuclear, as 
well as cytoplasmic, receptor levels (Thorsen & Stoa, 1979), This has been 
demonstrated to decrease the number of false-positive results (Laing et al.,
1977), if only those patients whose tumours contain receptors both in the 
cytoplasmic and nuclear fractions are treated with hormone therapy. There 
are, however, still a small proportion of patients who should respond, but 
fail. These tumours may have a defect in the acceptor site binding within 
the nucleus, so that even proving the existence of nuclear receptors would 
not alleviate the problem.
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As reported by Jensen & De Sombre (1977), malignant transformation may 
cause tumour nuclei to become independent of hormonal control, without 
shutting down receptor synthesis. In this case, several authors have 
suggested that what should be measured are not oestrogen receptors 
themselves, but rather the products of oestrogen action. The presence 
of these would prove, beyond any doubt, that oestrogens are functioning 
fully within the cell. Such products include caesin messenger RNA 
(Rosen & Socher, 1977), but this was found in only 70% of the hormone- 
dependent rat mammary tumours examined - no improvement on the kind of 
response rate obtained using measurement of cytoplasmic and nuclear 
receptors. Another marker of hormonal stimulation in the breast is the 
synthesis of a-lactalbumin, one of the proteins responsible for the lactose 
synthesis. This was found in some, but not all hormone-dependent rat 
mammary tumours, its absence possibly reflecting some damage to the gene 
responsible for its synthesis during malignant transformation (Ip & Dao, 
1978, Woods et al., 1979, Hall et al., 1979). The assay for this has 
proved unreliable (see Results, section 3,4.5.3). Peroxidase is another 
protein which has been used as an indication of oestrogenic stimulation 
(De Sombre et al,, 1975, Anderson et al., 1975, Lyttle & De Sombre, 1977a). 
This has been shown to be produced by oestrogen action on the rat uterus 
(Lyttle & De Sombre, 1977b), where it may act to cross-link the uterine 
proteins (Keeping & Jellinck, 1978). It has been isolated and purified 
successfully from hormone-dependent rat mammary tumours (De Sombre &
Lyttle, 1978). However, the success of this method in predicting response 
to hormone therapy is in doubt, as Duffy & Duffy (1977) found peroxidase in 
both benign and oestrogen receptor-deficient mammary tumours. Follow up 
from patients treated on the basis of peroxidase levels will be necessary
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to evaluate the reliability of the basic concept. The other marker of 
oestrogen action, which has received a great deal of attention, is the 
progesterone receptor. Oestradiol stimulates the synthesis of this 
protein within the cell (Asselin et al., 1977), and, thus, its presence 
was deemed a good indication of oestrogenic stimulation of growth,
Hsueh et al., (1974) attempted to measure progesterone receptor using an • 
exchange technique for added endogenous steroid. Miller et al.,(1975) 
then used an electrophoretic technique. The problem encountered in the
3
measurement of progesterone receptors was that adding H-progesterone to 
a cytoplasmic or nuclear preparation of a tumour cell filled, not only 
progesterone receptors, but also corticosteroid binding globulin (CBG).
It was thus impossible to determine how much radioactivity was due to 
binding to just the progesterone receptors. This was solved by the intro­
duction, in 1974, of a synthetic progestin: 17,21-dimethyl-19“norpregna-4, 
9-diene-3,20-dione (R5020), This has a high affinity for the progesterone 
receptor, and a very low affinity for CBG (McGuire et al., 1977b). One 
problem found in breast tissue is that R5020 will also bind to the cellular 
glucocorticoid receptor, and it was suggested that natural progesterone 
plus unlabelled cortisol might be a better way of eliminating the binding 
of progesterone to other proteins (Pichon & Milgrom, 1977). Keightley
(1979), on the contrary, found that R5020 gave much more •stability in 
binding, and less likelihood of interference from other steroids, and
Duffy & Duffy (1979) report that both the natural and synthetic progestins
3bind to the same site and that H-progesterone plus cortisol offers no 
advantages over R5020.
After the discovery of R5020,Horwitz et al,, (1975a) proposed that 
progesterone receptor should now be assayed, in addition to oestrogen
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receptors, in the cytoplasm of mammary tumours. They hypothesised that 
tumours containing oestrogen receptor but no progesterone receptor should not 
be treated with hormone therapy, as the oestrogen system within the tumour 
would not be fully functional. They found only 56% of tumours containing 
cytoplasmic oestrogen receptor also contained progesterone receptor.
McGuire et al., (1976b) further reported an improved response rate to 
hormone therapy if both oestrogen and progesterone receptors were present.
The same role of the progesterone receptor as index of oestrogen- 
responsiveness was noted in endometrial tissue (Martin et al., 1979). A 
further report from McGuire (1978) indicated that the assay of progesterone 
receptors might not be as successful as expected, as some tumours lacking 
this receptor, but containing oestrogen receptor had responded to hormonal 
therapy. Allegra et al,, (1979b) came to the same conclusion. A new 
method of measuring the progesterone receptor which pays special attention 
to the stability of the complex formed between the receptor and R5020 has 
now been developed (Powell et al,, 1979), in the hope that this will improve 
the success rate. However, a further problem in this area is the discovery 
by Ip et al., (1979) that the rat mammary tumour system MTW9B contains both 
oestrogen receptor and progesterone receptor, but is not hormone-dependent. 
This suggests that there may be an important step in the mechanism of 
oestrogen action even later than the induction of progesterone receptor 
synthesis, and a marker of this must be sought as a means of determining 
hormonal stimulation. The same conclusion can be reached from a report by 
Watson et al., (1979) of another mammary tumour cell line (MXT 3590) in 
which oestradiol directs progesterone receptor synthesis, but not tissue 
growth. Westley & Rochefort (1979) report the discovery of markers for 
this later step - three intracellular proteins produced as a result of 
oestrogenic stimulation, and inhibited by tamoxifen.
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If the defect making the tumour a "false-positive" one does not lie in 
the cellular mechanism, it may be in the make up of the tumour itself.
Some tumours are made up of a mixed population of cells, some of which 
are hormone-dependent and some independent, or autonomous (Sluyser &
Evers, 1975), If the sample in which receptor content is measured is 
hormone-dependent, but unrepresentative of the tumour as a whole, it will 
contain receptors, but the tumour will only partially respond to hormone 
therapy. There may be a short-lived response, due to the death of the 
dependent cells, but this will be reversed as the autonomous cells take 
over. Mixed populations may represent tumours which are changing over 
from being hormone-dependent to autonomous, as observed by Kim & Depowski 
(1975) and Bulbrook (1977b).
One other possible cause of no response, where one would be expected, 
is that the type of hormone therapy may fail to be the best one for the 
particular tumour in question. Although each form of hormonal therapy 
may have the same overall success rate, there is evidence (McGuire et al., 
1976b) that one particular form will be more successful than another in any 
one tumour.
The approach which has the potential to overcome all these defects, whether 
they make the tumour a "false-positive" or a "false-negative", would be the 
institution of an in vitro system to study the effects of different types of 
treatment on the epithelial cells of the tumour. Although this is probably 
the ideal method, it is not without difficulties. This area will be covered 
fully in Part II of this thesis.
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1.3.2.5 Other Clinical Aspects of Oestrogen Receptors
Although the measurement of oestrogen receptors was intended to be used as 
an index by which response to hormonal therapy could be predicted, it has 
been suggested that it may also be of use in determining the likelihood of a 
tumour’s response to chemotherapy and also the patient’s prognosis. From 
data on the relationship between disease free interval and oestrogen receptor 
content (Block et al., 1978, HMhnel et al., 1979), it appears that receptor- 
containing tumours grow less aggressively than tumours lacking receptor 
(Meyer et al., 1977). On the basis that chemotherapy acts by attacking 
rapidly-growing cells, the relatively faster growing receptor-deficient cells 
should respond more successfully to this form of treatment (McGuire, 1978).
Two reports have been published recently dealing with this topic. One, 
from Kiang et al., (1978), states that, in fact, more receptor-containing 
tumours respond to chemotherapy (80%) than do those tumours lacking receptor 
(37%). Unfortunately, the other report (Lippman et al., 1978) states the 
exact opposite, with the receptor-deficient tumours more likely to respond 
favourably. Kiang et al.also suggest that hormone therapy may act against 
subsequent attempts to apply chemotherapy by destroying chemosensitive factors 
Both of these papers have defects in the way tumours were selected for the
study or how they were evaluated for response, making each subject to
suspicion. The problem of which one of these reports, if either, is right 
will be solved when more groups evaluate their results in terms of the 
relationship between chemotherapy response and oestrogen receptor content.
The answer to the problem will prove very important to all those involved in
the treatment for breast cancer.
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1.4 OESTROGEN RECEPTORS IN NON-TARGET TISSUES
1.4.1 OCCURRENCE
Although most of the preliminary work on the nature and action of oestrogen 
receptors was carried out using the immature rat uterus as a model, 
oestrogen receptors have been located in many different tissues. These 
tissues vary widely from more to less expected sources. More expected 
locations are human endometrium (Tseng & Gurpide, 1978, Soutter et al.,
1979), cervix (Sanborn et al., 1978) and placenta (McCormack & Classer,
1978) and rat ovary (Saiduddin & Zassenhaus, 1977). Less expected receptor- 
containing locations have been the kidney (Bojar et al., 1975), pancreas 
(Rosenthal & Sandberg, 1978), liver (Duffy & Duffy, 1978) and human and canine 
prostate (Ekman et al., 1979, Dube et al., 1979). Oestrogen receptors have 
also been detected in the rat adrenal gland, showing that oestradiol does 
act directly on this organ, as was hypothesised (Calandra et al., 1978).
The important questions which arise from these findings are, whether the 
receptors are functional in these various tissues, and would their presence 
in carcinoma tissue of the same organs justify the use of hormonal therapy.
1.4.2 PREDICTIVE VALUE OF OESTROGEN RECEPTORS IN NON-TARGET 
TISSUE TUMOURS
In addition to the normal tissues detailed above, oestrogen binding proteins 
have also been demonstrated in kidney carcinoma tissue (Bojar et al., 1975), 
human prostatic carcinoma (Ekman et al., 1979) and human colonic tumours 
(McLendon et al., 1977, Alford et al,, 1979). Other sites where oestrogen 
binding proteins have been identified are malignant me laioma (Fisher et al., 
1976), leukaemia (Lippman et al., 1973) and endometrial carcinoma 
(Follow et al., 1975). Whether these proteins represent true receptors
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and whether their presence indicates that the tumour will respond to a 
form of hormonal therapy, is not yet clear. Some follow up of patients 
with these lesions treated with hormone therapy is necessary.
The idea that tumours of the intestinal tract may be hormone-dependent is 
particularly appealing. Berg (1975) suggested that hormone-dependent 
tumours may be linked to diet. The same is thought to be true of colorectal 
cancer, the prevalence of which in particular areas is thought to reflect the 
kind of food eaten. Another line of reasoning is that cancer of the gastro­
intestinal tract is the most common form of cancer linked to breast carcinoma, 
which is itself known to be hormone-dependent in a number of ca,ses 
(Hermann 1972). The presence of oestrogen receptors in colonic tumour 
tissue should thus give a good indication that the tumour might respond to 
endocrine manipulation.
Oestrogen receptors are not the only steroid receptors to be found in these 
solid tumours of non-endocrine tissues. Androgen and progesterone receptors 
are also in evidence, either of which could act in some form of hormonal 
sensitivity. Since these receptors can be mimicked by plasma proteins, 
care must be taken to avoid contamination with plasma. If, however, 
measurement of cellular receptor can be clearly identified, the relevance of 
its presence must be elucidated.
As Friedman et al. .(1978) state, the presence of receptors may merely be an 
indication of longer potential survival, but only further investigation in 
this field will elucidate the true relevance of their synthesis.
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1.5 OBJECTIVES
The aim of the investigations involved in this part of the project was 
to study the actions of steroid hormones, and oestradiol in particular, 
in normal and neoplastic tissues. The approach adopted was investigation 
of the nature and distribution of oestrogen receptors in the various 
fractions of these tissues, and a reliable, routine method of doing this 
was sought. It was hoped that, once this method was successfully established, 
it would prove useful not only in the better understanding of steroid 
mechanisms, but also aid in the treatment of cancer patients by more 
accurately predicting their likelihood of responding to a hormonally-based 
therapeutic regime.
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2. MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 FINE CHEMICALS were obtained as follows:-
DTT (dithiothreitol)
Norit A activated charcoal 
(untreated powder)
Bovine serum albumin 
(fraction V)
Phenyl methyl sulphonyl 
fluoride (PMSF)
Dimethyl sulfoxide 
(DMSO)
Deoxyribonucleic acid (DNA) 
(calf thymus type V sodium 
salt, highly polymerized)
Dextran blue (MW 2,000,000)
Monothioglycerol
Dextran T70
Sephadex G25
Triton X-100
Trasylol (Aprotinin in 
isotonic solution contain­
ing 0.9% benzyl alcohol)
The Boehringer Corporation (London) Ltd 
Sigma, London
Sigma, London
Sigma, London
Sigma, London
Sigma, London
Sigma, London 
Sigma, London 
Pharmacia, Sweden 
Pharmacia, Sweden
Koch-Light Laboratories, Colnbrook, England 
Bayer, Germany
All other chemicals used were, wherever possible, AnalaR reagents, supplied 
by BDH Chemicals Ltd., Poole, Dorset.
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2.1.2 BUFFERS
N-2-hydroxypiperazine-N’-2-ethane sulphonic acid (HEPES) was obtained from 
The Boehringer Corporation (London) Ltd.
TRIS (hydroxymethyl) aminoethane was obtained from Sigma, London.
2.1.3 STEROIDS
3
(6,7- H) oestradiol-176 (40-80 mCi/ml) was obtained from The Radiochemical 
Centre, Amersham.
Oestradiol-176 and diethylstilboestrol (DES) were routinely obtained from 
Sigma, London, although initial trials were carried out using materials 
supplied by NIH Steroid Reference Collection.
2.1.4 SCIITT ILLATION MATERIAL S
The following materials were obtained from Koch-Light Laboratories, 
Colnbrook, England.
Toluene (AR grade)
2,5-diphenyloxazole (PPO)
1,4-di- {2-(5-phenyloxazolyl)}-benzene (POPOP)
Triton X-lOO was obtained from Rohm and Haas, Croydon, England.
2.1.5 LIVESTOCK
Rat uterine tissue was obtained from female Albino Wistar rats (Glasgow 
University colony).
2.1.6 HUMAN TISSUE
Tumour tissue of various kinds was kindly supplied by the following Health 
Board hospitals;-
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Victoria Infirmary, Glasgow 
Western Infirmary, Glasgow 
Gartnaval General Hospital, Glasgow 
Royal Infirmary, Glasgow 
Stobhill General Hospital, Glasgow 
Royal Beatson Memorial Hospital, Glasgow 
Southern General Hospital, Glasgow 
Hairmyres Hospital, East Kilbride 
Monklands General Hospital, Airdrie 
Belvidere Hospital, Glasgow 
Ballochmyle Hospital, Mauchline, Ayrshire
Normal breast tissue was kindly supplied by Canniesburn Hospital, Bearsden.
Breast tumour tissue for quality control comparison was sent from the 
Imperial Cancer Research Fund, London.
Lyophilized breast tumour and calf uterine material was supplied by 
Christie Hospital, Manchester.
2.1.7 MISCELLANEOU S
Polystyrene tubes used in the receptor assay, and plastic pots used for 
human tissue collection were obtained from Sterilin Ltd., Teddington, England,
Glass microfibre filter discs (GF/C, 2.5 cm diameter) were obtained from 
Whatman Ltd., England.
Glass/glass tissue grinders were obtained from either Kontes, USA or Cowie 
Scientific, Middlesbrough, England.
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Glassware was washed and rinsed in glass distilled water as the assay 
of receptors was found to be adversely affected by the presence of 
divalent metal ions.
All solutions were made up in glass distilled water.
2.2. METHODS
2.2.1 TISSUE HANDLING
2.2.1.1 Collection
Tissue was collected fresh from the operating theatre, where a piece 
was selected from the area adjacent to the section removed for pathological 
examination. Collection was into an empty sterile container which was 
then transported on ice to the laboratory for analysis,
2.2.1.2 Storage
Wherever possible, analysis of oestrogen receptor content was carried out 
on the same day as collection. However, when it was not possible to assay 
the tissue on the same day, storage of the sample was at -20°C in a medium 
of 50% (v:v) glycerol:0.25M sucrose, 1.5 mM MgCl^, 10 mM HEPES (N-2- 
hydroxy-piperazine-N’-2-ethane sulphonic acid) (pH 7.4) (see Results, 
section 3.1,1). Before assay, the tissue was rehydrated in 0.25M sucrose,
1.5 mM MgCl^, 10 mM HEPES (pH 7.4) at 0°C for 15-30 minutes,
2.2.1.3 Preparation of Fractions for Receptor Assay (See Figure 5)
Tissue was dissected free of all possible adhering fat as this was found 
to interfere with receptor measurement. A sample of at least 150 mg
Figure 5 - Preparation of Tissue Fractions for Receptor Assay
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(see Results, section 3.3) was then selected from as near as possible to 
the cut made for the pathological specimen (see "Collection” above).
This sample was homogenised in 1.5 mM EDTA (ethylene diaminetetra acetic 
acid), 0.25 mM DTT (dithiothreitol), 10 mM HEPES (pH 7.4) (HED buffer) 
at a concentration of 50 mg/ml. Homogenisation was carried out using 
2 X 10 second bursts at a setting of 150 on an Ultra-Turrax homogeniser 
(Model TP 18/2), followed by the use of a glass/glass tissue grinder 
(see Results, section 3.1.2), The homogenate was kept cool throughout 
this process as any heating which occurred would be detrimental to the 
receptors.
The homogenate was then centrifuged at 5000 g for 5 minutes in a Sorvall 
RC5 Superspeed Refrigerated Centrifuge at 4°C. The resultant supernatant 
("cytosol") was retained in this crude form for receptor assay, as results 
obtained using a higher speed supernatant (100,000 g) were not found to be 
significantly different in relation to DMA content. The pellet was washed 
once with 0.15 M NaCl, 10 mM HEPES (pH 7.4), and finally resuspended in the 
original homogenisation volume, using the saline solution. A glass/glass 
tissue grinder was used again at this stage, to ensure an even suspension of 
the nuclear material ("nuclear suspension"). As in the case of the cytosol, 
the purification of the nuclear suspension by centrifugation through 2.4 M 
sucrose, in no way enhanced the results of the receptor assay, and so these 
forms, although crude, were adopted for routine receptor measurement.
2.2.2 PREPARATION OF ^H-OESTRADIOL SOLUTIONS
3Stock H-labelled oestradiol-173, the purity of which had been checked by
“7LH”20 chromatography,was prepared at a concentration of 10 M in absolute
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alcohol, and this was stored at -20^C. Appropriate amounts of this were
3
aliquotted out to give a series of seven concentrations of H-oestradiol-173
“10 "9 • * “ ^
ranging from 4 x 10 M - 4 x 10 M. Another two aliquots to give 4 x 10 M
were measured out, and to these were added either unlabelled oestradiol-173
or diethylstilboestrol (DES) both in absolute alcohol, in 100-fold excess.
The ethanol was evaporated down in all cases in a stream of compressed air,
and 1 ml of HED buffer added to give oestradiol concentrations in the range
quoted. The ^H-oestradiol-173 solutions were then stored at 4°C for no
longer than one week.
2.2.3 ASSAY OF RECEPTORS
2,2.3.1 Incubation of tissue fractions with steroid.
3
50 pi aliquots of each H-oestradiol-173 solution prepared as detailed 
above were mixed with 150 pi aliquots of cytosol or nuclear suspension 
in polystyrene test tubes. This gave a final range of concentrations of 
steroid in the tubes of Ix, 1.5x, 2x, 4x, 6x, 8x 10 ^H-oestradiol-173
"*9 3 “7
and 10 M H-oestradiol-173±10 M  unlabelledoestradiol or DES. The tubes
were then incubated at 4°C for 18 hours or 20°C for 2 hours (see Results, 
section, 3.1.3.1). A set of control tubes was also set up for the cyto­
plasmic assay which were identical to those above except that HED buffer 
was substituted for cytosol. The incubation conditions were as for the 
test sets,
2.2,3.2 Separation of unbound from bound steroid
This was achieved by different methods for cytosol and nuclear assays,
(a) Cytosol
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(i) Sephadex column chromatography
After incubation, 100 pi of the cytosol/steroid mixture was removed from
the tube and mixed with 25 pi of dextran blue, which served as a marker dye.
This was applied to the top of a Sephadex G25 column made in a pasteur
pipette using a glass wool plug as support, and kept at O^C throughout.
The sample was washed through the column using 10 mM HEPES, 1.5 mM EDTA
(pH 7.4) (HE buffer). Four-drop fractions were collected directly into
plastic scintillation vials, measuring both background and radioactivity
3
representing bound H-oestradiol-173. The column was then washed with 
HE buffer ready for re-use. 10 ml Triton-toluene scintillant (1400 ml 
toluene/PPO (2,5-diphenyloxazole) (5g/l)/P0P0P (l,4-di-{2-(5-phenyloxazole)}- 
benzene) (0.24 g/1): 600 ml Triton-X100:200 ml absolute alcohol) was added 
to each vial, and the vials counted.
(ii) Dextran-coated charcoal adsorption
After incubation, 900 pi HE buffer was added to each tube, and the tubes 
mixed. 500 pi of dextran-coated charcoal solution (DOC), (0,15% w/v Norit A 
charcoal, 0.0015% w/v dextran T70 in 0.25M sucrose, 1,5 mM EDTA, 10 mM HEPES
(pH 7,4)) was then added, and the tubes mixed again. The charcoal "stripping"
was continued for 15 minutes at 0°C, with periodic mixing of the tubes. At 
the end of this time, the charcoal was pelleted by centrifugation at 1000 g for 
5 minutes, 1 ml aliquots of each supernatant were transferred to plastic 
scintillation vials, 10 ml Triton-toluene scintillant added to each vial, 
and the vials counted.
Background and total values were obtained from the control set of tubes,
(b) Nuclear
After incubation, 100 pi aliquots from each tube were added to 5 ml aliquots 
of 0.15 M NaCl, 10 mM HEPES (pH 7.4). Each one was then poured down the'
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chimney of a millipore filter apparatus on to a prewetted glass fibre filter. 
The tube was then washed out with another 5 ml of saline, and the washing 
poured on to the filter as before. The chimney was washed down with 
3 X 4 ml aliquots of saline, which was sufficient to wash any unbound 
material from the filter. The chimney was then removed from the filter and 
the edges of the filter carefully washed with saline. The filter was 
removed from the Millipore apparatus and placed in a plastic scintillation 
vial. 50 pi aliquots of the original incubation mixtures were added to dry 
filters in scintillation vials, to give a measure of the total counts present. 
All vials were then placed at 60°C overnight to allow the filters to dry.
After cooling, 10 ml toluene/PPO (5g/l) were added to each vial, and the 
vials counted.
2.2.3,3 Counting of radioactive samples
All vials from cytosol and nuclear assays were counted on a Philips or a 
Searle Mk 11 Liquid Scintillation Analyser. The efficiency of counting 
was approximately 25% for cytosol samples and 35% for nuclear samples.
2.2.4 CALCULATION OF RESULTS
Results from the above assays were analysed by the method of Scatchard (1949). 
The Scatchard equation can be derived from the Langmuir adsorption isotherm 
by making various assumptions. The Langmuir adsorption isotherm may be 
expressed:
-  = i  + -  (1)
in 1^ 2 ^2
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(p = pressure, x = amount adsorbed, m = mass of adsorbent, and and k^ 
are constants, k^ being an index of the total capacity of the system).
Where p = total available ligand; in conditions of a large excess of 
ligand, p = free ligand (F).
In a closed system, the amount of adsorbent is constant, so m is constant 
and equation (1) can be rewritten:
i  = i  + I
X  k ^
where x ® amount bound (B)
The equation can now be rewritten:
® k,k^ k2
F 1 + k^F
B = k^k^F
1 + k^F
B = k^k^F -Bk^F
' 4  =
59 -
If is a binding constant, and k^ the total number of binding sites, 
the above equation can be rewritten:-
= nk ” kB
This is the Scatchard equation.
If B/F is now plotted against the concentration of oestradiol-173 bound, 
a straight line is obtained, with gradient equal to -Ka or -1/k D, and an 
X-axis intercept from which may be derived the total number of receptors. 
A more simple derivation is achieved by examining:-
H + R HR
(F) (RT-B) (B)
Kd = F (RT-B)
B
Vf “ SÎ - 1
Kd Kd
Thus, by this method, a single plot gives a measure of both the number of
receptors and the dissociation constant of the binding, which is a measure
of the affinity with which the receptor binds the ligand. The specificity
of the receptor for the binding of oestradiol-173 was measured by comparing 
3
the binding of H-oestradiol-173 alone and in the presence of a 100-fold 
excess of unlabelled oestradiol or DES (see Results, section 3.3.1.3). DES 
is preferred in this role, as it will not bind to proteins of a non-cellular 
nature, which would bind oestradiol with high affinity. The presence of 
DES as a competitor eliminates incorrect measurement which would result from 
contamination by such proteins, such as sex steroid binding globulin
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(King & Mainwaring, 1974). Since non-specific binding is principally 
non-saturable at the concentrations being considered in this assay system, 
the amount of radioactivity bound with or without competitor would be 
identical. Specific binding is saturable, however, and very few molecules 
of labelled steroid would be bound by a specific receptor in the presence 
of a large excess of competitor.
2.2.5 EXPRESSION OF RESULTS
2.2.5.1 Protein Determination
The protein content of each cytosol preparation was determined by the 
method of Lowry et al. ,(1951).
2.2.5.2 DNA Determination
The DNA of each nuclear suspension was determined by the modification by 
Katzenellenbogen & Leake (1974) of the method of Burton (1956).
2.2.5.3 Final form of results
Scatchard analysis yielded levels of receptor for both cytosol and nuclear 
preparations expressed as fmol/ml, When protein and DNA analysis had
been completed, cytosol levels were expressed in units of fmol/mg cytosol 
protein and nuclear levels in fmol/mg DNA.
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3. RESULTS
3.1 ■OESTROGEN RECEPTOR ASSAY CONDITIONS
To design a reliable assay for oestrogen receptors in both cytoplasmic 
and nuclear fractions of the cell, with possible applications to routine 
measurement, assisting in the choice of therapy for breast cancer patients, 
several parameters had to be determined. Experiments to establish the 
optimal conditions for such an assay system were carried out using 
principally rat uterine or human breast tissue, but the source of tissue 
will be defined in each case. The uterus of the immature rat has been 
used widely in the elucidation of oestrogenic actions, but variation between 
this model and the human breast does exist. This fact will be considered 
when interpreting the significance of results.
3.1.1 TISSUE STORAGE
Since it is not always practicable to assay the oestrogen receptor content 
when fresh tissue is made available, satisfactory storage conditions which 
would preserve the functional integrity of the receptors were sought. 
Different forms of storage were thus tested by' examining the effects of 
such storage on the receptor content of tissue, relative to that of the 
same tissue when fresh. The results of these studies showed that, although 
storage of tissue at -20°C did not appear to be harmful to the cytosol 
receptors after one short period of storage (48 hours), repeated freezing 
and thawing or lengthy periods at this temperature, might prove so. This 
was not, however, the experience of Keightley et al., (1978), who found 
myométrial cytosol receptor was stable when stored at -20°C or -70°C for
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up to one week. The nuclear receptors in breast tumour tissue appeared 
much more sensitive to the freezing and thawing process, being totally 
abolished.
When tissue was stored at -20°C in a solution composed of sucrose buffer 
(0.25M sucrose, 1.5 mM Mg Cl^» 10 mM HEPES, pH 7.4)/50% glycerol (v:v), 
which did not permit freezing of the material, no apparent adverse effect 
on the receptors was noted. This latter method was adopted for storage 
of all types of receptor-containing tissue where necessary, as it was 
judged less harmful than any other storage regime.
To assess the time period over which receptor viability could be maintained 
under these conditions, a large piece of breast tumour (approximately 750 mg) 
was divided into several portions of approximately 150 mg each. The 
oestrogen receptor content of these was assayed after various lengths of 
storage. Table 1 demonstrates that the receptors, when tissue was retained 
in this storage solution, were stable for up to three weeks. However, the 
results in Table 1 may be fortuitously good, as variation in receptor content 
across tissue can occur (see Section 3.2.1). Rat uteri stored in this way 
have been found to contain functional receptor after up to six months.
Breast tissue might also be stored for this length of time if necessary, 
although full investigation of the effects of long-term storage on this 
tissue has not been carried out (preliminary results from our laboratory 
show that receptor was stable in stored breast tumour tissue for up to 
three months).
Storage in solid CO^ and lyophilization of material have been found to 
maintain oestrogen receptor presence (see section 3.3). These processes
Table 1 Oestrogen Receptor Content of Breast Tumour
Tissue Stored Under Sucrose Buffer (0.25 M 
Sucrose, 1.5 mM MgClp, 10 mM HEPES, pH 7.4)/
50% Glycerol (v/v) for Varying Lengths of Time
A large piece of breast tumour tissue was 
divided into portions of approximately 150 mg.
The oestrogen receptor content of one portion 
was determined immediately as described in the 
methods section. The other slices were stored 
in sucrose buffer/50% glycerol (v/v) at -20°C 
for varying lengths of time before rehydration at 
0°C in sucrose buffer, followed by oestrogen 
receptor determination as for the fresh portion.
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.Time of storage 
(Days)
Oestrogen receptor level 
(fmol /mg cytosol protein)
0 396
9 316
14 421
18 400
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do not interfere with receptor binding to oestradiol, thus permitting 
measurement of the receptor level. However, whether the receptor remains 
functional after such treatment has still to be determined. The effects 
of storage of tissue in liquid nitrogen on oestrogen receptor levels have 
not been investigated fully. This form, followed by pulverization, is 
used by many workers for the preparation of tissue fractions. However, 
samples of breast tumour tissue stored in this way have often yielded a 
high level of cytosol receptors, while no nuclear binding could be detected. 
This method of storage, like freezing in buffer at low temperatures, thus 
has a selective deleterious effect on the nuclear receptors, emphasising 
that they may be less stable than the cytoplasmic form (see section 3.1.3.1).
3.1.2 TISSUE FRACTIONATION
The method used to prepare cytosol and nuclear fractions from all types of 
tissue handled was as detailed in section 2.2.1.3. As stated therein, the 
fractions prepared are crude in nature, but, as noted also by McGuire 
et al., (1977c) when preparing breast tumour cytosol for oestrogen receptor 
analysis, no purification process significantly enhanced the yield of 
receptors. In this project, this was found to be the case for both cytosol 
and nuclear fractions. . In addition to purification attempts, studies were 
also carried out to ensure that oestradiol binding observed in the nuclear 
fraction represents a separate nuclear receptor and does not merely reflect 
an insufficient degree of washing the nuclear pellet, leading to contamina­
tion of a cytoplasmic origin. To establish this, human breast tumour tissue 
was homogenised and centrifuged as described in section 2.2.1.3 to produce 
a cytoplasmic fraction and nuclear pellet. The pellet was split into two 
equal portions at this point and washed with either saline or Triton X-100
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(0.1% in homogenisation buffer). The Triton X-100 should remove any 
cytoplasmic material from the nuclear pellet.
The results in Figure 6 show that the use of this detergent has slightly 
decreased the level of receptors in the nuclear fraction, as determined 
by Scatchard plot analysis. It is also clear, however, that the dissocia­
tion constants of binding, which are derived from the slopes of the lines 
(see Section 2.2.4), are virtually identical. From the very small 
difference in receptor level made by the inclusion of a detergent wash, 
and from the finding that, in some tissue, receptor is detected exclusively 
in the nuclear fraction (see section 3.4.1), it is clear that there is in 
fact a separate nuclear receptor for oestradiol. The satisfactory abolish­
ment of cytoplasmic material from the nuclear fraction is also demonstrated, 
emphasising the acceptability of the method of preparation. Thus, a step 
incorporating a Triton X-100 wash of the nuclear pellet to remove any 
residual material of non-nuclear origin could be added to the standard pro­
cedure for the fractionation of tissue, although little effect on the level 
of nuclear receptors would result.
The presence of a thiol reagent during the preparation of tissue fractions 
is required to protect the sulphydryl groups reported to participate in the 
interaction between receptor and oestradiol (Jensen et al., 1967, Muldoon, 
1971). McGuire & De La Gar.za (1973b) found that the thiol reagent di­
thiothreitol (DTT) was satisfactory for this purpose, 8S receptor being 
completely lost in its absence at all temperatures and still very labile 
at high temperatures even in its presence. In my experience, DTT success­
fully maintained the integrity of receptors in rat uterine and human breast 
and endometrial tumour tissue at 0°, 4°, 15° and 20°C for up to 24 hours,
Figure 6 - Effect of Washing with Triton X-100 on Nuclear Receptor Level
The nuclear pellet of breast tumour tissue was prepared as 
in Section 2.2.1.3. Before resuspension, it was washed 
with either 0.1% Triton X-100 (□"[Zl) saline ( # - # ) .  
Nuclear suspensions were formed from each pellet, and 
the receptor concentration in them determined by Scatchard 
analysis.
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and for a short time at 37°C. Keightley et al,, (1978), however, have 
subsequently found no difference in binding characteristics with or without 
DTT in studies on myométrial receptor.
Failure to detect oestrogen receptors in human colonic carcinoma tissue 
(see Section 3.4.7) was thought possibly to reflect some inadequacy of DTT 
not previously encountered. A comparison was drawn, therefore, between 
the efficacy in colonic tissue of 0.25 MM DTT and 10 mM monothioglycerol, 
another thiol agent. Figure 7 shows a representative result of such a 
comparison. Neither agent is successful in producing a Scatchard plot, 
which would suggest the fault lies not in the thiol reagent employed, but 
in the receptor deficiency of the tissue. 0.25 mM DTT and 10 mM mono­
thioglycerol were equally effective in protection of the receptor in breast 
tissue. DTT was preferred due to ease of handling. This concentration of 
DTT (0.25 mM) is high enough to protect the receptor without interfering in 
the determination of the cytoplasmic protein content.
Another necessary constituent of the homogenisation buffer was ethylenediamine* 
tetracetic acid (EDTA). This was found to be essential, especially where 
nuclear binding was being measured, as the nuclear receptor appeared to be
inhibited by the presence of magnesium and calcium ions. EDTA has been
reported to be harmful to cellular organelles (Wittliff, 1975), but this
does not appear to effect the system under study here.
A further consideration in the preparation of tissue fractions was the 
selection of the type of homogeniser for the fractionation process. Initial, 
rough chopping of the tissue was carried out using anUltra-turrax homogeniser.
Figure 7 - Comparison of DTT (0.25 mM) and Monothioglycerol (10 mM)
Effectiveness in Detection of Oestrogen Binding in Biopsies 
from Human Colonic Carcinoma Tissue
Colonic carcinoma tissue was homogenised in HEPES-EDTA 
buffer, pH 7.4, containing either 0.25 mM DTT (0) or 10 mM 
monothioglycerol (•). Cytoplasmic and nuclear fractions 
were prepared as described in Section 2.2.1,3, and their 
receptor content determined by Scatchard analysis.
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but further, finer homogenisation was then required to produce an even 
homogenate. The two types of homogeniser available comprise a glass tube 
with either a ground glass or teflon-coated pestle. Experiments carried 
out on different tissue types comparing the two forms of homogeniser showed 
little difference in human colonic or endometrial tissue or rat uterine 
tissue, but with human breast tumour tissue, the yield of receptors was 
greatly depleted after teflon/glass homogenisation^ in agreement with a 
finding reported by Wittliff (1975) . Consequently, glass/glass homo­
genisation was used with all types of tissue prior to receptor measurement, 
although teflon/glass homogenisation yielded a better endometrial nuclear 
preparation, as determined by histological examination.
3.1.3 BINDING OF STEROID TO RECEPTORS
In order to construct a system where the maximum binding of oestradiol 
would occur, and thus the most accurate measure of receptor content result, 
the optimal values for the time, temperature and range of oestradiol 
concentrations were required.
3.1.3,1 Time and Temperature
The thermolabile nature of the receptors and the stability of the hormone/ 
receptor complex were investigated in a series of experiments in which either 
the uptake or displacement of labelled oestradiol was measured at different 
temperatures, over various lengths of time. Figure 8 shows the uptake of 
labelled steroid into the uterine nuclear fraction of a mature rat 
sacrificed on the day of pro-oestrous, when receptor content is thought to 
be at its highest although some controversy surrounds this timing, as 
discussed in the Introduction. A clear contrast can be seen between the
3
Figure 8 - Uptake of H-0estradiol-17g into the Nuclear Fraction of
Mature Rat Uterus
Nuclear suspension from a mature rat uterus was prepared as
, 3
in Section 2.2.1.3. Aliquots were incubated with' H- 
oestradiol-173 (10 ^ M) at 0*^ C (0— 0), 20°C ( ^ “ ^) and 
37°C ( O — Q), Samples were removed at various time points, 
applied to GFC filter discs, and unbound steroid removed by- 
washing, as described in Section 2.2.3.2,
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situation at 37^C compared to 20°C and O^C, At 37°C there is a rapid 
initial uptake of oestradiol into the nuclear fraction, which then appears 
to decline gradually. At the lower temperatures, there is a much more 
gradual uptake of label to a level which is maintained for up to 6 hours.
The same experiment was carried out on the nuclear fraction of human 
breast tumour tissue (see Figure 9). In this case,the instability of the 
receptor at 37°C is even more pronounced, with the same rapid uptake 
observed in the rat tissue being followed by a dramatic fall, presumably 
due to receptor degradation. At the lower temperatures of 4°C and 15°C, 
the receptor was stable for as long as 24 hours.
Figure 9 illustrates the situation in the nuclear fraction of tissue from 
a postmenopausal patient. When the same experiment was carried out on 
tissue from a premenopausal patient, a clearly different result was obtained, 
as shown in Figure 10. The receptor in the nuclear fraction of the pre­
menopausal patient’s tissue appears to be much more stable at 37°C than
3
was that from the postmenopausal example. The rapid uptake of H- 
oestradiol into the nuclear fraction is similar in both cases, but the pre­
menopausal level rises to a maximum higher than that obtained at 4^C or 
15°C and is maintained at this value, even up to 24 hours. This suggests 
that the receptor is much more stable in the highly active situation found 
in a premenopausal woman, where circulating levels of oestrogen are high.
This could also account for the intermediate level of resistance to heat 
found in the receptors of the uterine nuclear fraction from a cycling rat.
The study was carried out on only one premenopausal patient, however, due 
to the scarcity of large biopsies of premenopausal tissue containing 
receptors. It is realised that variation could occur between individuals,
3
Figure 9 - Uptake of H-0estradiol"17g into the Nuclear Fraction of
Postmenopausal Breast Tumour Tissue
Nuclear suspension was prepared from breast tumour tissue
of a postmenopausal patient as described in Section 2,2,1,3.
3
Aliquots of the suspension were incubated with H-oestradiol-
17S do"® M) at 4°C (0 - 0), 15°C ( À - À )  and 37°C-(A-À)-
Samples were removed at various time points, applied to GFC
filter discs, and unbound steroid removed by washing as
described in Section 2.2.3.2, The insert shows the Scatchard
plot of nuclear binding, which yielded a receptor concentration
"1 0
of 2560 fmol/mg DNA and a Kd of 1.1 x 10 M.
so
o
ê
3
Figure 10 - Uptake of H-Oestradiol-173 into the Nuclear Fraction.
of Premenopausal Breast Tumour Tissue
Nuclear suspension was prepared from breast tumour tissue 
of a premenopausal patient as described in Section 2.2.1.3.
3
Aliquots of the suspension were incubated with H-oestradiol- 
173 (10"9 M) at 4°C ( 0 - 0 ) ,  15°C (A- Â) and 37°C (£^-A). 
Samples were removed at various time points, applied to 
GFC filter discs, and unbound steroid removed by washing 
as described in Section 2.2.3,2
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and the results shown in Figure 10 may reflect an atypical situation.
Further investigation may serve to confirm the increased stability of the 
premenopausal receptor, or may reveal the existence of variability from 
one patient to another.
The situation in the cytoplasmic fraction of human breast tumour tissue 
was also investigated. Cytosol was prepared from a receptor-positive
3
breast tumour from a postmenopausal patient. The uptake of H-oestradiol 
into the cytosol was measured at 4°C, 15°C and 37°C as shown in Figure 11.
As with the postmenopausal nuclear fraction, the uptake declines rapidly 
at 37°C, but is maintained at the lower temperatures for up to ,24 hours, 
again reflecting the instability of the binding at the elevated temperature.
It has been suggested that any assay conditions which have been described 
for the detection of cytosol oestrogen receptors could measure only 
"unfilled'* sites, and not those bound to ligand. It is considered that these 
unfilled receptors would be less common in the cycling female, and this has 
been used as an explanation for the lower levels of receptor found in the 
cytoplasm of premenopausal, as opposed to postmenopausal, breast tumour 
tissue (see Section 3.4,6) (Sakai & Saez, 1976). It has been proposed that 
circulating levels of oestradiol should be taken into account when measuring 
cytosol receptor because of this (Mobbs & Johnson, 1976, Nagai et al., 1979), 
although results obtained here suggest that this would be of no great value 
(see Section 3.4.5.5.). However, Korenman & Dukes (1970), Feherty et al., 
(1971) and Liskowski & Rose (1976) all argue that, using a dextran-coated 
charcoal method similar to that used in this project, all cytoplasmic sites 
are measured, and that this proposal is invalid. There is also opposition
3
Figure 11 - Uptake of H-Qestradiol-173 into the Cytosol Fraction of
Postmenopausal Breast Tumour Tissue
A cytoplasmic preparation was made from breast tumour tissue
of a postmenopausal patient as described in Section 2,2.1.3,
3 “9
Aliquots were incubated with H-oestradiol-173 (10 M) at
4°C ( 0 - 0 ) ,  15°C (A - A )  and 37°C ( A - A ) .  Samples were
taken at various time points, and unbound steroid removed
by adsorption on to dextran-coated charcoal, as described
in Section 2,2.3.2. The insert shows the Scatchard plot
of cytoplasmic binding, which yielded a receptor concentration
“10
of 63 fmol/mg cytosol protein and a Kd of 0,99 x 10 M.
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to the idea that "filled" nuclear receptors are being measured by an 
exchange technique similar to that of Anderson et al., (1972) at low 
temperatures of 0°C or 4°C. Katzenellenbogen et al., (1973) stated 
that the exchange rate at these low temperatures is very little in uteri 
of immature rats. Following this, unfilled nuclear receptors were 
discovered firstly in MCF7 cells (Garola & McGuire, 1977a) and then in 
breast tumour tissue (Panko & MacLeod, 1978, Kato et al., 1978, Thorsen, 1979). 
On the basis of this, the concept suggested for cytosol binding by 
Chamness et al., (1975) that incubation at 0°C or 4°C caused filling of 
empty receptors, while exchange occurred only at 30°C is now proposed 
to hold true for nuclear binding also (Garola & McGuire, 1977a, Panko & 
MacLeod, 1978, Thorsen, 1979). However, the salt extraction of the 
receptors employed in these studies may alter their properties relative to 
those displayed when the receptor is bound to chromatin.
In order to clarify the situation as to whether exchange is possible during
incubation at different temperatures, a further group of experiments was
3designed which measured the dissociation of H-oestradiol from both cytosol 
and nuclear fractions of breast tumour tissue in the presence of excess 
unlabelled steroid. Cytosol and nuclear fractions were prepared as
-9 3
described in section 2.2.1.3 and incubated with 2 x 10 M H-oestradiol, 
the cytosol at 0°C and the nuclear at 37°C both for 30 minutes in order 
to fill all the receptor sites. Unbound steroid was then removed, either 
by the action of dextran-coated charcoal stripping or by washing; for the
cytosol and nuclear fraction respectively. Incubation of the fractions
"7 « 0was then carried out in the presence of 10 M unlabelled oestradiol at 4 C
and 20°C, and the dissociation of labelled steroid measured by the amount 
of activity remaining in aliquots sampled at various times.
The result of such an experiment-performed on the nuclear fraction of post­
menopausal breast tumour tissue is shown in Figure 12. Both at 4°C and 
20°C, considerable exchange of the unlabelled for labelled steroid has 
occurred. The same situation is observed when the experiment is performed 
on the cytoplasmic fraction of the same tissue (Figure 13). Again, much 
exchange of the unlabelled for labelled oestradiol occurs at both temperatures 
That this is exchange rather than heat or protease digestion of the receptor 
can be demonstrated by the fact that the same concentration of receptors is
recoverable in each fraction by a second exchange at the end of 24 hours.
3
Figure 14 shows a comparison of the displacement of H-oestradiol by
unlabelled oestradiol in the two tissue fractions at 4^C or 20°C. At each
temperature, approximately the same amount of interaction occurs in both
fractions. However, slightly more displacement occurs at 20°C than at 4°C
and, by 2 hours the level of exchange at 20°C is as high as it reaches
within 24 hours at 4°C, although this is only 80%. This observation could
be of value in designing a more rapid method of assaying oestrogen receptor
content. It has been confirmed by comparing the Scatchard plots obtained
after incubation of cytosol and nuclear fractions from breast tumour tissue
with oestradiol at 20°C for 2 hours and at 4°C for 18 hours. These findings
are also consistent with those obtained from immature rat uterine cytosol
“9which was preincubated with 10 M unlabelled oestradiol and then incubated 
3
with H-steroid as above. The resultant Scatchard plots are shown in 
Figure 15. Virtually no difference in receptor level or dissociation 
constant of binding can be seen between the two situations.
The results from this set of experiments confirm that exchange of added for 
bound steroid may occur in both the cytoplasmic and nuclear fractions of
3
Figure 12 - Dissociation of H-Oestradiol-173 from the Nuclear
Fraction of Breast Tumour Tissue in the Presence of 
Excess Unlabelled Oestradiol at 4°C and 20°C
Nuclear suspension was prepared from breast tumour
tissue as described in Section 2.2.1.3. Preincubation
3 . ”9
was carried out in H-oestradiol~173 (2 x 10 M) at
37^0 for 30 minutes, followed by removal of unbound 
material by washing in HED buffer. Aliquots wer,e then
é —7
incubated with unlabelled oestradiol-173 (10 M) at 
4°C (X - X) and 20°C ( □ - □ ) .  Samples were removed 
at various time intervals, applied to GFC filter discs, 
and unbound steroid washed away as described in 
Section 2.2.3.2. The activity remaining at each time 
point was expressed as a percentage of the initial value.
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Figure 13 - Dissociation of H-Oestradiol-173 from the Cytosol
Fraction of Breast Tumour Tissue in the Presence of 
Excess Unlabelled Oestradiol at 4°C and 20°C
Cytosol was prepared from breast tumour tissue as 
described in Section 2,2.1.3. Preincubation was 
carried out in ^H-oestradiol-176 (2 x 10  ^M) at 0°C 
for 30 minutes, followed by removal of unbound 
steroid by dextran-coated charcoal stripping as 
described in Section 2.2.3.2. Aliquots were then
-7
incubated with unlabelled oestradiol-17$ (10 M) at 
4°C (X - X) and 20°C (O - o ) . Samples were removed 
at various times, and any unbound steroid adsorbed 
on to dextran-coated charcoal as before. The activity 
remaining at each time point was expressed as a 
percentage of the initial value.
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Figure 14 - Comparison of Dissociation of H-Oestradiol-176 from
the Cytosol and Nuclear Fractions of Breast Tumour 
Tissue in the Presence of Excess Unlabelled Oestradiol 
at 4°C and 20°C.
Breast tumour tissue was fractionated by the procedure
described in Section 2.2.1.3. The cytoplasmic and
3
nuclear fractions were then preincubated with H- 
oestradiol-173 (2 x 10  ^M) for 30 minutes at 0°C and 
37°C respectively, followed by removal of unbound steroid 
by dextran-coated charcoal stripping of the cytosol or 
washing of the nuclear fraction. Aliquots of each were
« ^ V Q
incubated with unlabelled oestradiol (10 M) at 4 C and 
20°C. Samples were removed at various time intervals 
and unbound steroid removed by the methods described in 
Section 2.2.3.2. Dissociation, in each case, was
expressed as percentage of initial activity. A  ▲ represents
dissociation from the cytosol at 4°C, X - X that from the
nuclear fraction at 4°C,1-— Bthat from the cytosol at
o o
20 C and 0 - 0  that from the nuclear fraction at 20 C.
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Figure 15 - Comparison of Scatchard Analysis of ,H-Oestradiol-176
Binding at 4°C and 20°C to Rat Uterine Cytosol Pre- 
incubated with Unlabelled Oestradiol
Cytoplasmic fraction from immature rat uterus was 
prepared as described in Section 2,2,1.3. Pre- ,
incubation was carried out with unlabelled oestradiol-
—•Q O
17B (2 X 10 M) at 0 C for 30 minutes, and unbound
steroid removed by dextran-coated charcoal stripping.
3
The cytosol was then incubated with a range of H-
« a ”10 ”9
oestradiol-173 concentrations from 10 M - 10 M
at 4^C for 18 hours (X. - X) and 20°C for 2 hours ( O - o ) .
Unbound labelled steroid was removed as described in 
Section 2.2.3.2, and the receptor concentration deter­
mined by Scatchard analysis.
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breast tumour tissue at 4°C, although slightly less than at the higher 
temperature of 20^C. This, in turn, suggests that during the assay of 
cytoplasmic and nuclear receptors in breast tumour tissue, at low 
temperature total receptor concentration is determined, and not merely 
the level of "unfilled" sites. However, the possibility remains that 
a. small proportion of total filled sites remains unexchanged after 18 hours 
at 4^C. A further observation which can be made is that, in the case of 
postmenopausal breast tissue at least, no alteration in stability of the 
hormone/receptor complex results from its binding to nuclear acceptor sites.
For standard measurement of oestrogen receptors in breast tumour tissue,
3
it was concluded that incubation with H-oestradiol should be carried out 
at either 4°C for at least 18 hours or 20^C for 2 hours. Both of these 
times give only 80% exchange of added oestradiol for any endogenous 
oestradiol, but careful observance of these conditions on a routine basis 
will ensure that the same amount of exchange can occur on each occasion.
As observed by Hawkins et al., (1975), the use of these lower temperatures 
is advisable, because, as demonstrated in the experiments on the uptake of 
^H-oestradiol, at 37°C, equilibrium is not properly established before 
receptor degradation commences.
3.1.3.2 Range of Oestradiol Concentrations
To determine the most suitable range of oestradiol concentrations for the 
detection of oestrogen receptors, Scatchard plots were constructed from the
results of binding experiments using wide ranges centred about the value of
***1-0 « ^
2 X 10 M, which represents the circulating level of oestrogens in the
human body. Figure 16 shows a representative example of such a plot,
-11 -9 3The range used here is 5 x 10 M - 4 x 10 M H-oestradiol. The best
Figure 16 - Scatchard Flot of Results Obtained from an Oestrogen
Receptor Assay Carried Out on Breast Tumour Cytosol 
3
Using a Range of H-0estradiol-17g Concentratiors'of
-11 -g
5 X  10 M - 4 X  10 ^ M.
Receptor analysis was carried out on the cytosol
of a breast tumour biopsy, adopting the procedure
3summarised in Figure 19. H-oestradiol-l?^ was added
« * ""11 ""9 *
in concentrations from 5 x 10 M to 4 x 10 M in
order to assess the optimal range for receptor detection. 
Scatchard analysis was performed on the results obtained, 
and a plot constructed.
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range of concentrations can be chosen from the sloping part of the graph.
At the end of the plot nearest to the origin, the concentrations are too 
low to detect all the receptor present. Chamness & McGuire (1975) have 
suggested that there is also more chance of receptor degradation when the 
concentration of ligand is low, accounting for the apparent decrease in 
binding. At the other end of the range, the concentrations used more than 
saturate the amount of receptor present, and the line levels off due to the 
introduction of non-specific, or low affinity, binding as observed also by 
McGuire (1975). The optimal range for the measurement of oestrogen 
receptors thus lies in the mid-part, and expansion of this part should give
a more meaningful plot. From these studies, oestradiol in the range
—10 ~9 , ^
10 M - 10 M was chosen as being most effective in the detection of
oestrogen receptors from all tissue types examined.
3.1.3.3 Determination of Specificity
In order to ensure that the binding demonstrated in these assays is due to 
specific oestradiol receptor, not only should a Scatchard plot be constructed 
to enable determination of the dissociation constant of the interaction, but 
also the specificity for oestrogen binding should be checked. Specific 
binding is, by definition, saturable by physiological levels of steroid. 
Non-specific binding, however, is unsaturable at these concentrations.
To determine which kind of binding is present, or what percentage of 
binding is specific, the incubation of both tissue fractions with labelled 
oestradiol should be set up in duplicate with an excess of an unlabelled 
oestrogen added to one set of incubations. Since the unlabelled steroid 
is in excess, this should fill the majority of the saturable specific 
sites, and any labelled oestradiol bound would then represent non-specific 
binding. By comparison of the bound activity in the presence and absence
85 -
of excess unlabelled steroid, the level of specific oestrogen receptors 
could be measured.
This operation was carried out using as competitors both unlabelled
oestradiol-176 and the synthetic oestrogen, diethylstilboestrol (DES).
The advantages of using the latter oestrogen is that it will not interact
with non-cellular binding proteins such as sex hormone binding globulin
(SHBG) (King & Mainwaring, 1974), and so the presence of these substances
can be detected. The use of unlabelled oestradiol as the competitor
would not be effective in this respect, as it would bind to SHBG as readily 
3
as H-oestradiol. The role of plasma proteins as a source of erroneous 
results has been widely recognised, and alternative competitors have been 
suggested. These include another synthetic oestrogen (R2858) (Okret 
et al., 1978), and 5a-dihydrotestosterone (Ratajczak & HUhnel, 1976, 
nHhnel & Twaddle, 1979), but DES appears to perform equally efficiently 
as either of these. Hhhnel & Twaddle (1979) also suggested that the 
influence of SHBG would never be so great as to change the classification 
of tissue from receptor-negative to -positive, which has been partially 
confirmed by studies carried out here, comparing the level of receptor using 
either excess unlabelled oestradiol-17g or diethylstilboestrol as competitor, 
It was found that, in the nuclear fraction, no difference was encountered 
using either competitor, although a small difference was found in levels 
of receptor detected in the cytoplasmic fraction using these two competitors, 
This difference was sufficiently small to discount concern about the con­
tamination of cytoplasmic preparations by plasma proteins. This con­
clusion holds for breast tissue, but may not be true for other types of 
tissue of a more sanguineous nature, such as colonic carcinoma, Due to this 
fact, it is advisable that DES, rather than oestradiol, should be used as
— 86 —
cold competitor with all tissue types.
In order to assess the amount of competition required, assays were carried
out on breast tumour cytosol and nuclear fractions using 100-fold excess
3of DES at all concentrations of H-oestradiol. It was found that the use
3 -9
of competitor at only the highest concentration of H-oestradiol (10 M)
was just as effective in determining the specificity of binding as adding
it at every concentration, and this system was adopted routinely although
for an exact, quantitative study, competition at each concentration should
be used. A comparison was made also between 100- and 1000-fold excess
competitor, but the higher level did not increase the efficiency of the
determination.
3.1.3.4 Protease Activity
A further consideration in the maintenance of the receptor during binding 
studies is the possibility of attack by proteases. The presence of these 
enzymes would cause the receptor content of the tissue to be underestimated. 
Proteases were found to interfere particularly with an assay system for 
nuclear receptors using protamine sulphate precipitation (Zava et al., 1976). 
For this reason, the assay system was altered, and the protease inhibitor 
Trasylol included (Garola & McGuire, 1977b), although the original method 
may have been invalid since salt extraction of nuclear receptors was used. 
Clark & Peck (1976) reported that it is the nuclear receptors resistant to 
KCl extraction which are important in long-term responses to oestrogens.
To determine the effect of proteases on the receptor level in either the 
cytoplasmic or nuclear fraction of breast tumour tissue in the present system, 
studies were carried out on the uptake of H-oestradiol into these fractions 
in the presence and absence of the protease inhibitors phenylmethylsulphonyl-
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fluoride (PMSF) (ImM) and Trasylol (5000 units/ml), either alone or in 
combination. The results of one such study are shown in Figure 17.
The level of uptake of labelled steroid with or without these agents is 
not significantly different in either tissue fraction. Thus, no one 
regime used here could be said to give an increase in the amount of 
steroid bound by either the cytosol or nuclear fraction of breast tumour 
tissue. The binding properties of these fractions are not being effected 
adversely by proteases, and the use of protease inhibitors is probably not 
required in this assay system.
3.1.4 SEPARATION OF UNBOUND FROM BOUND OESTRADIOL
After incubation of labelled oestradiol with tissue fractions, the unbound 
steroid must be separated from the bound in order to determine the amount 
of binding which has occurred during the interaction of receptors with 
oestradiol. Due to the different nature of the cytoplasmic and nuclear 
fractions, different methods had to be employed to achieve removal of 
unbound material in each case.
3.1.4.1 Cytoplasmic Fraction
In initial attempts to separate unbound oestradiol, Sephadex G25 chromatography 
was used in the case of the cytoplasmic fraction. This method required 
much supervision, as four-drop fractions were counted into scintillation 
vials, and the columns had to be recharged by washing before another sample 
could be applied to them. A simpler and quicker method was found to be 
adsorption of the unbound steroid by dextran-coated charcoal (DCC), Steroid 
not involved in receptor interaction can be adsorbed by the charcoal, being 
able to penetrate the dextran coating (Nugent & Mayes, 1966). DCC has the
3
Figure 17 - Uptake of H-0estradiol-17g into the Cytosol and
Nuclear Fractions of Breast Tumour Tissue in the 
Presence or Absence of PMSF (1 mM) or Trasylol 
(5,000 units/ml)
Cytosol and nuclear fractions of breast tumour tissue 
were prepared as described in Section 2.2.1.3, but at 
twice the normal concentration. Each was divided 
into aliquots which were diluted 1:1 with HEPES-EDTA 
buffer (# - #), Trasylol (10,000 units/ml) ( ■ - ■ ) ,
PMSF (2 mM) ( A - A )  or Trasylol (10,:000 units/ml) +
3
PMSF ( 2 mM) ( □ “ □), and incubated with H-oestradiol-
O176 (10 M) at 20 C, Samples were removed from each 
at various time intervals, unbound steroid removed as 
described in Section 2.2.3.2 and the uptake of oestradiol 
recorded. The upper group of lines refers to the 
cytosplasmic and the lower one to the nuclear fraction.
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additional advantage that it will strip steroid from loose binding inter­
actions, and thus decrease the level of low affinity binding. The use 
of DCC has subsequently been criticized, however, as having an unacceptably 
high sensitivity level and requiring too much tissue (Hazato et al., 1979). 
This was not found to be the case here, where as little as 5 fmol/mg protein 
of receptor could be detected reproducibly and the aspect of the assay 
system limited by the supply of tissue was simply the range of oestradiol 
concentrations which could be used to construct the Scatchard plot (see 
Section 3.3).
A comparison was drawn between results obtained using Sephadex chromatography 
and dextran-coated charcoal to separate bound and unbound steroid. This 
determined that the level of binding detected by the two methods was 
virtually identical. Due to the ease of operation with the charcoal 
stripping method, this was preferred to Sephadex chromatography.
Agargel electrophoresis has been reported to be very useful in this context, 
as it also separates plasma proteins from receptors (Wagner, 1972, Hawkins 
et al., 1975), but the workers involved have returned to the DCC method. 
Polyacrylamide gel electrophoresis was also suggested as an alternative 
(Ritzen et al., 1974), but, like the agargel form, the method is much more 
complicated than the use of DCC.
The concentration of charcoal reported as being most efficient in removing
unbound steroid from solution varies, (Korenman, 1968, Katzenellenbogen
et al.; 1973, Hawkins et al., 1975) and so this concentration along with the
proportion (v:v) to use in order to achieve maximum stripping, were
3
investigated. Solutions of H-oestradiol in buffer were prepared at
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concentrations of 10 M, 10 M and 10 M. Aliquots were then incubated
with varying amounts of either 0.25% or 0.15% DCC (w:v) suspended in a 
sucrose-containing buffer. Figure 18 shows the relative efficiencies 
of these two DCC suspensions in removing the oestradiol. One point 
illustrated in Figure 18 is how easily a piece of contaminated charcoal 
can be disturbed and picked up during the aliquotting of the charcoal 
stripped supernatant. A large error can result from this, as shown in 
the graph demonstrating the efficiency of 0.15% DCC. Great care must be 
taken to ensure that the charcoal pellet is not disturbed, and that any 
fine pieces of charcoal floating on top of the supernatant are not trans­
ferred to the scintillation vial along with the liquid. Both concentrations 
of DCC in Figure 18 appear equally efficacious in the removal of free steroid, 
with 0.5 - 1 volumes giving maximum effect. This information was then used 
in preparing the most efficient assay system for oestrogen receptors (see 
Figure 19).
3.1.4.2 Nuclear Fraction
Once the charcoal had adsorbed the unbound steroid in the cytoplasmic 
incubation mix,it could be centrifuged down, and in this way removed from 
solution. This method could not be employed with the nuclear fraction, 
however, since it is in the form of a suspension of nuclear material.
Instead, the method used was to trap the particles of nuclear material on 
a filter paper and wash away any unbound steroid under suction. Glass 
fibre filter discs were preferred to paper ones for this purpose, as they 
collected the nuclear material more efficiently, while not retaining any 
unbound steroid after washing with 15 ml of saline.
Once the material had been applied to the filter and washed, the filters
Figure 18 - Comparison of the Efficiencies of Two Concentrations
of Dextran-Coated Charcoal (DCC) in Adsorbing Free 
Oestradiol-173
3H-oestradiol-173 was prepared at concentrations of 
lo'lO ^ ( • - • ) ,  10*9 M ( A - A )  and lo"® M ( 0 - 0 )  in 
HED buffer. To aliquots of each of these were added 
various volumes of dextran-coated charcoal (0.15% or 
0.25%). 0.15% DCC was prepared by equilibrating
charcoal (0.15% w/v) with Dextran T-70 (0.0015% w/v) 
in 0.25 M sucrose, l.SmMMEDTA, 10 mM HEPES (pH 7.4), 
0.25% DCC was prepared in the same way, using 
corresponding amounts of charcoal and Dextran T-70. 
Incubation of steroid with DCC was carried out for 30 
minutes at 0°C with shaking, followed by centrifugation 
at 1000 g for 5 minutes. The amount of oestradiol not 
adsorbed was determined by the radioactivity remaining 
in solution.
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Figure 19 - Assay System for the Determination of Oestrogen
Receptor Levels
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Tissue Biopsy 
Specimen
Fresh or 
Stored at -20^C 
in Sucrose/Glycerol
Cut Section and Remove Fat
Homogenise in Hepes-EDTA-DTT (pH 7.4)
Centrifuge at 
5,000g
Supernatant
i
*  Incubate at 20 C for 2 hours 
or Overnight at 4 C with
^H-Eg +DES
I
Treat with DCC
j
Construct Scatchard Plot
Pellet
j
Homogenise in 0.1% Triton x 100 
and wash 2x in 0.9% NaCl
j* Incubate at 20 C for 2 hours or 
Overnight at 4^C with3H-E« +DES
I
Collect on F ilter
4
Wash with 30 volumes NaCl
IConstruct Scatchard Plot
Incubation in the presence of Trasylol/PM SF (5000 units/m l 
and 100 mM) may give a minor improvement.
“ 93 "
were dried before counting. This was carried out at 60°C for 18 hours, 
although incubation at this temperature for up to 60 hours did not 
diminish the activity. Solubilization of the activity by incubation with 
hyamine hydroxide (IM in methanol) at 60°C for 20 minutes gave no enhance­
ment of the level of activity measured.
Having taken all the considerations described in the preceding sections 
into account, it was possible to construct an assay system for the measure- 
ment of oestrogen receptors, allowing optimal sensitivity whilst having 
potential for routine application. This is summarised in Figure 19.
3.2 REPRODUCIBILITY OF THE OESTROGEN RECEPTOR ASSAY
To examine the reproducibility of results obtained from the receptor assay 
summarised in Figure 19, studies were conducted on the variation of 
receptor content across one piece and within a bulk homogenate preparation 
of breast tumour tissue.
3.2.1 VARIATION ACROSS TISSUE
A piece of breast tumour tissue was sliced into six parallel portions of 
approximately 150 mg each. Separate cytoplasmic and nuclear fractions 
were prepared and oestrogen receptor levels assayed independently in each 
one. The results of this study are shown in Table 2. It can be seen 
that considerable variation in the numerical value of the receptor occurs 
in both the cytoplasmic and nuclear fractions of the tissue. However, 
very little variation in the value of the dissociation constant occurs.
This means that each piece of this tissue assayed here would be pronounced
Table 2 Variation in Oestrogen Receptor Level
and the Dissociation Constant of its 
Binding to Oestradiol-173 in the Cytosol 
and Nuclear Fractions of Six Parallel 
Sections from a Breast Tumour Biopsy
A large piece of breast tumour tissue was 
divided into six parallel slices of 
approximately 150 mg. Each was treated 
as described in Section 2.2.1.3 to yield a 
cytosol and nuclear fraction. The oestrogen 
receptor content and Kd of binding for each 
fraction was determined by Scatchard analysis, 
as described in the methods section.
(R^ - cytoplasmic oestrogen receptor,
R^ - nuclear oestrogen receptor)•
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Slice
No, fmol/mg protein
—lo 
KdCXlO Mi fmol/mg DNA KdCXlO^^^Ml
1 124 0,9 1933 3.8
2 171 1.0 1395 2.0
3 484 1.0 658 2.5
4 146 1.6 658 2.9
5 423 1.0 1778 2.6
6 526 1.2 753 2.7
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receptor-positive, and so the assay conditions used can be said to 
produce reproducible results at a qualitative level. Hawkins et al.,
(1977) state that the receptor variability across a breast tumour is 
very high compared with other tumours, and suggest a requirement for 
replicate sampling, but this does not appear to be necessary with the 
assay system developed in this project, if receptor presence, rather than 
absolute amount, is the parameter sought.
3.2.2 VARIATION WITHIN ONE HOMOGENATE
A large piece of breast tumour tissue (approximately 1 g) was homogenised 
and cytosol and nuclear fractions prepared from the bulk homogenate. These 
fractions were then used to set up six separate oestrogen receptor assays 
from each. The results of this study are shown in Table 3. Here, the 
variation in receptor level is small ("v± 20%) for both cytoplasmic and 
nuclear fractions. In common with the results presented in Table 2, very 
little variation in the dissociation constant value occurs. This is 
further evidence, therefore, that the assay conditions produce reproducible 
results.
3.3. QUALITY CONTROL OF 'THE RECEPTOR ASSAY SYSTEM
In order to assess the assay systems being used by various workers throughout 
the country for the determination of oestrogen receptor levels in breast 
tumour tissue, portions of tissue from the same tumour were frozen in solid 
CO^j and despatched to the appropriate groups for receptor measurement by 
their own methods. In addition to solid tumour samples, some homogenates 
were prepared also, and frozen portions circulated in the same way. The 
findings of this study have been published (King et al., 1978, 1979a), The
Table 3 Variation in Oestrogen Receptor Level and
the Dissociation Constant of its Binding 
to Oestradiol-173 in the Cytosol and 
Nuclear Fractions Prepared from One Bulk 
Homogenate from a Breast Tumour Biopsy
Cytosol and nuclear fractions were 
prepared from a large piece of breast 
tumour tissue (approximately 650 mg) as 
described in Section 2.2.1,3, Each 
fraction was then used to set up six 
parallel assays for oestrogen receptor as 
described in the methods section.
(R^ - cytoplasmic oestrogen receptor,
R^ - nuclear oestrogen receptor).
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Assay
No.
Rn
fmol/mg protein Kd CX10“^°M) fiaol/mg DNA
-10 
KdCXlO M)
1 362 1.2 1442 1.7
2 368 1.3 1695 2.1
3 358 1.4 1305 1.3
4 345 1.2 1137 0.9 '
5 389 1.3 1389 1.2
6 373 1.4
-  V. . ..................
1316 0.9
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assay system established in the course of this project compared favourably 
with those of other workers.
One important observation to emerge from this trial was that one piece of
tumour assayed in this laboratory using full Scatchard analysis was found
to contain specific binding on the grounds of successful competition by DES,
but no high affinity binding could be detected using the criterion of a
linear Scatchard plot. From the evidence provided by the competition data
alone, this tumour would have been pronounced receptor-positive, but, by
the inclusion of incubation with a full range of oestradiol concentrations
and the construction of a Scatchard plot, an abnormality in the receptor
was detected, which renders the tumour unlikely to respond to hormonal
therapy on the grounds of receptor content. This clearly demonstrates the
advantage of constructing a Scatchard plot whenever the supply of material
allows, although this is not a universally accepted conclusion. Johnson
et al., (1975) and Johnson & Nakamura (1977) suggest that it is possible to
obtain as accurate a result by constructing a Scatchard plot bearing only
two points. An error in either of these points, no matter how small, would
tend to change the receptor concentration and the Kd radically using this
method. McGuire et al., (1977c) compared various methods, and determined
3that a single concentration of H-oestradiol with and without unlabelled
competitor was sufficient for accurate receptor measurement, which is
contradicted by the finding reported above. This "single spot" assay was
also favoured by Mobbs & Johnson (1976), except where a very high level of
receptor is involved. Hawkins et al., (1975), however, employed a full Scatchard
3
analysis using seven different concentrations of H-oestradiol (very similar 
to the system established in this project). Slightly more tissue is 
required by the present system (150 mg is needed to construct a Scatchard
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plot and check specificity) than for a one spot assay, but invaluable 
additional information is supplied which is very important in defining 
the exact nature of the steroid binding observed. The need for this extra 
data is emphasised further in studies on oestrogen receptor content of 
colonic carcinoma tissue (section 3.4.7), where a one-spot assay has been 
found to reveal a binding agent, the identity of which is not confirmed 
as a true oestrogen receptor by Scatchard analysis, Chamness & McGuire (1975) 
stressed that caution should be applied to the interpretation of Scatchard 
plot results, as they concluded, in a review on the subject, that many 
errors could, and do, arise from incorrect use of the data.
Another quality control study currently in operation has the added objective 
of assessing the feasibility of storing tissue homogenates in lyophilized 
form prior to oestrogen receptor assay. This has been successfully tried
K^enders et el«, (1978), using a variety of tissue sources. In the present study 
portions of lyophilized material from breast tumour tissue and calf uterus 
have been circulated to workers for oestrogen receptor measurement. Pre­
liminary results from this study confirm the consistency of the assay system 
described in this thesis with those of other workers and also demonstrate 
that lyophilization abolishes neither cytoplasmic nor nuclear oestrogen 
receptor level from either of the two tissue types used,
3.4 OESTROGEN RECEPTORS IN HUMAN TISSUE
For either cytoplasmic or nuclear fraction of any tissue type to be termed 
"oestrogen receptor-positive", three criteria must be satisfied. The 
first of these is that it must be possible to construct a Scatchard plot 
from the results of a receptor assay, which yields an unambiguous straight line.
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Secondly, the Kd value derived from that straight line must be of the order
-10 . , . . -10
of 10 M, in human tissue at least, with values in the range 0,5 - 5 x 10 M
being acceptable. The last condition is that specificity of binding must
be established by competition with excess unlabelled oestradiol-173, or, 
preferably, diethylstilboestrol (see Section 3.1.3.3), If these three 
criteria are met, this should establish beyond any doubt that the binding 
detected is indeed characteristic of cellular, high-affinity, specific 
oestrogen receptor. Receptor can be detected down to a level of 5 fmol/mg 
protein in the cytosol or 25 fmol/mg DNA in the nuclear fraction (equivalent 
to 100 receptor molecules/cell) although the vast majority of receptor- 
containing samples have receptor levels greatly in excess of these figures.
Where the supply of tissue is not great enough (i.e. less than 100 mg) to 
enable a Scatchard plot to be constructed, the first and second of these 
criteria cannot be met, and the third one must be satisfied alone. This is 
not so satisfactory, as explained in section 3,3. In cases where a 
sufficient supply of material is available, and Scatchard analysis thus made 
possible, failure of the binding to satisfy any of the criteria detailed 
above leads to the classification of the tissue as "receptor-negative",
3.4.1 RECEPTOR PROFILES IN BREAST TUMOUR TISSUE
Using the assay system established in sections 3.1 - 3.3, cytoplasmic and 
nuclear oestrogen receptor levels were measured in 1000 samples of mammary 
tumour tissue. This total represents primary and secondary tissue, and 
comes from all age groups of women, of varying menopausal status.
Table 4 shows a summary of cytoplasmic receptor content from these assays.
Table 4 Summary of Cytoplasmic Oestrogen Receptor
Presence in 1000 Biopsies of Breast Tumour
For definition of receptor-"positive" and 
-"negative" see Section 3.4. The 1000 
biopsies include samples of primary and 
secondary disease from both pre- and 
post-menopausal patients.
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Receptor Content No. of Patients Percentage
Positive 461 46
Negative 539 54
- 101
To be classed as "receptor-positive", the tumour cytosol must satisfy the 
criteria detailed above. No "cut-off level" of receptors is set below 
which tissue would be regarded as "receptor-negative". Approximately half 
of the cytosols assayed were found to contain receptor displaying the 
required characteristics. This is approximately the same level of receptor- 
positive biopsies as reported by other workers (e.g. Walt et al., 1976, 
Allegra et al., 1979a), though lower than some (Roberts et al., 1978,
Hawkins, et al., 1979, King et al., 1979b).
Table 5 shows a summary of the receptor patterns which emerged when both 
nuclear and cytoplasmic receptor levels were considered together. The 
majority of biopsies were found to contain no receptor in either fraction, 
while approximately one third of those samples assayed contained receptor 
in both fractions. Using the property of containing both types of receptor, 
rather than a cut-off point for cytosol receptor alone, a lower percentage 
(30%) of potentially responsive patients is identified than in studies using 
cytosol receptor measurement as the only index (e.g. McGuire et al., 1975,
King et al., 1979b, Byar ej[ aJ^., 1979), In the present study, those tumours
containing cytosol, but no nuclear receptor, were initially thought to be 
unlikely to respond to hormone therapy.
The interesting groups in Table 5 are those with receptor in only one 
fraction, no detectable level being present in the other. These represent 
abnormalities in the receptor, which would not have been discovered had 
receptor content been assessed in the cytoplasmic fraction alone. This 
would have led to a possible mistake in the interpretation of the best 
therapeutic regime for these two groups of patients. In the case of 
patients whose tumours contained cytoplasmic, but no nuclear oestrogen
Table 5 Analysis of Cytoplasmic and Nuclear Oestrogen
■Receptors in 1000 Biopsies of Breast Tumour
The presence (+) or absence (o) of both 
cytoplasmic (R^) and nuclear (R^) oestrogen 
receptors are summarised. For definition 
of "positivity" and "negativity" see Section
3.4, The 1000 biopsies include primary and 
secondary samples from both pre- and post­
menopausal patients.
- 102 -
Receptor Content No. of Patients Percentage
+/+ 343 34
o/o 479 48
+/ o 118 12
o/+ 60 6
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receptor, the absence of nuclear receptor suggests that either the 
receptor is abnormal and unable to translocate into the nucleus, or the 
translocation mechanism within the cell is not functioning correctly.
Another explanation could be that the level of circulating oestrogen was 
either very low or completely non-existent, meaning that there was no 
stimulus for the receptor to bind to the chromatin. This is unlikely, 
since the presence of oestradiol is necessary to promote synthesis of its 
own receptor, and cytoplasmic levels would be undetectable also in the 
absence of circulating steroid. There is also direct evidence (see 
Section 3.4.5.5) that circulating oestradiol can be present in such cases.
The first two defects could be caused by malignant transformation of the 
cells. In either event, although oestradiol can be bound within the cell, 
it cannot enter the nucleus, or even cause the receptor to enter the nucleus, 
and thus will not elicit any of the typical cellular responses to hormonal 
stimulation. A patient with such a tumour should, thus, receive no benefit 
from hormone therapy, unless by an indirect pathway. This type of situation 
has also been noted by Thorsen & Stoa (1979), but they found that 25% of 
their samples contained cytoplasmic receptor alone - a higher proportion 
than that reported here (12%),' However, their study was carried out on 
only 16 patients.
To try to elucidate the type of defect present in these cells, tissue with 
detectable oestrogen receptors in the cytosol only was homogenised, the 
cytosol fraction prepared and incubated with unlabelled oestradiol. Unbound 
steroid was removed, and cytosol incubated with nuclear material from 
immature rat uterus or receptor-positive breast tumour tissue. In this 
way, translocation into these normal chromatins could be achieved if the
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receptors were not defective. After incubation between the cytosol and 
nuclear fractions, they were separated again, and Scatchard plot analysis 
carried out on each one to determine whether any change in receptor levels 
had occurred.
Figure 20 shows results from such an experiment. No translocation of 
receptor could be detected in any system, using as the criterion a rise in 
receptor levels. Thus, the fault in these samples containing cytosol 
receptor only may lie with the receptor’s inability to become transformed. 
This experiment was conducted only once with each system, however, due to 
the lack of suitable material, so the conclusions are merely tentative.
The other incidence of abnormal receptor is that where it is found 
exclusively in the nuclear fraction of the tissue. This phenomenon has been 
reported by other workers also (Panko & MacLeod, 1978), but the significance 
of the receptor’s presence in the nucleus is not understood fully as yet.
It is not possible, therefore to predict how such a tumour would respond to 
hormone therapy. It should, however, become possible after observing the 
response of some such tumours which are subjected to hormonal therapy. As 
discussed later (see Section 3.5,1), this approach leads to the suggestion 
that the nuclear receptors are not functional without their cytoplasmic 
counterparts, and the tumours in this group are not likely to respond to 
hormone therapy.
Tissue containing cytoplasmic receptor only was reassessed, examining the 
absolute value of these receptor levels. Histogram 1 shows the comparison 
of cytoplasmic receptor concentrations in 118 such biopsies and 118 samples 
containing receptor at both levels, randomly selected. The majority of 
samples containing no nuclear receptor have cytoplasmic levels lower than
Figure 20 - Measurement of Oestrogen Receptor Levels in Rat Uterine
Nuclear Fraction Before and After Incubation with 
Cytosol from +/o Breast Tumour Tissue
Cytosol was prepared as described in section 2.2,1.3 
from breast tumour tissue (+/o) known to contain 
receptors in the cytoplasmic fraction alone. This was
- Q
incubated with 2 x 10 M unlabelled oestradiol-173
at 0°C for 30 minutes, and then unbound steroid removed
by DCC stripping as described in section 2.2.3.2. The
stripped cytosol was used to resuspend the nuclear pellet
from immature rat uterine pellet, and this suspension
incubated at 37°C for 30 minutes. The nuclear material
was pelleted again, and washed before Scatchard analysis
3
of the receptor content was performed, using H-oestradiol- 
173. The receptor content of the nuclear material before 
(0 “ 0) and after (• - #) incubation with the tumour 
cytosol was compared to determine whether any translocation 
had occurred between the two fractions.
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Histogram 1 - Comparison of the Distribution of Cytoplasmic^
Oestrogen Receptor Levels in +/+ and +/o Breast 
Tumour Biopsies
The levels of cytoplasmic oestrogen receptor were 
compared in the same number of cases of +/+ and +/o 
(shaded) breast tumour tissue.
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30 fmol/mg cytosol protein, the mean value in the case of +/+ biopsies 
being significantly higher than this. However, there are a number of cases 
where +/o values are in excess of 30 fmol/mg cytosol protein, and also some 
+/+ samples with cytoplasmic receptors of a lower level. Thus, a low titre 
of cytosol receptors could not be taken alone as an indication of a tumour^s 
inability to respond to hormonal therapy. Further evidence of this is that 
tumours containing low levels of cytosol receptor, but also nuclear receptors 
have, nonetheless, responded to hormonal manipulation. On this basis, a 
cut-off point for cytosol receptor level, below which no tumour would be 
predicted to respond to hormonal therapy would not be advocated.
The inclusion of both cytoplasmic and nuclear determinations of oestrogen 
receptor levels thus splits breast tumour tissue into four categories. 
Cytoplasmic assay alone would not detect the lack of nuclear binding found 
in some cases, whereas measurement of only nuclear receptors would fail to 
recognise those biopsies exhibiting nuclear binding alone. Together, these 
categories constitute a high enough percentage of total biopsies to make it 
essential that they be identified, as both could lead to application of 
inapplicable therapeutic regimes if they were not fully investigated.
Receptor levels were also determined in some cases of male breast cancer.
This has also been reported by other workers (Leclerq » 1975). It
was found that, as in the female occurrences, the levels of receptor varied 
from tumour to tumour, some containing none at all. The number of male 
biopsies examined was too small to enable any statistically significant con­
clusions to be drawn.
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3.4.2 REPRODUCIBILITY OF OESTROGEN RECEPTOR STATUS FROM ONE LESION 
OF A TUMOUR TO ANOTHER
A very important aspect of the measurement of oestrogen receptors in breast 
tumour tissue is whether the receptor status determined in the primary 
disease will be duplicated in subsequent lesions. This is also of importance 
when considering more than one metastatic site. If the receptor level is 
to be used in the selection of the ideal therapeutic regime for the patient, 
then the knowledge of whether the presence, or indeed absence, of receptors 
is maintained during the transition from primary to secondary disease, and, 
further, will remain consistent in several metastatic lesions is essential.
If these facts could be assumed, then inoperable lesions could be treated 
with the most potentially effective therapy on the basis of the receptor 
status determined in the primary disease or another metastic lesion.
To determine whether this is the case, a comparison was drawn between 
receptor levels found in tissue from the same patient biopsied from different 
lesions. In some cases, this represents a transition from primary to 
secondary disease, while in some, the samples come from different metastatic 
sites. Table 6 shows the results obtained in 32 cases where a primary 
biopsy was followed some time later by a secondary. In 63% of cases, the 
receptor status is the same for both samples, no matter what length of time 
had elapsed between operations. However, there are a significant number of 
instances where the exact receptor status is not reproduced. The loss of 
receptors over time could be understood, since it has been reported that 
hormone-dependent tumours do become autonomous (Kim & Depowski, 1975), although 
the time taken for this process to occur appears to vary. The appearance 
of receptors where none could be detected before is less easily explained.
Table 6 Cytoplasmic and Nuclear Oestrogen Receptor
Status in Biopsies of Primary and Secondary 
Breast Disease from the same Patient
The receptor content of the cytoplasmic (R^) and 
nuclear (R%) fractions of primary breast tumour 
was compared with that of a secondary lesion 
from the same patient. The time interval 
between first diagnosis and recurrence of 
disease was also noted.
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Patient Age
Time between 
biopsies (months)
—  -- ----—
Primary 
Status Cr ^/R^)
Secondary 
1 Status (R^/R^)
517535 59 35 o/o o/o
529941 41 11 o/o o/o
490197 64 19 +/+ +/+
543284 58 19 o/o o/o
206073 40 10 o/o o/o
335662 56 17 +/+ o/o
554902 78 8 o/+ +/o
517288 59 8 +/+ +/+
512434 44 14 o/o o/o
338381 52 21 +/o o/+
190658 Unknown 13 +/o o/+
533839 38 21 o/o o/o
550668 43 31 o/o o/+
559665 64 7 +/o o/o
528446 68 16 +/+ +/+
528171 68 2 o/o o/o
297738 46 11 o/o o/o
519488 49 12 o/o o/o
420564 52 21 o/o +/+
348637 57 5 o/o o/o
525191 77 12 o/o o/o
498101 43 6 o/o o/o
227746 75 23 o/o o/o
551907 64 12 +/+ +/+
263806 80 4 o/o o/o
526290 44 19 +/+ +/o
341527 52 5 o/o o/o
518777 49 23 +/+ o/o
297515 71 18 +/+ +/o
305543 67 15 o/+ +/o
409965 46 32 H-/+ +/+
653306 Unknown 23 +/+ o/+
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if the initial absence were not caused by pre-operative treatment, although 
this phenomenon has also been reported by Korsten et al,, (1975) and 
Liskowski & Rose (1976). The present findings do not agree completely with 
the conclusions of King (1975) or Jensen et al., (1977), who found that the 
receptor status in the primary consistently determined the status and response 
of the secondary lesions but the number of patients in their studies was 
much less than is reported here. In the majority (75%) of instances here, 
where the secondary receptor status varied from that of the primary, 
defective receptor was involved, in that one or both biopsies contained 
either cytoplasmic or nuclear binding alone. Since, in these situations, 
the receptor is obviously abnormal in some manner, the fact that it is also 
apparently unstable is not entirely surprising. This would suggest that 
only results where receptor status is the same in both tissue fractions are 
of positive value in this respect. Overall, however, the results in 
Table 6 suggest that, in the majority of cases, receptor status and, therefore, 
hormone-responsiveness are the same in the primary and secondary lesions.
There are exceptions, which means that the concepts of routinely assaying 
primary tissue to aid in therapy of a secondary (Jensen, 1975) or determining 
whether a second tumour is another primary or a secondary on the basis of 
receptor content (Kiang & Kennedy, 1977b) should be treated with caution.
Table 7 shows the comparison of receptor levels in two or more secondary 
biopsies from the same tumour. The receptor content of some of these 
tumours was also determined at the primary level, and so they are also 
included in Table 6 . The reproducibility of receptor status between biopsies 
in this case is very similar to that found in the transition of primary to 
secondary disease (70% in Table 7), Again, the majority of variability 
(83%) appears to occur where abnormal receptors are involved, emphasising
Table 7 Cytoplasmic and Nuclear Oestrogen Receptor
Status in Biopsies of more than one 
Secondary Deposit from the same Breast 
Cancer Patient
The receptor content of the cytoplasmic 
(R^) and nuclear (R^) fractions was 
compared between the first metastasis 
and any subsequent secondary sites. The 
time elapsed between biopsies was noted.
Ill -
Patient Age
Time between 
biopsies (months!
1st
metastatic
sample
2nd
metastatic
sample
3rd
metastatic
sample
CRc/\)
529941 41 2 o/o o/o -
503664 48 13 & 9 o/o o/o o/o
543284 58 4 o/o o/o -
612828 1jinknown 23 +/o o/o -
517288 59 14 & lO •+/+ +/+ o/o*
576240 47 18 o/o o/o -
190658 1onknown 6 o/+ +/+ -
416889 60 14 o/o o/o -
297738 46 6 o/o +/+ -
560179 64 10 o/o o/o -
519488 49 7 o/o o/o -
420564 52 1 +/+ +/o -
482442 49 11 & 12 +/o o/o +/+
525191 77 7 o/o o/o -
249687 tonknown 10 o/o o/o
170263 72 25 o/o o/o —
AF/V 1inknown 14 +/+ +/+ -
526290 44 10 +/o o/o -
518777 49 3 o/o o/o
544403 45 30 +/+ +/+ -
*patient withdrawn from tamoxifen only 10 days previously (see text)
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that care is required in interpreting the therapeutic requirements of 
further lesions from such tumours.
In some cases, the treatment the patient was receiving (the antioestrogen 
tamoxifen) was found to effect the ability to detect receptor. In two 
specific instances, patients receiving this drug had assays performed on 
their tissue, from which it was concluded that no receptors were present, 
but, after tamoxifen therapy was discontinued, further biopsies were 
performed and found to contain both cytoplasmic and nuclear receptors.
One of the patients was given a further course of tamoxifen and again 
receptor became undetectable. The time between biopsies here was 3-4 
weeks. Another patient, on whom several biopsies had been performed, all 
containing receptor, was administered tamoxifen. The tumour continued to 
grow, and another biopsy was submitted for receptor assay 10 days after the 
last tamoxifen treatment. This contained no receptor at all. Although 
the plasma half-lives of the drug have been reported by Nicholson et al., 
(1979) as 7-14 hours and 7 days, it appears to have a relatively prolonged 
effect, probably due to an action on receptor synthesis. This demonstrates 
that previous, as well as current, therapy should be taken into account when 
interpreting receptor levels.
3.4.3 RECEPTOR LEVELS IN CASES OF BILATERAL BREAST CANCER
Receptor measurements have been carried out in a few cases of bilateral 
breast cancer. In each case, the disease in the second breast was a new 
primary tumour, and did not represent metastatic spread. Although the 
number of instances encountered is very low, (4 cases out of 900), it is 
clear that, while some second tumours have the same receptor status, and
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thus potential to respond to hormone therapy, as the first, others have 
entirely different abilities to bind oestradiol. This suggests that the 
stimuli responsible for the malignant transformations in the two tissues 
are not always consistent in their effect on the receptor-synthesising 
mechanism within the cells, some activating the machinery and some not.
This would rule out any suggestion that breast disease in the second breast
could be treated on the basis of receptor levels found in the first.
3.4.4 RECEPTOR LEVELS IN "NORMAL" BREAST TISSUE AND BIOPSIES 
OF BENIGN BREAST TUMOURS
Receptor measurement was performed on several samples of "normal" breast 
tissue, obtained from patients undergoing plastic surgery, and tissue from 
benign tumours of the breast. The assay system was the same as that used 
for receptor measurement in breast tumour tissue in all respects. In 
every case, binding was undetectable using this system. Since the lower
limit of sensitivity is 5 fmol/mg cytosol protein, or 25 fmol/mg DNA in the
nuclear tissue fraction, this finding was taken to mean that no receptors 
were present. This is in agreement with a report of Block et al., .(1975), 
that normal breast tissue exhibited hardly any uptake of oestradiol, 
presumably due to lack of receptors. Wittliff et al., (1972) and 
Sakai & Saez (1976) acknowledged that binding was reduced in normal breast 
or benign disease relative to malignant tumours, but that some was present. 
Feherty et al., (1971) and Hawkins et al., (1975), however, both detected 
receptor activity in benign tissue, but reported widely varying occurrence 
figures of 7% and 21% respectively, and much lower concentrations than those 
encountered in tumour tissue. The failure to measure any receptors at all 
in this type of tissue in the present study may reflect an insufficient
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number of attempts if a level as low as 7% (Feherty et al., 1971) is 
accurate, but this seems statistically improbable. A problem in the 
analysis of "normal" tissue derived from anaplastic reduction material is 
that it is very fatty. However, tissue used in the present study was 
carefully selected to represent mammary epithelium, free of fat. Failure 
to do so could lead to binding of oestradiol by fat being misinterpreted 
as an indication of receptor presence.
3.4.5 CORRELATION OF OTHER FACTORS WITH RECEPTOR STATUS IN 
BREAST TUMOURS
To explore the possibility of other guides to prediction of response to 
hormone therapy by breast tumours, the connection between receptor levels 
and various other parameters was examined. Although the receptor assay 
in its present form is both straightforward and reproducible, another system 
requiring less tissue, or indeed no tissue at all might be preferable in 
some cases. Any parameter which did fluctuate with receptor levels could 
act also as a confirmation of results obtained by receptor assay.
3.4.5.1 . Tissue Protein and DNA Content
One area examined as a possible guide to receptor content was the protein 
and DNA content of the tissue fractions. The protein levels were found to 
vary very little from tissue to tissue - on average within only a three­
fold range (approximately 2-6 mg/ml) - although levels outside this range 
were occasionally encountered. It is advisable to keep protein values 
within as small a range as possible to allow direct comparison of receptor 
levels from one sample to another. In contrast to the experience with 
protein values, the DNA content was not so consistent, and varied over a
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15-fold range (9-127 pg/ml). No correlation could be drawn between 
receptor levels and either protein or DNA content of the relative tissue 
fractions. The ratio of protein to DNA content was also considered in 
relation to the receptor status, but, again, no pattern could be detected.
3.4.5.2 Tumour Histology and Clinical Staging
The overall histology of the breast tumour biopsies was compared with the 
oestrogen receptor content. No particular histological feature was found 
which was consistent with receptor status. This has been reported also 
by Johansson et al., (1970) and Rosen et al., (1975). When studies were 
carried out on the connection between clinical staging and receptor status, 
no stage was found to be associated with any one receptor classification 
more than another. This is demonstrated in Table 8, where 133 patients, both
pre- and post-menopausal were considered. The observation that no 
correlation exists is in agreement with those of Maass et al., (1972, 1975). 
Maynard et al., (1978) and Maynard & Griffiths (1979) find a definite 
connection between histological grade and receptor content in post-, but 
not pre-menopausal women. They found that the better-differentiated tumours 
rarely lacked receptor, but that no correlation could be identified between 
any detailed histological feature and receptor status, confirming the present 
findings.
3.4.5.3 Lactalbumin Content
Samples of tissue to be assayed for oestrogen receptor content were split, 
and a portion despatched to Dr. A, Howell, Queen Elizabeth Hospital,
Birmingham for detection of lactalbumin, using an immunoperoperoxidase staining 
technique. A comparison was drawn between receptor status and lactalbumin 
absence or presence. Although the level of lactalbumin, when present.
Table 8 Comparison of Receptor Status and
Stage of Tumour in 186 Primary Breast 
Tumour Biopsies
Receptor content of the cytoplasmic (R^) 
and nuclear(R^) fractions of breast 
tumour biopsies was compared with the 
stage of tumour. Stage I disease 
represents a tumour of less than 2 cm, with 
no nodal involvement and no métastasés.
Stage II describes any size of tumour up to 
5 cm, which may also have nodal involvement 
but no métastasés. In Stage III disease, 
tumours are greater than 5 cm in size, have no 
métastasés, but may have little or extensive 
nodal involvement. Stage IV tumours are of 
any size, may, or may not, have any degree of 
nodal involvement, but display distant 
métastasés,
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*=/%n
Number of Patients
Stage I Stage II Stage III Stage IV
+/+ 25 27 4 1
■o/o 37 54 6 3
+/o 7 7 0 1
o/+ 6 8 0 0
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varied from sample to sample, giving rise to a grading system for positivity, 
this did not coincide reproducibly with the presence or absence of receptor, 
as shown in Table 9. Thus, this test could not be applied to the prediction 
of receptor status or likelihood of response to hormonal therapy.
3,4.5.4 Plasma Receptor Levels
Receptor status of plasma from breast cancer patients was compared with that 
of tumour tissue from the same patients, following a report by Tisman & Wu 
(1977) that plasma receptors could be detected in some cases of breast cancer. 
This would provide the basis of a much simpler system to monitor patients, 
if receptor could be detected reproducibly and correlated with response to 
hormone therapy. Accordingly, blood, with anticoagulant added, was 
collected immediately preoperatively from breast cancer patients. The 
blood was centrifuged, and the plasma collected. The plasma was assayed in 
an identical fashion to the tissue fractions. Figure 21 shows the 
Scatchard plots obtained from oestrogen receptor assays on the cytoplasmic 
and nuclear fractions of breast tumour tissue and plasma from the same patient 
This was typical of the type of plot obtained using 15 plasma samples, 
regardless of the receptor content of the tumour, the menopausal status or 
the sex of the patient and is in accordance with the findings of Leclerg 
et al., (1973), who could not detect any oestradiol receptor in plasma.
From the Scatchard analysis, it is clear that something is binding oestradiol, 
but it is not the same high-affinity, specific receptor encountered in 
breast tumour tissue, and its presence is not consistent with the presence of 
that receptor in solid tissue. The same effect on the Scatchard plot was 
noted by Ratajczak & Hhhnel (1976) studying binding in the presence of plasma.
Table 9 Comparison of Receptor Status and
Lactalbumin Content of 26 Breast 
Tumour Biopsies
The overall receptor status of 26 breast 
tumour biopsies was compared with the 
lactalbumin content, as determined by 
immunoperoxidase staining. Lactalbumin 
grading was given as negative, grade I 
(small number of positive cells, small areas), 
grade II (moderate number of positive cells, 
not all of section) or grade III (many 
positive cells throughout the section).
(R^ - cytoplasmic oestrogen receptor,
R^ - nuclear oestrogen receptor).
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Receptor Status Lactalbumin Content
Negative Grade I Grade II Grade III
+/+ 3 4 2 1
o/o 3 2 1 2
+/o 2 2 1 1
d/+ - - 2 -
3
Figure 21 - Scatchard Plots of H-Oestradiol-176 Binding in
the Cytosol and Nuclear Fractions of Breast Tumour 
Tissue and in Plasma from the Same Patient
Cytosol and nuclear fractions were prepared from
breast tumour tissue, as described in Section 2,2.1,3.
Blood, collected immediately preoperatively from the
same patient and stored in a heparinized container,
was centrifuged at 1000 g for 10 minutes at 0°G to
yield plasma. The receptor content of all three
fractions was determined by incubation with a range 
3
of H-oestradiol-176 concentrations followed by 
removal of unbound steroid with DCC in the case of 
the cytosol and plasma or by washing of the nuclear 
material. The resultant Scatchard plots are shown 
of cytoplasmic, nuclear and plasma binding of steroid.
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3.4.5.5. Plasma Steroid Levels
The correlation between tissue receptor levels and plasma steroid con­
centrations in breast cancer patients was studied. Blood was collected 
immediately preoperatively, during operation and postoperatively from 
these patients and radioimmunoassay performed to measure plasma levels of 
oestrogens, progestins and glucocorticoids by Dr. J.K. Grant, Department 
of Steroid Biochemistry, Glasgow Royal Infirmary. No correlation could be 
identified between the levels of any of these steroids and the levels of 
receptor present in the tumour tissue. This finding, along with the failure 
to detect any receptors in blood plasma (see previous section), rules out the 
possibility of using a simple blood test in the identification of the 
receptor status of tumours.
3.4.5.6 Correlation of Nodal Status with Oestrogen Receptor Status 
When a mastectomy is performed in cases of breast cancer, any enlarged 
axillary lymph nodes are biopsied at the same time to test for tumour 
content. The nodes may or may not be cleared, depending on the findings 
of these investigations. Two recent reports are at variance over the 
correlation between nodal involvement in breast cancer and receptor W e i s  
in the tumour. HMhnel et al., (1979) report that absolutely no correlation 
exists, while Allegra et al., (1979a) find that receptor-positive tumours 
are likely to be associated with nodes lacking tumour content. The latter 
case might be expected, since both receptor positivity and absence of nodal 
involvement have been reported independently as giving a better prognosis 
for the patient.
The receptor results in the present study were examined in relation to the 
nodal status of the patient, where this had been determined. Table 10 shows
Table 10 Comparison of Receptor Status and Nodal
Status in 110 Primary Breast Tumour Biopsies
The overall receptor status of 110 breast 
tumour biopsies was compared with the 
tumour involvement of the lymph nodes. 
Node-negative patients had no nodal 
infiltration by tumour, while those in the 
node-positive category had nodes with some 
degree of tumour content. (R^ - cytoplasmic 
oestrogen receptor, R^ - nuclear oestrogen 
receptor). The percentage occurrence in 
each nodal category is indicated for each 
receptor category.
Node -ve Node +ve
No, of Patients % No, of Patients %
+/+ 16 47 18 53
o/o 22 42 30 58
+/o 4 36 7 64
o/+ 8 62 5 38
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the results of such a comparison carried out on 110 patients, both pre- 
and post-menopausal. No clear correlation appears to exist between 
receptor status and nodal status in these patients, in agreement with the 
report of HËhnel et al., (1979).
3.4.6 EFFECT OF AGE AND MENOPAUSAL STATUS ON RECEPTOR LEVELS 
IN BREAST TUMOUR TISSUE
The receptor profiles of some breast tumour biopsies were reassessed accord­
ing to the patient’s menopausal status. Table 11 shows the distribution 
of receptor status in relation to menopausal status. It is clear that there 
is a slight variation in the distribution of patients between the first three 
classes of receptor status, but the most dramatic finding is the complete 
absence of tumours containing only nuclear receptor in premenopausal women.
Since the premenopausal group concerned contains 68 patients, it is unlikely 
that this phenomenon represents an artefact produced by a statistically 
insignificant number of samples. The ability of receptors to "exist" in 
the nucleus when none are detected in the cytoplasm may represent some change 
brought about at the time of the menopause, or an alteration in the permeability 
of the cell membranes.
A comparison was drawn also between the mean cytoplasmic and nuclear receptor 
levels in pre- and post-menopausal, receptor-positive patients. Table 12 
demonstrates the variation in these mean values. It shows that in the case 
of both cytoplasmic and nuclear receptors, levels are significantly higher 
in postm'en.î'pausal patients. This is also illustrated if a graph is con­
structed of cytoplasmic (Figure 22) or nuclear (Figure 23) receptor level 
against age of patient. In both fractions, a dramatic rise is seen in
Table 11 Comparison of the Distribution of
Oestrogen Receptors Between the 
Cytoplasmic and Nuclear Fractions of 
Breast Tumour Tissue in Pre- and Post­
menopausal Patients
The presence (+) or absence (o) of 
cytoplasmic (R^)and nuclear (R^) 
oestrogen receptors is summarised as in 
Table 5, but taking into consideration 
the menopausal status of each patient. 
The figures include biopsies of both 
primary and secondary lesions.
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Receptor Content Premenopausal Po stmenopaus al
No. of patients Percentage No, of patients Percentage
+/+ 22 32 69 36
o/o 34 50 81 42
' +/o 12 18 26 ’ 13
o/f 0 0 17 9
Table 12. Variation, in Mean Cytoplasmic and Nuclear
Oestrogen Receptor Levels Between Pre- and 
Post-menopausal Patients
The mean value for cytoplasmic (expressed in - 
fmol/rag cytosol protein) and nuclear 
(expressed in fmol/mg DNA) oestrogen receptors 
in breast tumour tissue was determined for 
pre- and post-menopausal patients. A student’s 
T test was performed on each population to 
determine the difference between them.
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Mean Receptor Value
Tissue Fraction Premenopausal Po stmenopausal Significance
Cytoplasmic 49 95 p < 0.001
Nuclear 1115 1750 p < 0.001
Figure 22 - Levels of Cytoplasmic Oestrogen Receptors in Breast
Tumour Tissue as a Function of Age
Levels of cytoplasmic oestrogen receptor are summarised 
for 150 patients (chosen at random) as a function of age. 
Premenopausal patients are indicated by (0), perimenopausal 
by (A) and postmenopausal by (#).
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Figure 23 - Levels of Nuclear Oestrogen Receptors in Breast Tumour
Tissue as a Function of Age
Levels of nuclear oestrogen receptor are summarised for 
150 patients (chosen at random) as a function of age. 
Premenopausal patients are indicated by (0), perimenopausal 
by (A) and postmenopausal by (•).
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receptor levels around the age group 45-50 (the menopause region).
This same age effect on cytoplasmic receptor has been noted by many
workers, (e.g. Hilf & Wittliff 1974, King et al., 1979b). Allegra et al.,
(1979a) found no such correlation between cytoplasmic receptor levels
and age once the menopausal effect was taken into account. This is in
agreement with the findings illustrated here (Figure 22). The rise in
receptor levels seen at the menopause age is a sudden, rather than a
gradual, change. The latter effect would be noted if age had caused
the rise rather than the menopause. The reason for the influence of the
menopause on receptor levels is not clear. From the evidence accumulated
in earlier sections, the assay being used here measures total receptor
levels, so that there can be no suggestion of endogenous steroid masking
receptors in premenopausal patients. Another proposed explanation has
been that cytoplasmic receptor levels may be lower in premenopausal patients
due to the large percentage residing in the nucleus as a result of higher
circulating levels of oestradiol. The present finding that nuclear
levels of receptor are significantly higher in postmenopausal patients tends
Further
to discount this theory.^ Maynard & Griffiths (1979), in a study of nuclear 
oestrogen, found no difference in levels between pre- and post-menopausal 
tissue. This was also a preliminary observation in the present study, but 
a difference became apparent as more data became available.
Whatever the real reason may be for the dramatic change in receptor levels 
after the menopause, it has been noted consistently, and Mobbs & Johnson 
(1976) suggest that different cut-off points should be set in pre- and post­
menopausal situations to allow for it.
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3.4.7 RECEPTOR LEVELS IN TISSUE OTHER THAN BREAST
Just as the determination of receptor status in breast tumours has 
proved an invaluable aid in the selection of therapy for such disease, 
it was postulated that the same test might be of value in the treatment 
of other forms of cancer, even those of tissues not normally regarded as 
responsive to steroids. One area which seemed appropriate for such a 
study was the gastro-intestinal tract. Colorectal tumours constitute 
the predominant form of cancer in the male in the West of Scotland, but 
no successful therapeutic regime has been discovered, as yet. Chemotherapy 
gives very unsatisfactory results, so hormonal therapy is a possible 
alternative, although its use at present would be merely tentative, in the 
absence of positive proof of hormonal involvement. There is some 
suggestion that the colon might be sensitive to hormonal manipulation.
As mentioned in the introduction, cancer of the gastro-intestinal tract 
and hormone-dependent tumours have been linked by a common dependence on 
diet (Berg, 1975). Colorectal cancer is also one of the most common forms 
of cancer associated with breast cancer (Hermann, 1972). Water uptake in 
the colon is effected by changes in plasma oestradiol levels found in 
pregnancy and during the menstrual cycle, also suggesting some hormonal 
involvement. These arguments are all fairly tenuous but the presence of 
oestrogen receptors in colonic carcinoma tissue, even in only a percentage 
of cases, would suggest a firm basis for hormonal control in this area and, 
consequently, for a trial of hormonal therapy for this type of cancer.
With this aim in mind, oestrogen receptor levels were measured in colonic 
carcinoma tissue samples. Tissue was transported and stored, where 
necessary, as for breast tissue (see Methods, section 2.2.1). The method 
of fractionation of the tissue was again identical to that used for breast
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tumour samples, except that use of anlJltra-turrax homogeniser was not
necessary due to the much softer nature of the colonic tissue. Great
care was required also to avoid contamination of the fractions with
plasma, since this tissue was much bloodier than breast tumour tissue.
Such contamination could lead to erroneous results due to binding of
added steroid by plasma proteins, but this should be revealed by competition
experiments using excess unlabelled DES, which will not, itself, interact
with the major plasma binding proteins. Measurement of oestrogen
receptor levels was carried out using basically the system described for
breast tissue in Figure 19. Some variations in methodology were compared
with this procedure to determine the viability of the assay system using
the different tissue type. One of these was to assess the effectiveness
of the thiol reagent dithiothreitol (DTT) in protecting the sulphydryl
groups of colonic oestrogen receptor. As described in section 3.1.2, a
comparison was made between DTT and monothioglycerol, another commonly
used thiol reagent. No difference could be detected in the binding measured
using either of these agents (see Figure 7). The temperature of incubation 
3
with H-oestradiol was also varied to allow for the fact that the hormone/ 
receptor complex in either fraction of colonic tissue might be more stable 
at low temperatures than the complex found in breast tissue preparations. 
Using incubations at 4°C or 15°C, either of which would be successful in 
breast tissue fractions, no binding could be detected.
Receptor assays were carried out on 25 samples of colonic carcinoma tissue 
from both male and female patients, all with advanced disease, and aged 
mainly over sixty. In no case, even with the variations noted above, could 
oestrogen receptor of the type found in breast tumour tissue be detected.
In one case, a Scatchard plot was successfully constructed for only the
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cytosol of a colonic sample, the nuclear fraction containing no evidence 
of binding. However, the binding was not competed out by DES, and so 
was deemed to reflect a non-cellular form. In a further two cases, a
small level of specific binding could be detected by assay at a saturating
3 . -9 .
concentration of H-oestradiol (10 M) with and without excess unlabelled
DES. However, in these cases, no satisfactory Scatchard plot could be 
constructed, and the origin of this binding could not be determined. 
Experiments were carried out to measure the uptake of H-oestradiol into 
several colonic tumour samples. Tissue slices were incubated with the 
labelled steroid, washed, fractionated and the level of activity in each 
fraction measured immediately. The results from these studies indicated 
no evidence of steroid binding in any case.
These results, along with further results from this study have been
published recently (Leake et al., 1980), and show that oestrogen receptor
of the type found in breast tumour tissue cannot be detected in colonic
carcinoma tissue, if binding is to satisfy the criteria set down in section
3.4. Response to the anti-oestrogen tamoxifen in such patients was also
minimal. This is in contrast to the findings of McLendon et al., (1977)
and Alford et al., (1979), both of whom found variable levels of receptor
in 24-30% of colonic neoplasms. Alford et al., used very high levels of 
3
H-oestradiol in their assay procedure, and used unlabelled oestradiol as 
competitor. As this would not rule out binding to non-cellular proteins, 
the binding they observe may not be attributable to a true oestrogen 
receptor, especially since the tissue type is more likely to be con­
taminated by other binding proteins than is breast tissue. Further work
in this area may reveal the reason for the discrepancy between the findings 
from the present study and those in the other reports.
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Apart from colonic carcinoma tissue, receptors were measured in a limited 
number of tumours from other sites. Assay of oestrogen binding in three 
samples of ovarian carcinoma and four biopsies from endometrial carcinoma 
tissue demonstrated not only that the assay system developed for breast 
tumour tissue was successful in determining receptor levels in these other 
tissues, but also that, as with breast, not all tumours from any particular 
target site in the body contain receptor. In addition, the viability of 
the assay system in these areas suggests that, if receptors are present in 
colon, they should be detected by the same method established for breast 
tissue.
3.5 PATIENT. FOLLOW-UP
3.5.1 RESPONSE TO HORMONE THERAPY IN RELATION TO RECEPTOR STATUS
In order to assess the reliability of the assay system in providing an 
index of response to hormonal therapy by breast tumours, follow-up data 
were compiled on patients, the receptor content of whose tumours had been 
determined. The amount of this information which is of value in this respect 
is limited by a number of factors. Firstly, only patients with recurrent 
disease are given therapy to which the objective response can be measured 
and the findings may not be conclusive in all cases. Secondly, only 
patients receiving solely hormonal therapy can be included. The majority 
of hospitals are currently participating in various trials of mixed forms 
of therapy in order to elucidate the most successful therapeutic regimes.
In these trials, the various combinations of therapy are allocated to 
patients at random. The augmentation of hormonal with another form of 
therapy, whether chemotherapy or radiotherapy, means that no assessment of
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response to the hormonal part alone can be made, and so the patient must 
be excluded from this study. The last limiting factor is that, as a 
result of criteria established by the British Breast Group (1974), 
regression of a tumour must be observed for at least six months with no 
new lesions appearing during that time for a response to be recorded as 
having occurred. This means that six months must elapse, therefore, before 
any report relevant to this assessment can be made. If the tumour ceases 
to show regression at any time during the six month period, then a failure 
is reported. These criteria have been criticized as being too harsh by 
Stoll (1977), who found instances which he felt should be classed as 
responses, but which failed to satisfy the time limit specified. The 
British Breast Group rules also state that 50% decrease in tumour diameter 
should be noted, which, as pointed out by Stoll, means that the neoplasm 
must shrink to 1% of its original volume.
The strict nature of these criteria is emphasised when a report by 
Engelsman et al..(1973) is considered. They found, using different rules 
for response, that 80% of receptor-positive tumours responded to therapy, 
although their numbers are very low and thus may not be entirely significant 
Regression was required for only 3 months in their scheme instead of six. 
This figure is much higher than those of other workers who consider cyto­
plasmic levels of receptor as the sole index of responsiveness. In spite 
of these facts, the British Breast Group rules have been adhered to in the 
follow-up data presented here.
Response to hormone therapy was assessed in 124 tumours, biopsies of which 
had been assayed for the presence of oestrogen receptors. These results 
are summarized in Table 13. The hormonal therapy applied represents a
Table 13 Response of Breast Tumours to Hormone
Therapy in Relation to their Oestrogen 
Receptor Content
The response of breast cancer patients to 
various forms of hormonal therapy, both 
additive and ablative, was determined and 
compared with the receptor status of their 
tumour, British Breast Group rules, as 
described in Section 3,5, were adhered to 
in determining "response". Only those 
exhibiting a complete response to a hormonal 
regime are included in the table.
(R^ - cytoplasmic oestrogen receptor,
R^ - nuclear oestrogen receptor).
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Receptor Status Total No, 
of Patients
No, of Patients 
with, complete 
response
Percentage
Response
+/+ 42 30 71
o/o 57 5 9
+/o 17 4 24
o/+ 8 1 12
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mixture of ablative and additive forms comprising mainly oophorectomy, 
stilboestrol and tamoxifen administration. It is shown that approximately 
70% of patients who should, on the basis of containing both cytoplasmic 
and nuclear oestrogen receptors, respond to a hormonal form of therapy 
do, in fact, show a favourable reaction. Of those patients whose tumour 
tissue contained no measurable receptor in either fraction, only 10% 
responded to any form of hormonal therapy. These patients had principally 
received tamoxifen and presumably responded through some indirect pathway, 
such as the inhibition by tamoxifen, of prostaglandin synthesis (Tisdale, 
1977). The tumours which had been found to contain cytoplasmic, but no 
nuclear, receptor, and thus would not be expected to display hormone- 
dependence, demonstrated a slightly better response to hormonal manipulation 
than those containing no receptor at all. In the last group, representing 
the interesting situation where receptors were found solely in the nuclear 
fraction of the tissue, response was no greater than that observed in tissue 
lacking receptor completely. The numbers in this group are low, and the 
percentage could change as more data are accumulated.
The finding that the last group of patients whose tumours lacked cytoplasmic 
receptor did not respond to hormone therapy is a guide to the functioning 
of these presumably unfilled nuclear receptors. It has not been possible 
up till now to determine whether these receptors are functional, although 
Zava et al., (1977) postulated that they did act to give oestrogen 
stimulation of growth in MCF7 cells, and moreover that such cells might not 
respond to ablative therapy but to antioestrogens. This is not
completely reliable as a guide to this type of situation in vivo, since 
the receptors in MCF7 cells have been shown to be atypical of the normal 
cellular form. The results obtained in this study show conclusively that
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the presence of the receptor exclusively in the nucleus does not suggest 
a favourable response to hormone therapy, ablative or additive. These 
abnormal receptors are thus not functional in stimulating tissue develop­
ment in response to oestrogens.
The fact that the group containing only cytoplasmic receptor responded 
more favourably than the tumours containing no receptor is unexpected.
The preliminary result shown in Figure 20 suggests that these receptors 
may be unable to enter the nucleus, and hence no oestrogen stimulation 
of growth should occur. Any benefit experienced as a result of hormonal 
therapy would then have occurred via an indirect pathway. Another possible 
reason for response would be that the biopsy assayed for receptor content 
had contained a very low level of nuclear receptors which were not detected 
by the assay method. This seems unlikely, however, due to the sensitivity 
of the procedure. It is possible that the percentage response obtained here, 
is, in fact, an artefact caused by the lower number of patients in this 
group. Further follow-up information may yield a percentage closer to that 
encountered for tumours with no receptor present.
The fact that only 70% of patients who should respond to hormone therapy 
actually do so, while 90% of those with no receptors in either fraction 
show no favourable response,confirms the idea that a receptor-negative result 
is of more predictive value than a receptor-positive one (Maass et al.,1972, 
1975, Jensen, 1975, King, 1975, Lippman, 1976). However, the inclusion 
of a determination of nuclear receptor content has increased the success rate 
over that obtained when only cytosol receptors were measured. The
principal benefit has come from the ability to identify false-positive 
tissue, containing only cytosol receptor. Some of these tumours do
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respond to hormone therapy, as mentioned above, but this is only a 
fraction of the number of the genuinely receptor-positive cases which 
show a favourable response.
The nuclear assay has also proved useful in identifying the small percentage 
of tumours containing receptor at this site only. These tumours do not 
appear to respond to hormonal therapy either, and if no cytoplasmic deter­
mination of receptor content were carried out, then this group would be 
the "false-positives". A combination of both assays is thus essential for 
the maximum yield of predictive information on the behaviour of any tumour.
Initial studies on receptor content of colonic carcinoma tissue were carried 
out with the aim of establishing whether the same type of index for 
hormonal response could be prepared for these tumours. However, useful 
follow-up data were stictly limited". The advanced stage of the biopsies 
received meant that patient death occurred very soon after biopsy in the 
majority of cases, and hormonal treatment was not considered for others.
Subsequent expansion of this work has included the administration of the 
antioestrogen tamoxifen, and determination of response to this therapy 
relative to receptor content has been performed (Leake et al., 1980).
3.5.2 RELATIONSHIP BETWEEN DISEASE FREE INTERVAL AND RECEPTOR STATUS
A comparison was made between receptor status and the time which elapsed 
between the diagnosis of primary breast cancer and any recurrence. This 
could be made only where receptor status had been determined in the primary
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tumour, the absence of this information leading to the exclusion of 
some cases. Figure 24 shows that the disease free interval is longer 
in receptor-containing tumours than in those containing no receptor at 
all, which was noted also by Maynard & Griffiths (1979). In the remaining 
two classes of tumour bearing receptor in one fraction only, too few 
recurrences have been noted (due to the lower incidences of these types 
of tumour) to draw any meaningful conclusions about relapse times. Pre­
liminary data (Figure 25) show that these two groups of patients exhibit 
similar patterns of recurrence and that this is closer to that observed 
in receptor-negative than receptor-positive cases (Figure 24). From the 
findings of the response to hormone therapy by these tumour types, they 
appear to behave as receptor-negative, but this conclusion in respect of 
relapse rate awaits more follow-up data. A much higher proportion of 
receptor-negative patients relapse within a three-year period after initial 
diagnosis than do receptor-positive patients.
These findings are in agreement with those of Knight et al., (1977),
Block et al., (1978) and HEhnel et al., (1979) that receptor-positive 
tissue displays a much longer disease free interval, and that the patient’s 
prognosis was greatly improved over that of a patient bearing a receptor- 
negative tumour. This may be accounted for by the observation of Meyer 
et al., (1977) that receptor-negative tumours grow more aggressively than 
those possessing measurable levels of binding. The former would therefore 
spread to other parts of the body much more quickly. This may also form 
the basis of the suggestion by Byar et al., (1979) that the site of 
metastasis altered the prognosis of breast cancer patients and the 
observation in this study that receptor-positive tumours form mainly 
local métastasés, receptor-negative ones spreading further in the body.
Figure 24 - Disease Free Interval in Breast Cancer Patients in Relation
to the Oestrogen Receptor Status of the Tumour (+/+ and 
o/o Biopsies)
Oestrogen receptor content of both soluble and nuclear 
fractions of a biopsy of primary breast disease was 
determined at the time of simple mastectomy. Patients 
received no adjuvant therapy. Time and site of first 
clinical recurrence was noted. Percentage of patients 
remaining disease free was plotted against time for groups 
of 50 patients in the two categories: receptor-negative
and fully receptor-positive.
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Figure 25 - Disease Free Interval in Breast Cancer Patients in
Relation to the Oestrogen Receptor Status of the Tumour 
(+/o and o/+ Biopsies)
Patients in the two groups whose primary biopsies 
yielded abnormal oestrogen receptor were analysed in the 
same manner as those referred to in Figure 24,
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which was also noted by Walt et al,, (1976).
3.5.3 RELATIONSHIP BETWEEN NODAL STATUS, RECEPTOR STATUS AND 
DISEASE FREE INTERVAL
Nodal status, like receptor status, has been implicated in determining 
the length of the disease free interval in cases of breast cancer. Hühnel 
et al., (1979) discovered a considerably shorter disease free interval 
in tumours with lymph node involvement. When receptor status was con­
sidered also, receptor-negative tumours with nodal involvement were found 
to give the worst prognosis, although the effect of receptor content 
decreased as time progressed, possibly due to the effect of hormone- 
dependent tumours becoming autonomous. The influence of the nodal 
involvement did not lessen, however, this being the determining factor on 
prognosis at the end of their study.
The incidence of recurrences in tumours for which both receptor and 
nodal status had been determined in the present study was considered. The 
resultant graph is shown in Figure 26. Only tumours in the +/+ and o/o 
receptor groups are represented, since the relevant information was not 
available on a sufficient number of samples in the other two groups. The 
receptor-positive, node-negative group of tumours gave the best prognosis 
in Figure 26, receptor-negative, node-positive ones showing the highest 
recurrence rate. The other two classes (receptor-positive, node-negative 
and receptor-negative, node-positive) displayed a very similar pattern 
over the first 20 months considered. As time progressed, however, the 
effect of nodal status appeared to become predominant. This same effect 
was noted by Hhhnel et al., (1979), but to a greater degree. Follow-up 
of these patients for a longer period of time may reveal whether receptor
Figure 26 - Disease Free Interval in Breast Cancer Patients in
Relation to the Oestrogen Receptor Status and Nodal 
Involvement of the Tumour
Biopsies of primary breast cancer were assayed for oestrogen 
receptor status and corresponding nodal status determined by 
routine pathological section of the axillary tissue and 
histological examination of all identified nodes.
Percentage of patients remaining disease free is plotted 
against time for both.fully receptor-positive (•) and 
receptor-negative (0) in relation to presence or absence 
of nodal involvement (+ve or -ve), Figures in brackets 
indicate numbers of patients in each group.
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status or nodal status is the governing factor in the prognosis of 
breast cancer sufferers.
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4. DISCUSSION
The mode of action of steroid hormones in normal, as opposed to 
transformed, target cells is presently accepted as basically the two- 
step mechanism simultaneously proposed by Gorski et al. and Jensen et al. 
in 1968. A greater understanding now exists of the intermediate processes 
which has led to suggested modifications of either certain steps (Linkie 
& Siiteri, 1978) or the concept as a whole (Sheridan et al., 1979), but, 
generally, a steroid enters the target cell, becomes associated with a 
specific receptor protein, enters the nucleus and elicits genetic responses. 
The hormone can enter the cell by passive diffusion. The receptor molecules 
available to it may be free in the cytoplasm, or loosely bound to the cyto­
plasmic membrane (Wittliff, 1975), but this is not certain as yet. Follow­
ing the interaction between the hormone and receptor, there is a heat- 
dependent activation step, involving the addition of a further polypeptide 
subunit to the receptor (Notides & Nielsen, 1974, Leake, 1976). This was 
thought, initially, to occur within the cytoplasm, and constitutes a major 
requirement for entry of the hormone and receptor into the nucleus (Notides 
& Nielsen, 1974, Spelsberg, 1974). Linkie & Siiteri (1978), however, now 
propose that the activation process occurs within the nucleus itself, not 
representing an entry qualification. The actual site of activation is an 
important point in the understanding of receptor functioning. The concept 
that it occurs inside the nucleus would explain the discovery of unfilled 
receptors within the nucleus of some breast tumour material (Garola &
McGuire, 1977a, Panko & MacLeod, 1978, Kato et al., 1978, Thorsen, 1979) 
and the proposal by Sheridan et al., (1979) that these are always present. 
Another reason for apparently empty nuclear receptors would be that 
receptor transport had been facilitated by binding to a weak ligand.
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Following translocation of the hormone/receptor complex, whether this 
happens before or after activation, it binds to the chromatin within the 
nucleus at specific acceptor sites, presumably defined by their three- 
dimensional conformation (Leake, 1976). Binding at these sites may 
involve both non-histone proteins (Spelsberg et al., 1972, O'Malley et al., 
1972, Charreau & Baldi, 1977) and DNA (King & Gordon, 1972), although 
their actual nature is still somewhat uncertain (Yamamoto & Alberts, 1976). 
As a result of these interactions, responses are seen within the cell, 
beginning after 15-30 minutes with an increase in RNA polymerase B activity, 
and continuing for many hours with more long-term effects. Specific 
products of oestrogenic stimulation of breast tissue cells include a-lact- 
albumin, casein, progesterone receptor and oestrogen receptor itself 
(Sarff & Gorski, 1971, Clark et al., 1977) a mixture of recycling and 
de novo synthesis of this latter protein occurring following release of 
the hormone/receptor complex from chromatin (Neithercut, 1977). Recently, 
even later protein markers of stimulation have been noted, suggesting 
further processing of the complex (Westley & Rochefort,1979).
The preceding paragraphs dealt with the situation encountered in a normal 
breast cell undergoing oestrogenic stimulation (e.g. during pregnancy and 
lactation). In the normal, non-lactating breast, oestrogen receptor- 
containing cells are present in very small numbers,although the potential 
to commence synthesis of more receptor and activate the processes described 
above does exist. In the course of malignant transformation of the cells 
the receptor-synthesising machinery may be either activated or abolished, 
so that, in the latter case, the tissue is no longer capable of hormonal 
response. In the situation where receptor synthesis is "switched on", 
tumour tissue growth will come under hormonal control. Thus, these
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hormone-dependent tumours will be sensitive to hormonally-based therapies 
aimed at destroying the integrity of the stimulatory mechanisms within the 
cell.
Before the realisation that this process might occur during tumour formation, 
it was noted that not all breast cancer patients received positive relief 
from disease as a result of hormonal therapy, while some, as reported by 
Beatson (1896), benefitted greatly. Some prediction of which patients 
would respond was called for (Pearson & Ray, 1960, Baker et al., 1960).
Finally, Jensen et al.,(1971) postulated that tumours which were hormone- 
dependent could be identified by their oestrogen receptor content. It 
was suggested that, if a tumour contained this receptor, then the machinery 
discussed earlier must have been activated, and the tissue would fall under 
hormonal control. Removing the source of oestrogens or impeding their 
action would thus arrest tumour growth. Absence of these receptor proteins 
would, then, indicate a lack of hormonal control, and suggest that hormonally- 
based therapeutic regimes would have no beneficial effect on that tumour.
Many methods have been described for the measurement of oestrogen receptors 
in breast tumour tissue during the last decade, following the introduction 
of the concept that this might aid in the treatment of breast cancer patients. 
Techniques have advanced greatly since the initial studies of Folca et al., 
(1961) on the uptake of tritiated-oestrogens into patients' breast tissue, 
relative to their response to adrenalectomy. Simple assessment of cyto­
plasmic receptor levels has never given absolute accuracy in the prediction 
of response of breast cancer patients to hormone therapy. Additional guides 
have been sought, with the idea that some further marker of oestrogenic
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action would give a more reliable indication of hormone-dependence.
Markers proposed have been selected on the basis that oestrogenic- 
stimulation is not a simple domino response arising from the binding of 
soluble receptor and so measurement of the latter does not preclude 
lesion(s) at a later stage(s). Some substances which have been proposed 
as indicators of oestrogenic stimulation are, for example, progesterone 
receptor (Asselin et al., 1977),casein mRNA (Rosen & Socher, 1977) a- 
lactalbumin (Ip & Dao, 1978) and peroxidase (De Sombre et al., 1975,
Anderson et al., 1975, Lyttle & De Sombre, 1977a). Of these, the 
progesterone receptor has proved most popular, although doubt is now cast 
on whether measurement of both cytoplasmic oestrogen and progesterone 
receptor does, in fact, increase the success of predicting the response 
of breast cancer patients to hormonal manipulation (McGuire, 1978). Failure 
of tumours containing both species to react to hormonal stimuli (Ip et al., 
1979) has led to the suggestion that further steps in the stimulatory 
pathway must exist, which may be blocked as a result of malignant trans­
formation.
The assay system developed in this project considers the nuclear, as well 
as cytoplasmic oestrogen receptor concentration, on the basis that a major 
point of blockage in the oestrogenic pathway would exist at the entry of the 
receptor into the nucleus and its binding to the correct acceptor sites. 
Several properties of the receptor, and characteristics of breast tumours 
have also been explored in the course of designing and evaluating this 
procedure. Although the aim of the system was to demonstrate the presence 
of receptors in each cellular fraction, the nature of the process developed 
provides additional information about the binding observed. Such complete
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analysis requires at le^st 150 mg of tissue. An amended method for 
receptor quantitation can be carried out on as little as 50 rag, but with 
a consequently decreased yield of information. In these cases, a "one- 
spot" assay, such as those used by Mobbs & Johnson (1976) and McGuire 
et al., (1977c) is employed.
A "one-spot" determination of receptor concentration compares the binding 
3 .
of H-oestradiol-173 alone with that in the presence of excess unlabelled
steroid. This serves to quantitate the receptor, and at the same time,
reveal the degree of specificity of binding. The theory behind this is
that specific sites are, by definition, saturable, while, at physiological
levels of steroid at least, non-specific binding is unsaturable. When 
3
H-oestradiol alone is added to a receptor-containing preparation, it will
fill up specific receptors and any excess will bind to non-specific sites.
Radioactivity measured would then represent both specific and non-specific
binding, the proportion of one to the other being impossible to determine.
In the presence of excess unlabelled steroid, however, this would be
likely to fill the majority of the available specific sites, and a number
3of the non-specific sites. By far the majority of H-oestradiol bound 
would then represent non-specific binding. A comparison of binding under 
these two conditions would, thus, determine the level of specific binding.
A further point is that diethylstilboestrol (DES) is a better competitor 
than oestradiol itself, as the former does not interact with non-cellular 
binding proteins, such as SHBG (King & Mainwaring, 1974), which might 
contaminate the cellular fractions, A comparison of the efficiency of 
unlabelled DES or oestradiol in the role of competitor revealed no difference 
in the nuclear fraction, but a small difference in receptor levels detected
in the cytoplasmic fraction (see Results, section 3.1.3.3). This effect 
was not so great as to cause concern, but might be more evident in other 
tissue types, so that the use of unlabelled DES as competitor, in pre­
ference to oestradiol, is advised.
When an adequate amount of tissue (150 mg) is available for a more 
complete assay to be performed, not only the amount of receptor and its 
specificity, but also its affinity for oestradiol can be determined by the 
application of Scatchard analysis.
3
This requires measurement of H-oestradiol binding at several different
concentrations of steroid (seven are used in the present system). The
assay developed by Hawkins et al., (1975) is very similar in form to the
one described in this thesis. The authors, however, measure specificity
of binding at every point on the Scatchard plot. In the course of this
study, this procedure was found to be unnecessary on a routine basis (due
to the relatively low - 15% - non-specific binding found in most breast
tumours) and the tissue requirement is also kept to a minimum. Specificity
-9was determined at only the maximum concentration of oestradiol (10 M), 
while the absolute level of receptors (specific and non-specific) and the 
dissociation constant of binding (Kd) are derived from the Scatchard plot 
(see Methods, section 2.2.4, for a full explanation). Only when the level 
of non-specific binding is high, would the absolute level of receptors 
determined from the plot vary significantly from the specific number.
This would be detected using the "one-spot" test for specificity and, 
sample size permitting, the assay could be repeated with competition at 
each concentration. An assay of a similar form to the one reported here
- 149 -
was described by Feherty et al., (1971). That method required only 100 mg 
of tissue, but was more complicated in its operation. This fact would 
render it less suitable for application on a routine basis than the system 
described in this thesis.
In order to reduce the amount of material required to construct a Scatchard 
plot, Johnson et al., (1975) and Johnson & Nakamura (1977) have reported 
success in measuring receptors using a plot comprising only two points, 
as opposed to the seven deemed necessary by studies in this project.
They were able to detect receptors in as little as 50 mg of tissue using 
their system. The potential errors which could result from such a method 
are very great, however, and a "one-spot" study would appear to be 
adequate in cases of a limited supply of tissue.
Although the use of Scatchard plot analysis greatly enhances the yield 
of information from a binding study, the theory behind its application 
and the calculations involved in its construction appear complex. Mis­
understanding of the theoretical aspect can lead to errors in interpretation 
of results. This has been the subject of a review by Chamness & McGuire 
(1975), who concluded that misinterpretation of data caused delay in the 
publication of otherwise significant results, and they presented procedures 
for the correction of specific faults. The tedious nature of the cal­
culations involved in processing the results of a Scatchard analysis can 
be alleviated by the application of a computer programme, such as that 
designed by Aitken & Lippman (1977).
In spite of problems which might be raised due to errors in construction 
or interpretation of these plots, they are, nevertheless, of great value
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in providing useful information when properly applied. The fact that 
they can be used to determine the affinity of binding in addition to the 
amount of receptor means that it is possible to identify with greater 
certainty the nature of the receptor present. When used in combination 
with a competition study, therefore, three important parameters in con­
nection with steroid binding can be determined using relatively little 
material (concentration of receptor, its affinity and its specificity).
The use of a competition study on its own (a "one-spot" determination), 
although necessary in cases of minimal tissue availability, is not so 
satisfactory in its yield of information, as was demonstrated clearly in 
the course of quality control experiments, where "one-spot" assay results 
were shown to be misleading by comparison with results from the appropriate 
Scatchard plot (see Results, section 3.3).
An important observation made during the design of the present assay 
system was the instability of the hormone/receptor complex even at low 
temperatures. Katzenellenbogen et al., (1973),working with immature rat 
uterine material and Chamness et al., (1975) using mature rat uterus, 
found that exchange of added for endogenous steroid bound to the cytosol 
receptor did not occur to any measurable extent at 0°C, and determined 
that a temperature of 25°C or 30°C was necessary for any interaction to 
occur. Anderson et al., (1972), studying the nuclear receptor in the 
immature rat uterus, used incubation at 37^C for 1 hour to achieve exchange 
Studies carried out in this project revealed that exposure of nuclear 
receptor from postmenopausal breast tumour to these conditions would cause 
degradation, as demonstrated in Figure 9. However, stability of the pre­
menopausal form of the receptor, or nuclear receptor from mature rat uterus 
appears to be maintained for a longer period of time at this elevated
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temperature, as shown in Figures 10 and 8. This observation in pre­
menopausal breast tumour tissue may not be reliable, however, since the 
study on this tissue type was performed only once due to lack of suitable 
material. It is possible that the result obtained represents an atypical 
form of the receptor.
Figures 8-10 also demonstrate the ability of the nuclear receptors in 
these systems to allow the uptake of steroid at lower temperatures. Since 
the majority of receptors in the nucleus should be filled, this uptake 
should represent exchange of added for endogenous steroid. There may 
also be some filling of empty receptor sites, as these have been demon­
strated in the nuclei of breast tumour cells (Zava & McGuire, 1977, Kato 
et al., 1978, Thorsen, 1979) and form the basis of the mechanism of steroid 
action proposed by Sheridan et al., (1979). It is not possible to detect 
which of these situations prevails using the methods presented here.
3The uptake of H-oestradiol into breast tumour cytosol was also studied 
(Figure 11). The same pattern was noted as for the nuclear receptor.
This again fails to distinguish whether exchange occurs since the majority, 
but not all, of cytoplasmic receptors should exist in the unbound state.
The adverse effect of an elevated temperature (37°C) on these receptors 
is also shown in Figure 11. This had been reported previously by Feherty 
et al., (1971).
In an attempt to clarify the situation further, studies were carried out on
3 .the dissociation of H-oestradiol from nuclear and cytoplasmic fractions of 
postmenopausal breast tumour tissue in the presence of excess unlabelled 
steroid at 4°C and 20°C (see Figures 12 and 13). Preincubation of the
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3
separate fractions with H-oestradiol was carried out to ensure that all 
receptors would be filled with the steroid. Dissociation of labelled 
steroid in the presence of the unlabelled form in this system would, then, 
represent exchange since any possibility of heat degradation of receptor 
causing release of the labelled steroid is ruled out by studies carried out 
on the stability of binding at these temperatures (see Figures 9 and 11). 
Further reasons for destruction of receptor include action of agents such as 
proteases, but this can also be dismissed by the fact that labelled 
oestradiol can be taken up by the preparation to yield the original level 
of receptor after completion of the experiment (see Results, section 3.1.3.1)
The results of these studies were that exchange of added for endogenous 
oestradiol could occur up to a level of 80% at 4°C over a period of 24 hours 
in either tissue fraction, the same level being reached at 20°C after 2 hours 
Studies in our laboratory on oestrogen receptor in endometrial tissue has 
produced the same ability to demonstrate exchange, but this can be achieved 
to a level of 98% using the conditions above. Anderson et al., (1972), 
Katzenellenbogen et al., (1973) and Chamness et al., (1975) studying 
receptor in rat uterus, all came to the conclusion that a higher temperature 
was required to give exchange of added for endogenous steroid, possibly 
reflecting the variation in properties of the receptor in the two species.
The report by Anderson et al., (1972), however, does find a low level of 
exchange at 0-4°C over a period of 1 hour. It may be that, had this study 
been continued for a longer time, exchange of the order observed in the 
present study would have been achieved. An experiment performed in this 
project on immature rat uterine nuclear receptors revealed that they could, 
indeed, bind ^H-oestradiol at either 4°C or 20°C in the same way as could 
human breast tumour nuclear receptors (see Figure 15). This presumably
- 153 -
demonstrates the exchange properties of intact nuclear receptors even at 
low temperatures.
As stated earlier, it is not certain whether the difference noted between 
3 . .uptake of H-oestradiol in pre- and post-menopausal breast tumour biopsies 
shown in Figures 9 and 10 is truly significant. This is because the 
experiment could be performed only once with premenopausal tissue, due to 
a lack of receptor-positive premenopausal samples of a suitable size (at 
least 600 mg) on which to perform such a study. In general, premenopausal 
samples tended to be smaller than those from postmenopausal patients, 
probably due to detection of the tumours in the younger patients at an 
earlier stage. If, however, the finding here were to be repeated in 
subsequent studies on premenopausal tissue, it might reflect an increased 
stability of the hormone/receptor complex in conditions of high circulating 
levels of hormone; an environment encountered also in the cycling rat.
Since it has been demonstrated that the assay system in operation here 
causes exchange of added oestradiol for endogenously bound steroid, it 
follows that what is measured in the course of the assay is unfilled receptors 
plus 80% of the filled ones. This is using the times and temperatures for
incubation of 20°C for 2 hours or 4°C for 18 hours. This could be 
increased to 94% exchange using a 20°C incubation for between 4 and 24 hours, 
but, in practice,the overnight incubation at the lower temperature is more 
convenient. What is important is that the time and temperature should be 
monitored carefully, so that conditions are as nearly as possible identical 
for all tumours assayed. If this is done, then what is measured in each 
tissue fraction can be regarded as total receptor, the amount remaining 
undetected being very small. These conclusions invalidate the proposals
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that premenopausal tissue receptor levels are lower than postmenopausal 
ones due to endogenous steroid masking the majority of sites (Sakai & Saez, 
1976) , and that circulating levels of oestradiol should be considered when 
interpreting oestrogen receptor levels (Mobbs & Johnson, 1976, Nagai et al., 
1979), Further evidence that circulating levels of oestrogens do not 
influence breast tumour receptor concentrations comes from the finding 
during the course of this study that there is no correlation between the 
two parameters (see Results, section 3.4.5.5).
Even though the receptor assay measures total receptor, it is still 
apparent that cytosol receptor levels in premenopausal patients are lower than 
those of postmenopausal patients (Figure 22), A similar significant 
difference is also found at the nuclear receptor level (Table 12). The 
transition from low to elevated cytosol receptor levels appears to be 
associated with menopausal status rather than age, since the increase shown 
in Figure 22 is a sudden one rather than a gradual rise, which would be noted 
if age were the determining factor. This was also the conclusion reached 
by Allegra et al., (1979a). Having ruled out the possibility that receptors 
may be undetectable because of endogenous steroid being bound, another 
possible cause of the decreased premenopausal level would be that receptor 
resides mainly in the nucleus of these patients, having undergone, trans­
location in the presence of circulating oestradiol. The finding that 
nuclear receptor levels are also lower in pre- than in post-menopausal patients 
(Table 12), tends to overrule that theory. It may be that there is some 
form of down regulation in operation in the premenopausal woman, caused by 
the high levels of circulating oestradiol. Anderson et al., (1972) suggested 
that there is a maximal level of nuclear receptors required to give a
- 155 -
physiological response in the rat uterus, reflecting a limited number 
of acceptor sites within the nucleus. The proposed down regulation would 
save unnecessary synthesis of cytoplasmic receptor, but this property might 
be lost at the time of the menopause, allowing synthesis of greater amounts 
of receptor.
Other methods and conditions of the assay system established in this thesis 
are in good agreement with those published elsewhere. A satisfactory 
procedure for the storage of tissue has been designed, which maintains 
receptor integrity for at least 3 months, but has potential for much longer 
periods. A different storage system, involving the lyophilization of tissue 
is currently under investigation (see Results, Section 3.3) to assess its 
effect on oestrogen receptors. A reliable means of storage is of great 
value where it is desirable to assess primarily the receptor content of the 
tissue, and subsequently perform investigations on various aspects of receptor 
mechanisms. An adequate storage system is also required where assays are 
carried out on a routine basis and for quality control purposes. It may 
be necessary to repeat a determination for one reason or another, and it 
must be certain that the receptor status can be maintained throughout the 
period of storage. Storage in liquid nitrogen is a popular form, but this may 
be harmful to nuclear receptors, as judged by our experience (see Results 
section 3.1).
The procedure used here for the preparation of the tissue fractions yields 
very crude forms of each one, but this has been found to cause no interference 
in the measurement of receptors. Even the use of the detergent Triton X-100 
which would remove any non-nuclear material from the nuclear pellet was not
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observed to cause a significant change in receptor levels. Other workers 
use very rigorous methods to purify the tissue fractions, but McGuire 
et al.,(1977c) agreed with the present finding that this was unnecessary.
In common with the findings of McGuire & De La Garza (1973b) , it was noted 
that the thiol reagent dithiothreitol was successful in maintaining the . 
binding properties of the receptor. This is required due to the presence 
of sulphydryl groups on the receptor, which are reported to participate in 
the binding of steroid (Jensen et al., 1967, Muldoon, 1971). Keightley 
et al.,(1978) found that the presence of 1 mM DTT did not enhance the level 
of cytoplasmic receptors found in fresh or stored human myometrium assayed 
by a method similar to that presented here. The reason for this is not 
clear, as the receptors in this tissue should have the same basic form as 
those of the mammary gland.
No requirement for protease inhibitors was found in the determination of 
oestrogen receptor levels in human breast tissue. This is in contrast to 
the findings of Garola & McGuire (1977b) that protease activity interfered 
with the detection of receptors in breast tumour nuclear fraction. However, 
the method being considered (Zava et al., 1976) measured salt extracted 
receptors, which may be more sensitive to attack by these enzymes than 
receptor associated with chromatin.
When the receptor assay method was evaluated using replicate assays of the 
same cytosol and nuclear preparations (see Table 3), or assay of different 
slices from the same piece of tissue (see Table 2), little variation was 
seen on a purely qualitative basis. However, when a quantitative assessment
- 157 -
of the variation in receptor levels across a tumour was made, a five-fold 
variation was observed. The variation within a bulk preparation of cytosol 
or nuclear fraction was relatively small ('^ ±20%), so the difference in 
tumour slices reflects the heterogeneity of the tissue, rather than any 
fault in the assay system. Although Hawkins et al., (1977) proposed that 
this heterogeneity was so great that replicate tissue samples should be 
assayed, this does not appear to be necessary if a qualitative assessment of 
results is to be made. Engelsman et al., (1973) and Walt et al., (1976) 
found that response to hormone therapy was not effected by the absolute 
level of receptors in positive tissue. This suggests that the presence or 
absence of receptor in each fraction, along with a measure of its affinity 
and specificity, is all that is required to provide an index of potential 
response to hormone therapy. However, some groups have reported that a 
quantitative relationship may exist between receptor concentration and 
response rates.
By classing as "receptor-positive" only those biopsies containing receptor in 
both the nuclear and cytoplasmic fractions of the tissue, the occurrence of 
receptor-positivity is lowered relative to that found-by workers measuring 
cytosol levels alone (e.g. McGuire et al., 1975a, Wittliff et al., 1976,
Byar et al., 1979). Approximately 30% of the biopsies assayed in this 
study fell into the receptor-positive category using this criterion. A 
level of 50-60% or even greater has been reported on the basis of cytosol 
receptor measurement alone. This apparent discrepancy is attributable, at 
least in part, to the fact that the inclusion of a nuclear determination of 
receptors reveals a group of tissue samples which contain only cytosol 
receptor. A preliminary study was carried out to try to determine whether 
this receptor could be induced to translocate into a nucleus known to be
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responsive to oestrogenic stimulation. Figure 20 shows results which 
suggest that this is not the case. The findings from this study are too 
limited to state with any certainty what defect, if any, prevents the trans­
location of receptors in these cases. As with other studies in this project, 
further investigation was impeded by a lack of suitable amounts of appropriate 
tissue. The frequency of samples bearing cytosol receptors alone is low 
(12% of biopsies bear this receptor status), and the requirement for 500- 
600 mg of such tissue further limits the supply of material for this study.
The fault in the translocation processes of these tumours containing solely 
cytosol receptor could lie with the receptor, which might have structural abnor­
malities, preventing its entry into the nucleus. The other possibility i.s 
that the defect is at a cellular level, the translocation mechanism being 
faulty. It is not clear as yet how the receptor or the hormone/receptor
complex enters the nucleus, but if there were a facilitated entry process,
this would be a likely site of blockage. In this case, a structurally normal 
oestrogen receptor would be prevented from entering the nucleus by such a
defect. Investigations of the ability of cytoplasmic receptors from this
abnormal tissue type to enter the nucleus of tissue known to permit trans­
location (see Results, section 3.4.1) could aid in the elucidation of the 
type of defect in operation. Consistent failure to observe translocation 
in such a system would suggest that the receptor was at fault. It is 
possible, however, that the abnormality is not the same in every case.
If there is, in fact, no defect in the cell or receptor, then another 
explanation for the occurrence of tissue bearing this abnormal receptor 
status is that no oestradiol is present in vivo to cause translocation of 
the receptors. This is unlikely, however, since oestradiol has been shown
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to be necessary for the synthesis of its own receptors (Sarff & Gorski,
1971, Clark et al., 1977). The presence of cytoplasmic receptors thus, 
in itself, suggests the existence of circulatory steroid. Other evidence 
against this idea is the finding that plasma from patients bearing tumours 
with this receptor status has been demonstrated to contain oestradiol (see 
Results, section 3.4.5.5 ). A further explanation for the apparent 
absence of nuclear receptors would be that the nucleus does in fact contain 
a very low level of binding not detected by the assay system. The sensitivity 
of the assay tends to overrule this suggestion. Values as low as 25 fmol/mg 
DNA can be measured, although very few positive samples exhibit a level 
lower than 200 fmol/mg DNA. A final possibility for the absence of nuclear 
receptors in the presence of detectable levels of cytoplasmic binding is 
that some nuclear receptor may exist too tightly bound to chromatin to 
exchange with added steroid. This again would suggest a very low level of 
receptor, as it must all exist in this non-exchangeable form.
When patient follow-up data are analysed, only 24% of tumours with detectable 
receptor in the cytosol alone respond to hormone therapy. This suggests 
it is unlikely that functional receptor is present in the nucleus, but not 
detected because of some fault in the assay procedure. This in turn 
suggests that some translocation defect probably does exist within the cell, 
whether it be at the level of receptor structure or cellular functioning.
The 20% of tumours in this class which do respond to hormone therapy may 
do so through an indirect pathway, such as the inhibition, by tamoxifen, 
of prostaglandin synthetase (Tisdale, 1977) or the repression, again by 
tamoxifen, of prolactin stimulation of the tissue (Jordan & Dowse, 1976), 
although this latter action of tamoxifen has been discounted by Moseson 
et al., (1978). A proportion of the responders may represent a few cases
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where nuclear receptor levels are very low, or the receptor is non­
exchangeable, although this appears unlikely, as discussed above. The 
total number of patients in this group for whom response to hormone therapy 
has been assessed is still relatively low. This means that the figure of 
20% set for response rates of tumours containing only cytoplasmic receptor 
must be considered preliminary. Further follow-up information may reveal 
a figure closer to that encountered with receptor-negative patients, which 
would be predicted from a knowledge of receptor mechanisms. However, the 
fact that this percentage is higher than that for receptor-negative patients 
may prove to be significant, and indicate some other variable which should 
be considered^
Whatever the reason why 20% of tumours having only cytosol receptors respond
to some form of hormone therapy, the vast majority do not. The ability
to identify this group of patients is, thus, obviously of great value, since 
they are spared a regime of therapy, ineffectual for them, which may include 
the trauma of surgical procedures. However, modern endocrine therapy is 
additive and uses principally antioestrogens or chemical adrenalectomy by 
aminaglutethimide, Thus, the measurement of nuclear as well as cytoplasmic 
receptors is important, as it reduces the number of patients who would be
predicted to respond to hormonal manipulation, but do not. This was also
the conclusion of a study by Thorsen & Stoa (1979), although the number of 
patients they used (16) seemed to contain an unusually high incidence of 
cytosol-positive, nuclear-negative cases (25%), stressing the inadvisability 
of drawing conclusions from statistically insignificant numbers.
On the basis of the argument above, it might be concluded that the assay of
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nuclear receptors alone would be adequate in estimating the responsiveness 
of tumours to hormone therapy. However, the existence of a percentage (6%) 
of tissue bearing only nuclear receptors invalidates this proposal since 
the majority of such tumours do not respond to hormonal manipulation. The 
situation where receptors are detected only in the nucleus has also been 
reported by Zava & McGuire (1977) and Zava et al., (1977) studying MCF7 cells, 
and by Panko & MacLeod (1978) using breast tumour tissue. They all report 
that these receptors exist in the nucleus in an uncharged state, but the 
method used in this report would not distinguish between filled and empty 
receptors, due to the exchange properties which have been demonstrated. It 
is not clear what situation exists in the cell in these cases, but it 
appears that receptor may have translocated into the nucleus in the absence 
of hormone, or perhaps bound to a weak ligand. It is physiologically 
possible for oestradiol to pass into the nucleus from the cytoplasm on its 
own, but whether this would subsequently bind to the empty receptor residing 
in the nucleus, form the activated complex with it and, further, elicit a 
genetic response is open to question. Perhaps the best guide to the 
situation is the response of such tumours to hormone therapy. When follow- 
up information was compiled on this group of patients, it was found that 
only 12% of them did respond to hormone therapy. This therapy includes 
ablative and additive forms and, thus, the failure to respond to either type 
contradicts the proposal by Zava et al., (1977) that antioestrogen, but 
not ablative, therapy should be effective in these cases. Their study 
was performed on MCF7 cells, however, and it is recognised that the receptors 
from this source may not be typical of those found in solid tumour deposits.
The numbers of these patients who have been successfully followed-up is low, 
and the percentage response may change as more information is collected.
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At present, however, it appears that the empty nuclear receptor is not 
capable of stimulating growth of the tissue. Blocking the hormonal 
pathway is thus not effective in halting tumour development. These 
findings also suggest the presence of both the hormone and the receptor 
in combination in the nucleus is required in order to elicit a genetic 
response. It may be that the hormone directs the receptor to the acceptor 
sites on the chromatin. Since the receptor does not, on its own, cause 
growth, it may be able to interact with chromatin, but not at the appropriate 
active sites required to produce stimulation.
These ideas are valid only if the chromatin has remained undamaged through­
out the process of malignant transformation. If any damage has occurred, 
then it is possible that it is the inability of the chromatin to bind the 
hormone/receptor complex at the correct sites which causes the tumour to 
be unresponsive to hormonal stimulation. In any case, the physiological 
regulation of receptor synthesis may be modified in these cells. It has 
been suggested that it is the disappearance of receptor from the nucleus, 
rather than its reappearance in the cytosol which may be important in 
causing oestrogenic stimulation (Koseki et al,, 1977), Binding to the 
correct sites in chromatin may be required as part of this processing, and 
if processing is absent, receptor would be maintained in the nucleus, 
causing a block to any further stimulation.
When the receptor-positive tumours (i.e. those containing detectable 
levels of both nuclear and cytoplasmic receptor) are considered, 71% of 
those which would be predicted to respond do regress on hormone therapy.
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"Response" has been defined by the British Breast Group (1974). Amongst 
the criteria for response are that the size of the lesion must shrink to 
50% of its original, and this be noted over a period of six months, with 
no new lesions appearing. These rules have been criticized by Stoll (1977), 
as being too strict. He feels that the time period is too long, and that 
patients he would have regarded as showing a response cannot be classed 
as such due to their failure to complete the six month period. He also 
points out that to shrink in size by 50%, a tumour must decrease its volume 
to 1% of the original. This seems to call for a very great improvement. 
However, these rules have been adhered to in compiling the present follow- 
up data. Using less strict criteria, the success rate in predicting 
response to hormone therapy would be improved, but the figure of 71% 
based on both cytoplasmic and nuclear receptor status is still an improve­
ment over that obtained using cytosol receptor status alone, and the same 
rules governing the definition of response.
Although the figure of 71% of potential responders who do respond might be 
improved upon using altered criteria, there are still a number of cases 
where the predicted response fails to occur. There are many explanations 
for this observation. One possible cause is that the tumour consists of 
a mixed cell population, a percentage of which are hormone-dependent and 
the rest autonomous. This could arise in two ways. If the tumour had 
been derived from one well-differentiated cell which could synthesise 
receptor, then all the daughter cells would be hormone-dependent initially. 
They could then slowly become autonomous, as observed by Kim & Depowski 
(1975), giving firstly a mixed cell population, and then a totally auto- 
onomous tumour. The other way in which a mixed cell population could arise, 
would be by the tumour being formed from transformation of two different
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cells, one cell being well-differentiated and the other not. Autonomous 
cells appear to be more rapidly-growing than hormone-dependent ones, and 
the former would eventually become the predominant type. In either of 
these cases, sampling of the tumour might yield a receptor-positive result. 
However, when hormone therapy was applied, the hormone-dependent cells 
would respond, but the autonomous cells would continue to grow. The 
patient might, or might not, experience a short-lived relief from disease, 
depending on how great is the proportion of hormone-dependent cells. This 
fact might indicate that a combined therapy would be the best type in all 
cases of breast cancer. However, it is not now certain whether chemo­
therapy is of more benefit to autonomous or hormone-dependent tumours, 
since conflicting reports have appeared on the relationship between receptor 
status and response to chemotherapy (Kiang et al., 1978, Lippman et al.,
1978). It must be assessed whether either of these reports is accurate, 
since both contain apparent errors in the assessment of patients. The 
discovery of what correlation, if any, exists between receptor status and 
response to chemotherapy will be an important step in the treatment of 
breast cancer, since chemotherapy has severe side effects associated with 
it, which makes it desirable to decide whether any benefit will be experienced 
as a result of therapy.
Another explanation for why some apparently hormone-dependent tumours do 
not respond to hormonal manipulation is that there may be some control 
point further along the chain of reactions to hormonal stimuli which can 
be blocked without effecting receptor levels. This has been suggested 
also by Jensen & De Sombre (1977), and was the reasoning behind the 
concept that some physiological product of oestrogen action should be 
sought to give a more accurate measure of hormonal stimulation. As
- 165 -
mentioned earlier, the most popular of these products has been the 
progesterone receptor. However, none of the markers which have been 
suggested as yet, including the progesterone receptor, has formed a 
completely successful guide to hormonal-dependence. A marker of a later 
response has been discovered recently by Westley & Rochefort (1979) in 
the form of a secreted protein, which is detected easily by one-dimensional 
polyacrylamide gel electrophoresis. This protein appears to be specifically 
produced by oestradiol, but the study was carried out on MCE 7 cells, and 
tests would have to be performed on different tissues before confirming this 
to be a true marker of oestrogenic stimulation.
Since only 9% of receptor-negative tumours respond to hormone therapy, it 
can be stated that in 91% of the cases, the correct prediction of response 
is given. This is compared to a predictive accuracy of 71% when con­
sidering receptor-positive tissue. This emphasises the conclusion reached 
by Maass et al., (1972, 1975), Jensen (1975), King (1975) and Lippman (1976) 
that a receptor-negative result is of more reliable predictive value than 
a receptor-positive finding. In the present study, overall prediction 
of response of all patients to hormonal manipulation is correct in approxi­
mately 85% of cases. The success rate in the other reports was lower, as 
only cytoplasmic oestrogen receptor was measured, but their observation is 
still applicable to the case being studied here. It was found in this 
study that a receptor-negative result was also more often reproduced after 
the transition from primary to secondary disease (see Table 6), or in 
comparison between one secondary deposit and another (see Table 7). In 
only 2 cases out of 32 did the receptor status change from being negative 
in the primary to some degree of positivity in the secondary. This 
phenomenon of gaining receptors has been reported by Korsten et al.,(1975)
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and Liskowski & Rose (1976) also, but it is not readily explicable. One 
possible explanation could be that receptor synthesis was suppressed by 
some agent, e.g. tamoxifen (see Results, section 3.4.2) or cytotoxic 
drugs before the primary biopsy was taken. This practice is sometimes 
carried out to shrink a tumour in order to ease its removal. This was not 
the case, however, in either of the instances reported here. A further 
possibility would be that of heterogeneity of the tissue, discussed earlier 
in relation to false-positive results. If the piece assayed on either the
first or second occasion were unrepresentative of the lesion as a whole,
the consequence would be an atypical result. Studies carried out on the 
variation in receptor levels across a piece of tumour biopsy do not provide 
evidence of a difference of the magnitude required by this explanation, 
although heterogeneity may vary from one tumour to another.
The consistency of receptor-negativity is also noted when receptors are 
measured in more than one secondary deposit from the same patient. Here, 
in only one case out of 20 did a receptor-negative secondary lesion change 
to receptor-positive at a more advanced stage. It is not so easy, however, 
to assess the behaviour of receptor-positive biopsies on the same basis 
as has been used above. The smaller number of instances where repeat assays
have been carried out on such lesions reflects the longer disease free
interval and better overall prognosis observed in patients bearing hormonally- 
dependent tumours (see Results, section 3.5,2). If dedifferentiation of 
cells does occur, then all hormone-dependent tumours will become autonomous 
eventually, but this process may take a long time.
These findings of variation between primary and secondary tumour receptor 
levels and between those in different secondary lesions, although relatively
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small, differ from the conclusions of King (1975) and Jensen et al., (1977) 
that receptor status at one site would consistently predict response at 
another. The numbers of patients in their studies were low, however, 
which could account for this apparent anomaly. On the basis of the present 
results, it is clear that the discovery of receptor in one fraction only 
means that there is very little chance of another lesion producing the 
same result (see Tables 6 and 7). However, in neither of these classes 
can a response to hormone therapy be expected on the evidence from follow- 
up information (see Table 13). Since the alterations seen in Tables 6 
and 7 are mainly from one of these categories to the other, or into a 
state where no receptors are detectable in either fraction, the alterations 
in status do not generally reflect a change in predicted responsiveness.
This fact, along with the reproducibility of receptor-negative results 
and low reappearance of receptor-positive tissue, means that routine assay 
of receptor content in primary breast tumour biopsies to aid in the choice 
of therapy for subsequent lesions, as proposed by Jensen (1975), is a 
viable concept. Variations may occur, but these should not, in general, 
alter the optimal therapeutic regime. Roberts et al., (1978) conclude 
that surgery, which might prove harmful to some patients, should not be 
performed with the sole object of providing a sample of tissue for 
receptor assay, because of inconsistencies between receptor levels and 
patient response. From the data presented here, this might be agreed, 
but a receptor assay should be carried out if surgery is being performed 
anyway.
The study of variation in receptor levels measured in serial biopsies has 
also yielded some interesting information on the mode of action of the 
antioestrogen tamoxifen. This is a very popular drug for the treatment
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of breast cancer, but the reasons for its antioestrogenic actions are 
not fully understood. Clark et al., (1973) proposed that nafoxidine acted 
by detaining the receptor in the nucleus for an extended period of time 
(up to 19 days) but caused no cytosol receptor replenishment, thus blocking 
the action of further oestrogens. Competition for receptor sites and 
lack of replenishment were also suggested by Clark et al., (1974) and 
Katzenellenbogen & Ferguson (1975), although the repressed recycling 
of receptors was not observed by Nicholson et al., (1976) or Koseki et al., 
(1977), using levels comparable to those used in treatment of human breast 
cancer. Koseki et al., (1977) also demonstrated that the replenished 
cytoplasmic receptor could be translocated into the nucleus by oestradiol, 
and postulated that lack of replenishment was not the basis of anti­
oestrogenic effects. They suggested that the slow clearance rate of 
tamoxifen from the nuclear fraction was more likely to be the cause of 
the inhibition of oestrogenic stimulation, the active loss of receptor from 
the nucleus being of greater importance than its reappearance in the cyto­
plasm. A new theory on the mode of action of the drug has been proposed 
recently by Fishman & Fishman (1979). They find that tamoxifen binds to 
only some of the receptors available in the cytoplasm, others being sensitive 
to oestradiol alone. They further postulate that oestrogenic stimulation 
requires the translocation of both of these forms into the nucleus, which 
does not occur in the presence of the drug.
The findings from this project were that tamoxifen appeared to abolish receptor 
completely for at least 3-4 weeks. Since the clearance rate of the drug 
itself is considerably less than this (Nicholson, 1979), the absence of 
detectable receptor is thought to be the result of repression of synthesis, 
possibly at a genetic level, rather than a blockage of oestradiol by
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tamoxifen molecules already bound to the receptor. No receptor is 
found in either tissue fraction after tamoxifen treatment, so its effect 
must be on both receptor recycling and de novo synthesis of receptor, which 
is in agreement with the mode of action for anti oestrogens proposed by 
Clark et al., (1973).
When instances of bilateral breast cancer were encountered, it was found 
that the hormonal status of the disease in one breast was not always 
reflected in the other. The incidence of these cases was very low (4 cases 
out of 900 samples), but enough to demonstrate this fact. This may have 
great significance in the elucidation of the mechanisms involved in tumour 
formation. For a tumour to be hormone-dependent, activation of the genes 
employed in hormone receptor synthesis is required. This may or may not 
occur as a result of malignant transformation. The finding that two 
tumours of the same part of the body produced at different times may vary 
in hormone-dependence suggests that different stimuli may be involved in 
each case, given that either the cells initially transformed were both 
at the same stage of differentiation or that different stimuli react 
with different types of cell. The form, or forms, of malignant trans­
formation not causing receptor synthesis activation is(are) more common, 
and also more lethal than the other type, as shown by the poorer prognosis 
of patients with receptor-negative tumours (see Results, section 3.5.2).
The solution to why cells should react in different ways to these stimuli 
or whether some stimuli are specific for cells at a certain stage of 
differentiation may reveal their identity, and thus aid in the cure and, 
indeed, prevention of cancer.
The correlation between receptor status of the tumour and various other
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factors linked with the disease were studied. As discussed previously, 
in common with many workers, a connection was found between menopausal 
status and cytoplasmic receptor levels. No correlation between receptor 
status and age was found. In accordance with a report by Allegra et al., 
(1979a), the effect seen on comparing cytosol receptor levels with age is 
solely due to the menopause. In agreement with Johansson et al., (1970), 
Rosen et al., (1975), Maynard et al., (1978) and Maynard & Griffiths (1979), 
no link could be found between any particular histological feature and 
receptor status (see Results, section 3.4.5.2). The latter two reports 
did find a connection between histological grade and receptor status, but 
only in post menopausal patients. This is another example of,the effect 
of menopause on the tissue. Examination of clinical stage in relation to 
receptor status in the present study yielded no evidence of correlation 
when patients were considered without regard to their menopausal status 
(see Table 8), although the number of patients involved in some sub-groups 
was too small to allow definitive conclusions. Estimation of lactalbumin 
presence could not be correlated reproducibly either with receptor-positivity 
or-negativity (see section 3.4.5.3).
Another area studied was the level of oestrogen receptors in plasma of 
breast cancer patients. A report by Tisman & Wu (1976) suggested that the 
levels in the tumour were reflected by plasma levels. In common with 
Leclerq et al., (1973), no receptor activity could be detected in any plasma 
sample from patients with various forms of breast cancer (see Figure 21), 
ruling out the idea of using plasma instead of solid tissue to furnish an 
index of hormonal-dependence. Another study carried out on plasma compared 
the levels of various steroid hormones therein with the receptor status of 
the patients' tumours(see Results, section 3.4.5.5). This, again, showed no
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correlation which could be of use in the treatment of breast cancer.
These last two approaches could have proved very useful in the field of 
breast cancer treatment had they been successful, since a small amount of 
blood would have been the only requirement for the decision as to what 
type of therapy should be applied and could have been used to evaluate 
response to therapy. The use of blood would also provide a simple method 
whereby it could be decided whether any therapy at all should be prescribed. 
The prognosis of some patients is so poor, that it might be applicable, 
on an ethical basis, to save them further distress by surgical operations 
or complex therapeutic regimes which might serve only to cause more dis­
comfort.
It appears from the results above as a whole, that there is no other parameter 
which can replace the measurement of solid tumour receptor status in giving 
an index of hormonal-dependence.
Another useful finding from the study of follow-up data is the relationship 
between receptor status and patient prognosis (see Results, section 3.5.2), 
Only tumours with positive or negative receptor levels in both tissue 
fractions could be assessed in this study, as the numbers involved in the 
other groups were so small. It was clearly demonstrated that receptor- 
negative tumours exhibited a much shorter disease free interval than 
receptor-positive ones. This has also been observed by many other workers 
(Walt et al.. 1976, Knight et al..1977. Block et al.. 1978, Hhhnel et al.. 
1979, Maynard & Griffiths, 1979) and is emphasised in Tables 6 and 7, where 
repeat assays have been carried out on many more receptormegative than 
receptor-positive biopsies. Receptor-negative tumours were also noted to 
metastasise over a far wider area of the body, receptor-positive recurrences 
being limited to mainly local disease. This was also reported by Knight
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et al., (1977) and Byar et al., (1979), and probably reflects the more 
virulent nature exhibited by receptor-negative cells, as noted by Meyer 
et al., (1977). Both of these observations indicate that the receptor- 
negative tumours are more aggressive, and prognosis of patients bearing 
such tumours is much worse than that for those with receptor-positive 
lesions,
Nodal status has also been related to receptor level of tumour tissue 
(Allegra et al., 1979a) and patient prognosis (Hhhnel et al., 1979).
The correlation between these factors was studied for the results presented 
here. Table 10 illustrates that no correlation could be found between 
receptor status and nodal status. When considering disease free interval 
also, data were analysed only for patients with either cytoplasmic and 
nuclear receptor-negative or cytoplasmic and nuclear receptor-positive 
status. Node-positive, receptor-negative patients had much the worst 
prognosis, as would have been predicted. Equally, node-negative, receptor- 
positive patients had the best prognosis (Figure 26). Intermediate groups 
behaved comparably until 20 months after diagnosis, beyond which nodal, 
rather than receptor, status appeared to act as the more reliable guide 
to prognosis. This conclusion is in agreement with that of HMhnel et al., 
(1979).
In addition to breast tumour biopsies, measurement of oestrogen receptor 
levels was carried out on biopsies of tumours from other parts of the body. 
The majority of these assays were performed on colorectal carcinoma samples. 
It was thought that the presence of receptors in this area might provide 
a useful aid to treatment selection, just as it had in cases of breast 
cancer. No oestrogen receptors of the type found in breast tissue could
- 173 -
be detected in colonic neoplasms, using the method successful with breast 
tumour biopsies. This is in contrast to the findings of McLendon et al., 
(1977) and Alford et al., (1979), although the levels found by them were 
sometimes relatively low. Binding was observed in a few cases in this 
study, but it did not satisfy the criteria established in Results, section 
3.4 for true oestrogen receptor. The reasons why no receptors could be 
detected in colonic samples, whether from male or female patients, is not 
clear, since much circumstantial evidence, such as a link between colo­
rectal and breast cancer (Hermann, 1972), a connection of hormone- 
dependent tumours with diet (Berg, 1975) and the influence of the menstrual 
cycle and pregnancy on water uptake of the intestine, suggests potential 
hormonal influence in this area. One possible explanation is that all 
the biopsies obtained were from patients with well-advanced disease, which 
might have lost any hormonal-dependence due to dedifferentiation. Further 
work in this area, including studies of less advanced disease, and patient 
response to hormonally-based therapies, may yield further, relevant 
information.
Another tissue source in which oestrogen receptor levels were measured 
was breast tissue of either normal or benign tumour origin. Normal tissue 
was obtained from patients undergoing mammaplastic reduction. The 
majority of these patients were post menopausal and the normality of such 
tissue might be questioned. Care was taken, when measuring receptor 
levels in this tissue, to minimise adipose tissue contamination, since 
this could lead to erroneous results. In spite of the findings of
Feherty et al., (1971) and Hawkins et al., (1975) that receptor could be 
detected in benign tumour tissue (although in very low levels), no binding 
was found in any such sample examined in the present study and no receptor
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could be detected in any normal tissue samples either. This is in 
agreement with the theory that in the normal, non-lactating mammary gland, 
oestrogen receptor levels are so low as to be virtually non-existent, 
and the finding of Block et al., (1975) that normal breast exhibited only 
a very low level of oestradiol uptake.
The studies reported in this thesis could contribute much towards the 
treatment of breast cancer. By developing a reliable method of determining 
both cytoplasmic and nuclear levels of oestrogen receptor protein from 
breast cancer biopsies, it has been possible to increase the value of 
receptor measurements in providing an index of response to hormone therapy. 
Follow-up studies show that this is so, although there exists still a 
proportion of patients who should respond to hormone therapy, but do not.
It is hoped that the in vitro approach discussed in Part II may reduce the 
size of this percentage as well as aiding in the selection of patients for 
chemotherapeutic regimes. The reproducibility of the assay system has 
shown that, in the majority of cases, receptor status is carried from one 
disease site to another. This knowledge is particularly valuable in the 
treatment of inoperable, secondary deposits often associated with breast 
cancer. This has been suggested before, but the evidence reported here 
represents many more patients. Although other assay systems have been 
developed to determine the hormonal-dependence of breast tumours, the one 
discussed here appears to be more successful in terms of potential 
responders who do experience relief from hormone therapy of any kind.
The valuable information furnished about oestrogen receptors by this work 
includes the data on the stability of the hormone/receptor complex at low
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temperatures. Whereas it was thought that high temperatures were required 
to achieve the displacement of the hormone from this complex in either 
tissue fraction, it has been shown that exchange can occur at temperatures 
as low as 4°C or 0°C. Studies on the receptor content of both the 
cytoplasmic and nuclear fractions of breast tumour tissue have also revealed 
defects which may exist in steroid mechanisms of action. The most 
interesting- of these is the ability of the receptor to exist, unfilled, in 
the nucleus without causing oestrogenic stimulation. Many interesting 
facts may emerge from the knowledge of the role of this species in the 
nucleus - whether it will combine with hormone in situ, or whether it 
passes into the cytoplasm before this action takes place. The possibility 
of translocation induced by weak ligands has also to be considered.
Several plasma steroids could potentially promote translocation of oestrogen 
receptor especially in post menopausal women. The ability of anti­
oestrogen/receptor complex to induce some but not all oestrogenic responses 
raises the possibility of interaction with only a proportion of the 
acceptor sites.
Although the present detection method does not distinguish between empty 
and filled receptors, the ability to establish whether the empty form is 
present: in the nucleus at all times would help to clarify the question 
of whether the classical two-step mechanism of action of steroid hormones 
holds, or whether the new theory proposed by Sheridan et al., (1979), 
involving receptor freely passing from one tissue fraction to the other 
might pertain. The nature of the regulation of translocation should be 
clarified after further examination of the receptor in biopsies of the 
cytosol-positive, nuclear-negative type.
PART II
in vitro studies
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1. INTRODUCTION
1.1 DEVELOPMENT OF CULTURE TECHNIQUES
The establishment of a system whereby cells and tissues could be isolated in 
artificial surroundings away from the controlling and modifying influences of 
other parts of the body has long been recognised as a useful step in the 
understanding of the metabolic regulation of an individual tissue. The first 
recorded instance of such a system was in 1885 when Wilhelm Roux studied the 
actions of the medullary plate from a chick embryo in warm saline solution.
With this model, he was able to prove that closure of the medullary tubes was 
a function of the constituent cells rather than the action of pressure from 
surrounding tissues. This report was quickly followed in 1887 by one from 
Arnold, who noted migration and survival of leucocytes formed after trans­
plantation of alder pith into frogs. He also used warm saline as the bathing 
medium. Following these first demonstrations that cells in fact could be 
maintained for several days outside the body and without links with others, 
many reports appeared of similar findings with different types of tissue. These 
systems utilised different kinds of medium. Ljunggren in 1898 bathed skin 
in ascitic fluid and maintained its survival for some time. Agar was used by 
Loeb (1902) to grow epithelial cells from guinea pig epidermis. The 
cultivation of isolated plant cells was first attempted by Haberlandt in 1902, 
but his initial system failed, although subsequent models were more successful 
(Paul, 1975). Jolly in 1903 actually observed cell division in salamander 
leucocytes isolated by the hanging drop technique (see Willmer, 1965). De- 
fibrinated blood was the medium used by Beebe and Ewing (1906) in their attempts 
to grow a canine infectious lymphosarcoma.
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All these systems contributed towards an understanding of the requirements for 
growing isolated cells or tissues, but in 1907, a major breakthrough was made 
in this field by Ross Harrison. He grew nerve cells from the spinal cord of
a tadpole in clotted lymph from a frog. This system not only proved a
successful culture method but also furnished the answer to a very controversial 
question at that time; namely whether nerve fibres grow from nerve cells or are 
secreted by the tissues through which they pass. Harrison's work proved 
conclusively that the cell alone is responsible for the formation of the axone.
The method of using a clot as the culture medium was further developed by Burrows, 
who substituted plasma for the lymph clot. Together with Alexis,Carrel, he 
developed routine methods for the culture of normal and neoplastic animal cells 
(Carrel & Burrows, 1911a,b). Unfortunately, their method could not be used 
for human tumour cells, as these tended to liquefy the plasma clot.
One of the main problems which impeded a more widespread application of tissue 
culture techniques at this time was that of bacterial contamination. In the
absence of antibiotics, which were not used in tissue culture until around
1940, aseptic conditions were very difficult to achieve. Alexis Carrel used 
his surgical experience (Carrel, 1923) to attain a sterile environment, but, 
unfortunately, his tedious and complicated methods proved discouraging to many 
potential tissue culturists. However, using these techniques, Carrel (1912,
1914) did succeed in maintaining some connective tissue cells in an active 
state for thirty-four years (Parker, 1950).
Other innovations which served to make cell culture a more feasible system 
included the development of suitable culture vessels. Carrel introduced the method
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of cultivating cells in flasks, and Gey (1933) developed the roller tube 
which held more medium, thus permitting the growth of more cells. Following 
this, from the 1940's onwards, the potential of an in vitro system, applied to 
cancer research in particular, was being appreciated, and much effort was 
expended in the development of better media. The early workers in tissue 
culture had used saline as their medium, but it was realised that all require­
ments of the cells should be considered when preparing a growth medium. As 
reported by Fell (1965) and Willmer (1965), many investigators worked to 
develop the forms of media available today, their efforts being complicated by 
the different requirements of different cell types.
The term "tissue culture" is commonly used to encompass three different systems. 
The first of these, which was the type of system used in the early experiments 
discussed above, was literally tissue culture in that small fragments of tissue 
were used, and encouraged to grow in isolation, whilst continuing normal 
functions. Another method developed later was cell culture, in which the 
organisation of the original tissue is disrupted. The preparation of single 
cells can be achieved by digestion of the tissue in trypsin. The action of 
trypsin was first noted by Claude Bernard in 1856 who was interested in why the 
stomach and intestine are digested by their own juices after death. Fermi 
in 1910 then reported that cells can withstand prolonged treatment with trypsin 
which has since been disproved by Ceriani et al., (1978). Cells can endure 
brief exposure to the enzyme, however, and a method of using trypsin as a means 
of dispersing viable cells from their parent tissues was developed by Moscona 
& Moscona (1952) and by Dulbecco (1952) . Sanford et al., (1948) had demonstrated 
the cloning of single cells of one strain isolated from others before this.
This group also developed a method of preparing single cells after growing
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tissue in suspension (Evans et al., 1951). They, however, used a mechanical 
rather than enzymic method, passing the cells through a metal mesh.
The other culture method now used is organ culture. In this case, maintenance 
of the normal functions of the tissue is the chief aim, and the tissue is kept 
in an intact state, as close as possible to the conditions found in vivo.
1.2 MAMMARY TUMOUR CELL CULTURE
1.2.1 THE APPLICATION OE AN IN VITRO SYSTEM TO BREAST CANCER THERAPY
As discussed in Part I, there does not exist a reliable guide to aid in the 
selection of the optimal therapeutic regime for a patient with breast cancer.
It may be that a tumour will respond well to hormone therapy, chemotherapy or, 
indeed, a combination of the two, and that the identity of the actual agent(s) 
is critical. Clinical features, such as nodal infiltration or disease free 
interval can be useful predictive tools as can the presence or absence of 
oestrogen receptor proteins in the tumour, but there always exists a proportion 
of patients expected to respond to a form of therapy who do not. A routine 
method of quickly assessing the form which will give optimal benefit to the 
patient by observing the effect on the actual tumour cells in vitro would be 
of great value.
The establishment of a successful system for the cultivation of mammary 
epithelial cells from solid tumour would allow determination of hormone- 
dependence, and thus whether the tumour would respond to some form of hormonal 
therapy. The advantage of an in vitro assay system over the measurement of 
steroid receptors, or any of the products of hormonal stimulation, is that any
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physiological defects which are not made apparent by the latter systems might 
be made evident by the long-term behaviour of the cells in culture. Most 
forms of hormone therapy have been proposed on a purely empirical basis, but 
the establishment of an in vitro assay studying cell survival or proliferation 
would provide not only the information of whether a tumour should respond to 
hormonal manipulation, but also which particular form would be most beneficial 
to the tumour in question. This could be applied also to cytotoxic and 
combination forms of therapy, and several types of therapy could be tested at 
a single time. As mentioned in Part I, section 1.3.2.1, the form which the 
therapy takes is as important as the general type of therapy itself. The 
establishment of such a system was the aim of Burstein et al., (1971), Wellings
& Jentoft (1972) and Aspegren et al., (1975), all of whom used organ culture and
tested the short-term effects of various hormones. Due to problems in main­
taining the viability of the cells, these tests could last for only a few hours, 
and so long-term observations could not be made.
Another possible advantage of the in vitro system derives from the suggestion
that hormonal-dependence would give an indication of prognosis in cases of 
primary breast cancer (Barker & Richmond, 1971, Block et al., 1978). In 
addition to predicting the most effective therapeutic regime for any particular
tumour, the ability to grow neoplastic cells may give an insight into the
mechanisms by which mammary tumours in general survive and take over the body 
so successfully.
1.2.2 THE GROWTH OF MAMMARY TUMOUR EPITHELIAL CELLS
Despite the fact that the growth of mammary tumour cells could prove to be
an invaluable aid in the choice of therapy for breast cancer patients, it has
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been found to be a very difficult procedure, Whitescarver (1974) even 
published a review of the types of problems encountered. However, cultivation 
of normal mammary epithelium and other types of tumour tissue had been 
achieved (Lasfargues, 1953, Ebner et al., 1961). Many reasons have been 
proposed to explain why normal, but not neoplastic breast tissue was 
successful in culture. One of the main reasons proposed was that the 
tumour tissue contains a large proportion of dead cells due to previous 
therapy, necrosis or calcification (Whitescarver, 1974), and so the yield 
of viable cells is much smaller than from the same,amount of normal tissue. 
Other suggestions have been that tumour epithelial cells grow more slowly 
and thus are not so successful in establishing a hold over the stromal 
cells (Buehring & Williams, 1976), or that neoplastic transformation may 
cause a loss of junctional communication and, thus, organization between 
the cells (Fentiraan & Taylor-Papadimitriou, 1977).
The first report of successful culture of breast carcinoma cells came in 
1937 when Cameron & Chambers observed the pattern of growth from a tissue 
explant on a coverslip. Coman (1942) and Royle (1946) adapted the roller 
tube culture method developed by Gey (1933) to the growth of mammary tumour 
epithelium. These studies all examined the cultural characteristics of the 
cells moving out from the tissue explant. Coman noted differences between 
normal and malignant epithelium; in particular, that some isolated 
malignant cells broke away and displayed amoeboid movement, which may be 
related to invasive behaviour in vivo. One important common finding was 
that, prior to the appearance of the epithelial cells from the explanted 
pieces of tissue, stromal cells emerged. The presence of these fibroblasts 
is one of the major problems in the successful growth of mammary tumour 
epithelium. The mammary tumour is a solid one and contains a high proportion
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of fibrous stroma, giving rise to a high ratio of fibroblasts to epithelial 
cells (Foley & Aftonomos, 1965). It was thought at one time that epithelium 
might require the presence of fibroblasts for growth due to exchange of ions 
or other growth factors, but this may not be the case. (Fentiman et al.,
1976) . Fibroblasts replicate much more actively than epithelial cells 
(Owens et al., 1976), and, under normal tissue culture conditions, it has 
been observed that they quickly encircle epithelial colonies (Stoker et al., 
1978), investing the epithelial cells with a coating of collagen which the 
stromal cells exude (Lasfargues, 1973). This coating renders the epithelial 
cells inaccessible to trypsin, which is normally used to subculture colonies 
of cells. Thus, epithelial colonies die out after only a very short 
period of time (Ozzello, 1977). Of all the various difficulties encountered 
when attempting the culture of breast tumour tissue, the persistent appearance 
of fibroblasts has always been the major one.
The fragility of epithelial cells when isolated from their natural environ­
ment presents another considerable problem. It has been reported that even 
agitation of the culture vessel can cause damage to these cells (Wiepjes & 
Prop, 1970). Certainly, the method of dissecting tissue in order to 
release cells must be very gentle. This is complicated by the fact that 
tumour tissue can be so hard due to varying stages of calcification.
Lasfargues & Ozzello (1958) described a method whereby cells were "spilled" 
from tissue during slicing with a scalpel, which appeared to be a very 
successful procedure, but great care had to be taken during slicing not to 
damage the cells by undue pressure. Using this method, they managed to 
establish the first successful cell line of mammary tumour epithelium 
(BT20) from a primary duct cell carcinoma. This was serially cultivated 
for at least 20 months (Ozzello et al., 1960).
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Since there were dangers of damaging cells by this mechanical technique, 
the search for a more satisfactory procedure of breaking up tumour tissue 
continued. The alternative was an enzymic method, but the proteolytic 
enzyme trypsin was not successful as it could not digest the stroma, and 
also tended to cause cellular damage. Eventually, Lasfargues & Moore 
(1971) reported that collagenase digestion of tissue gave a high yield of 
epithelial cells. They claimed, moreover, that intermittent treatment 
with this enzyme (0.5 mg/ml) for 3 days every 3-4 weeks kept the culture 
almost free of fibroblasts. Even exposure to the enzyme for up to one 
week does not appear to harm epithelial cells (see Section 3.2.1.2), 
despite the presence of proteolytic factors in crude preparations of 
collagenase.
Collagenase was thought at one time to be a cytotoxic enzyme, and its 
application in this role had been discounted. However, collagenase is 
now known to act by attacking the dermal-epidermal junction (Kahl &
Pearson, 1967), although some less pure grades of commercial preparation 
contain proteolytic activities also. Collagenase has certain advantages 
over trypsin, the other digestive enzyme used in the isolation of single 
cells. Unlike trypsin, collagenase retains its full activity in the 
presence of calcium and magnesium ions and is not rendered inactive by 
serum (Lasfargues & Moore, 1971). Thus, tissue can be exposed to 
collagenase for a long period of time in the presence of a complete medium, 
which maintains the viability of the cells. It has been reported that 
viable cells can be recovered even after a long exposure of up to 5 days 
to collagenase (Freshney, 1972), Another advantage of collagenase is 
that stromal cells are dissociated first and, by careful timing of the 
digestion of the tissue by the enzyme, a stage can be reached where there
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are clumps of resistant epithelial cells which can be separated by 
sedimentation from the dispersed fibroblasts. The main point in favour 
of collagenase is that cellular damage is kept to a minimum, whereas 
sustained exposure to trypsin can cause epithelial cells much harm by 
stripping off the cell surface proteins (Ceriani et al., 1978).
1.2.3 SELECTION OF EPITHELIAL CELLS
The major aim of any approach has always been to discourage the growth of 
the stromal cells, and thus encourage the development of the epithelial 
cells. One of the most successful methods of achieving this was to cover 
the surface of the culture vessel with a coating, thereby preventing fibro­
blastic attachment - a property essential to stromal cell survival. The 
first type of covering to be used was reconstituted rat-tail collagen 
(Ehrmann & Gey, 1956). This was fairly successful, but had limitations, 
because the cells growing on the collagen coating caused it to tear, exposing 
areas of surface to which the stromal cells could then attach (Whitescarver 
et al., 1968). The same theory has been used more recently by Katiyar 
et al., (1978) who have used floating collagen gels to study mouse mammary 
epithelium.
Another method of covering the culture vessel surface which has been widely 
used is to grow a layer of different cells on it until they reach confluence, 
then arrest their division either by irradiation or mitomycin C treatment.
The desired epithelial cells can then be innoculated on to this "feeder 
layer". The feeder layer cells are now incapable of division, but it is 
not absolutely certain whether they support the growth of sparse viable 
cells by conditioning the medium or by direct contact. They also act to 
discourage the growth of fibroblasts and this alone promotes epithelial
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cell growth. The first report of the use of a feeder layer came from 
Puck & Marcus (1955) who used cells irradiated by X-rays or ultraviolet 
radiation to enhance the growth of HeLa cells. They considered that the 
feeder layer acted by conditioning the growth medium. Studies of Stoker & 
Sussman (1965), however, showed that the feeder effect is not due to a 
release of some factor into the medium. They used petri dishes half-coated 
with feeder layer of X-irradiated mouse fibroblasts and half left bare. 
Enhancement of growth of BHK21 cells occurred only on the coated half of the 
dish, demonstrating that the feeder effect is not diffusible. Rheinwald 
& Green (1975a,b) further studied the action of X-irradiated 3T3 cells as 
feeder layer, and noted that kératinocytes settled on the monolayer and 
pushed it aside, fixing to the surface of the culture vessel, while fibro­
blasts appeared unable to do this. However, a recent report from Armstrong 
& Rosenau (1978) concludes that enhancement of growth of neoplastic mammary 
epithelium on a feeder layer of embryonic mesenchyme may be due to a 
growth factor released into the medium, so the question of exactly how 
feeder layers exert their effect still remains unanswered. It is now 
generally accepted that feeder layers enhance epithelial cell growth, 3T3 
cells being popular for this purpose, but other fibroblastic cells and 
even foam cells from human milk (Taylor-Papadimitriou et al., 1977b) having 
proved successful.
Other methods of selection for epithelial growth in preference to that of 
stromal cells have involved the use of some agent or mechanical process which 
specifically inhibits either the growth or action of the fibroblastic cells. 
Puck et al., (1958) used the fact that fibroblasts have more stringent 
growth requirements than epithelial cells, eliminating the former by 
omitting foetal serum from the medium. Another method utilised the fact
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that fibroblasts do not contain D-amino acid oxidase (Gilbert & Migeon,
1975), which is found in epithelial cells. The fibroblasts could not, 
therefore, convert D-valine into L-valine - the form required by the cell. 
Sykes et al., (1970) reported a new method of actually separating fibro­
blasts from epithelial cells using a discontinuous Ficoll density gradient, 
and separation was also achieved by Owens (1974), using a carefully timed 
exposure to trypsin, which was enough to loosen the fibroblasts, but not 
the epithelial cells from the culture vessel. This last method would 
require great care as epithelial cells might also be lost. However, the 
use of another proteolytic enzyme, dispase, was introduced by Matsumura 
et al., (1975), which gave a greater yield of epithelium. Fibroblast growth 
has been selectively inhibited by preventing attachment to the culture 
vessel (Braaten et al., 1974, Steele et al., 1978). Cis-hydroxyproline
added to the medium (Kao & Prockop, 1977, Liotta et al., 1978) also 
interfered with the functioning of the stromal cells, this time by preventing 
collagen formation and thus inhibiting the smothering effect of the fibro­
blasts on epithelial cells.
1.2.4 STIMULATION OF EPITHELIAL CELL GROWTH
The methods used to select for epithelial cell growth, although fairly 
efficient, are not always completely successful in eliminating fibroblasts, 
which may reappear after a few passages. An alternative approach to the 
problem is to stimulate the epithelial cell development by the addition of 
some agent to the medium. One such agent is epidermal growth factor (EGF),
which is widely used for this purpose.
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The presence of EGF was first noted by Cohen (1962) , who reported the 
discovery of a protein of the mouse submaxillary gland, which caused premature 
eyelid opening in the new-born animal. Further studies (Cohen & Elliot, 1963) 
showed that this effect was due to a stimulation of keratinization by the 
protein, Turkington (1969) used EGF in the course of experiments on mammary 
gland development in vitro, and found that it specifically stimulated 
epithelial cell growth as determined by increased DNA and RNA synthesis. 
However, receptors for this factor, identified as glycoproteins in human 
placenta (Hock et al., 1979) were detected also in fibroblasts (Hollenberg & 
Cuatrecasas, 1973, Cohen et al., 1975). Moreover, EGF has been shown to 
stimulate uptake of RNA precursors (Hollenberg & Cuatrecasas, 1973), DNA 
synthesis (Armelin, 1973) and increased cell proliferation (Armelin, 1973,
Cohen et al., 1975) in fibroblasts. It can also cut the serum requirement 
of fibroblasts down to only 1% (Carpenter & Cohen, 1979), all of which 
establishes that EGF stimulation is not limited to epithelial cells.
The stimulation of growth seen with EGF is enhanced by the presence of serum 
(Hollenberg & Cuatrecasas, 1973). At one time it was thought that the poly­
peptide might be used in place of serum, but it has been found that it cannot 
replace serum completely (Stoker et al., 1976), It also increases the 
stimulation of epithelial cell growth and colony formation noted in the 
presence of feeder layers (Rheinwald & Green, 1977). Further to this 
finding, Taylor-Papadimitriou et al., (1977a) found that EGF was effective in 
increasing human mammary epithelial cell growth only in the presence of feeder 
layers. This was presumably due to the dual action of selection of epithelial 
cells by the feeder layer and their stimulation by EGF.
Another group of agents commonly used to stimulate mammary epithelial cell 
growth are hormones, and in particular the peptide hormone insulin. As
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discussed in the introduction to Part I, the development of the mammary gland 
is controlled by a milieu of hormones which interact with one another (Topper, 
1970). The maintenance of breast epithelial cell growth has also been shown 
to depend on this milieu (Young et al., 1978). The essential role of 
insulin in mammary tumours has been demonstrated in vivo by making tumour- 
bearing rats or mice alloxan- or streptozotocin-diabetic, which causes 
regression of the majority of tumours(Heuson & Legros, 1972, Puckett & 
Shingleton, 1972, Cohen & Hilf, 1974). The stimulatory effect of insulin 
was also noted when its administration reversed regression of mammary tumours 
in rats following hypophysectomy (Heuson et al., 1972) .
It is not fully understood how insulin achieves its action, although it has 
heen timed as a post-transcriptional event (Osborne et al., 1976), In 
contrast to the stimulatory effect of glucose, insulin does not act by 
increasing collagen synthesis, which would stimulate fibroblastic growth, but 
there is instead an increase in total cell protein (Villee & Powers, 1977).
It was thought that the protein synthesised might be EGF or that insulin might 
be itself mimicking this growth factor, but these modes of action have both been 
discounted(Turkington, 1969, Hollenberg & Cuatrecasas, 1973), Insulin action 
on casein synthesis (Turkington & Topper, 1966) and cell division (Voytovich & 
Topper, 1967) have also been reported. Studies on binding and degradation of 
insulin by the cell have been carried out in an attempt to elucidate the action 
of the hormone. These investigations, using labelled hormone, have shown 
that the concentration used is very important in determining how much 
stimulation will be achieved, and that brief receptor interaction appears to 
be sufficient to elicit a long-term response (Osborne et al., 1978). The 
question of exactly how insulin acts still remains unanswered.
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The actions of other hormones on the growth of mammary epithelial cells have 
been studied. Aldosterone and corticosterone were found to be involved in 
differentiation of the mammary gland (Turkington et al., 1967b). Prolactin, 
insulin and hydrocortisone were found to be required in combination to cause 
stimulation of various mammary gland functions (Turkington & Topper, 1966, 
Turkington et al., 1968, Turkington, 1970). Turkington et al., (1967a) found 
that prolactin alone induced casein synthesis, and prolactin in combination 
with hydrocortisone was noted as a requirement for differentiation (Voytovich 
& Topper, 1967). A quantitative role of prolactin in casein secretion has 
been reported also by Katiyar et al., (1978). Barker & Richmond (1971), 
however, found that prolactin and hydrocortisone had no effect on mammary 
epithelial cells at all. They also discovered that stilboestrol actually 
inhibited cell growth, an effect also noted in the treatment of breast cancer 
with high doses of this steroid. The way in which mammary cultured epithelial 
cells will respond to any hormone will depend on the integrity of the receptor 
for that hormone.
Other stimulatory conditions have been considered through the years. Ozzello 
et al.,(1960) used acid mucopolysaccharides, especially hyaluronate, to 
maintain the growth of their mammary carcinoma cell line BT20, They had 
previously used umbilical cord extract for the same purpose. It was considered 
that these substances conditioned the environment of the cells, making it 
very similar to that encountered naturally. However, it is not clear 
whether the mucopolysaccharides would be of value in general, or only for 
this one line of cells. Following the report by Puck et al., (1958) that 
epithelial cells had no requirement for foetal serum, Foley & Aftonomos (1965) 
added adult serum as well as foetal serum and found enhanced cell growth.
Stoker et al.,(1976) and Taylor-Papadimitriou et al., (1977a) further observed
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that human serum was more effective than bovine serum. This effect may be 
due to some factor which is missing from foetal calf serum. A similar effect 
was noted by Kaighn (1977), who found that dialyzed foetal bovine serum 
could not maintain human prostatic epithelial cells as efficiently as the 
untreated form.
1.2.5 MAMMARY CARCINOMA CELL LINES FROM SOLID TUMOURS
In spite of all the associated problems, some cell lines from solid breast 
tumours have been successfully established. As mentioned earlier, the first 
of these to be reported was BT20, isolated by Lasfargues from a duct cell 
carcinoma. Since then, some other lines have been described. However, it 
is essential when a cell line is set up to characterize the cells. Some cell 
lines have been used to try to find suitable markers for this purpose (Bassin 
et al., 1972, Plata et al., 1973). More recently, Lasfargues et al...(1978) 
reported the isolation of another two cell lines and used these to investigate 
the growth requirements of mammary epithelial cells. Although some cell 
lines have emerged from all the research carried out in this field, the 
successes represent only a very small fraction of the number of tumours selected 
for culture. Cailleau et al.,(1974) reported attempts to culture 200 breast 
tumours with no success at all. A routine method whereby every mammary 
tumour can be grown in culture relatively quickly is required if the cancer 
patient is to receive any benefit from this approach to the selection of therapy,
1.2.6 CELL LINES DERIVED FROM PLEURAL EFFUSIONS
Since the main problem connected with the culture of solid breast tumours is 
the presence of fibroblasts derived from the large proportion of stromal
- 191 -
tissue, it was decided that the culture of cells from pleural effusions of 
patients suffering from breast cancer might be an alternative method of 
studying the various aspects of the disease. Pleural effusions have very 
little if any fibroblastic content. The culture of cells from this source 
has now been attempted by many groups. The first report of success came 
from Soule et al., (1973), who established a cell line - MCF7”from a pleural 
effusion. This cell line has proved a useful tool to many workers wishing 
to study steroid hormone action as well as those interested in cancer 
mechanisms as the cells are derived from a hormone-responsive tumour and 
have been shown to contain oestrogen (Brooks et al., 1973) and progesterone 
receptors (Horwitz et al., 1975b) although these are not of the,normal cellular 
forms. Rose & McGrath (1975) characterized the MCF7 cells and were satisfied 
that they were mammary and epithelial due to their capacity to synthesise a- 
lactalbumin, although not all mammary tumours contain the compound (see Part I, 
section 3.4.5.3).
Amongst the investigations in which MCF7 cells have been utilised are the 
elucidation of oestrogen receptor mechanisms (Zava et al,, 1977, Zava &
McGuire, 1978), the action of androgens on oestrogen receptors (Zava &
McGuire, 1978), studies on oestrogen metabolism by mammary tumour cells 
(Lippman & Bolan, 1975, Brooks et al., 1978, Jozan et al., 1979), and the 
functioning of the antioestrogen tamoxifen, which is widely used in the 
treatment of breast cancer (Horwitz & McGuire, 1978). MCF7 cells have also 
been found to contain, in addition to oestrogen and progesterone receptors, 
receptors for glucocorticoids, androgens and thyroid hormones (Horwitz et al., 
1975b, Burke & McGuire, 1978). This may implicate a role for these other 
hormones in breast cancer.
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Despite the fact that this cell line has proved very useful in the field of
hormone research, the use of this and any other cell lines from pleural
effusions such as those of Allegra & Lippman (1978), Cailleau et al,, (1978) 
and Keydar et al., (1979) in cancer research may be limited. Pleural 
effusions do have the advantage that they are rich in tumour cells and 
correspondingly contain very few stromal cells (Cailleau et al., 1974).
Also, the cells can be easily isolated (Illiger et al., 1975),and sequential 
samples can be obtained if desired. However, as pointed out by Kirkland 
et al.,(1979),pleural effusions are not common, and may represent only a 
very small, highly selected class of cells and type of disease. This fact 
must limit the usefulness of this type of cell in the study of cancer.
1.3 IDENTIFICATION OF CELL TYPE
Even when cells have been isolated successfully from solid tumour tissue and
encouraged to grow by any of the means previously described, they must be 
characterized fully before relevant conclusions can be drawn from their 
behaviour. It is quite possible that during all the procedures involved in 
processing the tissue to give viable single cells, they may have undergone 
some form of dedifferentiation. When considering human mammary tumour 
epithelial cells, three points must be proved. The cells must firstly be 
of human mammary origin, secondly display malignancy and lastly show epithelial 
characteristics.
1.3,1 MARKERS OF HUMAN MAMMARY CELLS
Proof of mammary origin of cells may take the form of either some ultrastructural 
characteristic or the measurement of a specific product of the mammary gland.
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Buehring & Hackett (1974), using the electron microscope, noted intra- 
cytoplasmic ductlike vacuoles which are suggestive of mammary epithelium.
Rose & McGrath (1975), instead measured levels of a-lactalbumin, a specific 
product of the mammary gland. They found that its synthesis was often 
retained during transformation, so that its presence acted as a marker of 
either normal or neoplastic mammary cells. The presence of another specific 
product, casein, may not be such an efficient guide, since a smaller proportion 
of mammary carcinomas synthesise this (Hurlimann et al., 1976). Another marker, 
used by Ceriani et al.,(1977), was an antibody raised against the milk fat 
globule.
Chromosomal examination can be performed to determine the human origin of cells. 
At the same time, specific chromosomal markers associated with HeLa cells 
should be looked for (Nelson-Rees et al., 1974), These HeLa cells, derived 
from a cervical carcinoma, are a major source of cross-contamination. In 
addition to characteristic chromosomal banding patterns, HeLa cells can also 
be recognised by the presence of type A glucose-6-phosphate dehydrogenase 
(Ozzello, 1977). Several cell lines which were thought to have originated 
from different tissues have since proved to be HeLa (Buehring & Hackett, 1974, 
Nelson-Rees et al., 1974) upon being subjected to such investigations.
1.3.2 MARKERS OF MALIGNANCY
Since no correlation exists between structural differentiation and malignancy 
except that tumour cells display polyploidy which normal breast cells rarely 
do (Macpherson, 1970), other kinds of tests must be employed. Daniel &
De Ome (1965) suggested that the neoplastic cells might be returned to their 
site of origin, where they would be distinguished easily from the normal cells.
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This idea was carried further to produce the concept of introducing the 
supposedly malignant cells into thymectomized mice, which could not reject 
the cells due to their immunological incompetence. This method can only 
prove that cells are malignant if = they form a tumour in one of these mice.
If no tumour appears, it is not a positive indication that the cells are not 
malignant, and so this parameter is not really a reliable guide to tumouri- 
genicity (Plata et al., 1973, Marshall et al., 1977). The in vitro capacity 
of the cells to grow in soft agar can be used as supplementary evidence 
(Shin et al., 1975).
Das et al., (1974) examined the growth patterns of normal and neoplastic 
mammary epithelium in an attempt to find some easily recognisable difference 
between the two types of cell. However, they found that any difference 
must be very subtle. Any property specific to tumour cells would suffice.
One such property associated with mammary carcinoma cells is that of resorbing 
bone without the need for osteoclasts (Eilon & Mundy, 1978). This property 
is probably associated with the ability of breast cancer to form secondaries 
in the bone. It is not yet known if this is a general marker of malignancy, 
or restricted to breast cancer cells alone. Another property found to be 
associated with malignant cells was that they permitted invasion by fibroblasts 
more easily than do normal cells (Stoker et al., 1978). As this property is 
comparitive in nature, it might prove difficult to assess.
Murine mammary tumour virus-related antigen is a glycoprotein (Yang et al., 
1978) which has been found to be excreted by mammary tumour epithelial cells 
(McGrath & Blair, 1970, McClelland, 1979) and has been discovered associated 
with the MCE7 cell line (Yang et al., 1977). Cathepsin B, a proteinase has 
been found in elevated levels in malignant cells (Poole et al., 1978).
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As this enzyme can degrade both collagen and proteoglycan, it could be 
involved in metastasis formation. It may or may not prove a useful marker 
for tumour cells as again it is the comparison of the level of the proteinase 
in neoplastic cells relative to that in normal cells which is important.
A substance produced by cells which has become popular as an indicator of 
neoplastic growth is plasminogen activator. This is probably the factor 
responsible for the problems encountered by Orr & MeSwain (1954, 1955) when 
trying to grow human tumour cells in plasma clots. They noted that the 
tumour cells liquefied the clot, whereas normal cells did not. Unkeless et al., 
(1973) demonstrated this activity in virus-transformed fibroblasts, and 
purified and characterized the factor (Unkeless et al., 1974). They found 
that it was a serine protease of molecular weight 39,000 with arginine 
specificity, which preferentially cleaves one fraction of plasminogen. It 
is found in high concentration during the latent period between carcinogen 
administration and tumour formation, and so some role in tumour growth has 
been suggested (Hince & Roscoe, 1978). Its release has been found to be 
inhibited by interferon (Schroder et al., 1978). In addition to its activity 
in cleaving plasminogen, the protease has also been implicated in destroying 
large external transformation-sensitive protein which is found associated 
with normal, but not malignant epithelial cells (Pearlstein et al., 1976, 
Marshall et al., 1977).
Jones et al., (1975) developed a technique for the measurement of plasminogen 
breakdown by the activator using a fibrin overlay. Using this method, much 
work was carried out on the presence and identity of this factor in different 
cells. Nagy et al., (1977) found it in breast and cervical tumour cells, but 
not in normal cells of the same origin. Tucker et al., (1978) further
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investigated the similarities between plasminogen activating factors produced 
by different tissues. The finding of these studies was that the factor 
produced by brain tumours was different from that produced by all other tumours. 
This fact may have some significance in the mechanism of brain tumour formation.
Although plasminogen activator has been found associated with a wide range of 
tumours (Pearlstein et al., 1976, Howett et al., 1978), San et al., (1977) 
found no correlation between its production and malignancy in rat liver. This 
finding may limit the usefulness of the protease as a marker of neoplastic 
cells.
1.3.3 MARKERS OF EPITHELIAL CELLS
In contrast to properties of malignancy, epithelial nature can be distinguished 
easily by growth pattern (Bassin et al., 1972) and morphological characteristics 
Electron microscopy is a very good method of proving the epithelioid nature 
of cells. Identifying features include the presence of desmosomal junctions, 
tonofilaments, microvilli and large, irregular nuclei, and these have all 
been used repeatedly to define the epithelial content of cultures (Owens et al., 
1976, Cailleau et al,, 1978, Kanoza et al., 1978, Young et al., 1978). Another 
property of epithelial cells, made use of by Kanoza et al., (1978), is their 
ability to cover a collagen gel, and thus protect it from the degradative 
action of the enzyme collagenase.
A potential problem in the identification of mammary tumour epithelial cells 
is that it has been reported that the mammary gland contains two types of 
easily-distinguishable epithelial cells - E cells and E' cells (Hallowes et al.,
1977). It was found by Hallowes et al. that tumour tissue contains both
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types of epithelial cells, normal or hyperplastic tissue containing E cells only, 
However, Kirkland et al., (1979) could not corroborate this finding, with 
both kinds of epithelial cell being present in any mammary tissue.
1.4 OBJECTIVES
The aim of this in vitro part of my thesis work was to establish a successful 
method by which breast tumour cells could be introduced routinely into culture. 
This system, once in operation, could be of great value both in the deter­
mination of the most potentially effective therapy regime in any particular 
case of breast disease and in analysis of steroid receptor function. The 
immediate aim, therefore, was to determine the optimal conditions for the 
routine cloning of neoplastic mammary cells.
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2. MATERIALS AND METHODS
2.1 TISSUE CULTURE MATERIALS
2.1.1 MEDIA
Hams Flo (lOX) and Hams SF12 (lOX), a modification of Hams F12, were obtained 
from Flow Laboratories, Irvine, Scotland.
2.1.2 ANTIBIOTICS were obtained from the following
"Crystapen" benzylpenicillin (sodium)BP 
Streptomycin sulphate BP 
"KANASYN" Kanamycin sulphate BPC 
Mitomycin C 
Gentamicin
Fungizone (amphotericin g)
Glaxo
Sigma, London
Flow Laboratories, Irvine, 
Scotland
Gibco Bio-Cult, Paisley, 
Scotland
2.1.3 FINE CHEMICALS were obtained as follows:-
Foetal Calf Serum
Glutamine
N-2-hydroxypiperazine-N'-2- ethane 
sulphonic acid (HEPES) (IM)
Non-essential amino acids (lOOX)
Gibco Bio-Cult, Paisley, 
Scotland
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Sodium Bicarbonate (7.5%)
Hanks balanced salt solution (BSS)
Giemsa's stain (0.68% solution in 
methano1/glycerol)
Solvent methanol (microscopical 
reagent)
Flow Laboratories, Irvine, Scotland
BDH, Poole, Dorset
ti II
2.1.4 HORMONES were obtained as follows:-
Oestradiol-178
Insulin
Sigma, London
ft ti
2.1.5 ENZYMES were obtained as follows:-
Collagenase (type 1)
Trypsin (2.5% solution) 
Protease, neutral (Dispase II)
Sigma, London
Flow Laboratories, Irvine, Scotland 
The Boehringer Corporation (London) Ltd
2.1.6 MISCELLANEOUS
Tissue culture flasks were obtained from Falcon, Division of Becton, Dickinson 
& Co., Oxnard, California, USA and Corning, New York.
Nalgene Filter Units were obtained from Nalge Co., Division of Sybron 
Corporation, Rochester, New York, USA.
Millex Filtration Units were obtained from Millipore, London
Disposable plasticware was obtained from Sterilin, Teddington, England
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2.1.7 CELLS
Foetal intestinal cells (FHS 74 Int) were kindly supplied by Drs. Adelene 
Hackett and W.A. Nelson-Rees, Naval Biosciences Laboratory, Naval Supply 
Center, Oakland, California, USA.
2.1.8 HUMAN TISSUE
Breast tumour tissue was kindly supplied by hospitals of the Greater Glasgow 
Health Board.
Normal breast tissue was kindly supplied by Canniesburn Hospital, Bearsden, 
Glasgow.
Human foetal intestinal tissue and umbilical cord was kindly supplied by the 
Queen Mother's Hospital, Glasgow.
2.2 TISSUE CULTURE SOLUTIONS
2.2.1 COMPOSITION OF MEDIA
(i) Working media.
Both Hams FIO (lOX) and Hams SF12 (lOX) were treated the same way before use: 
Hams FIO (10X)/Hams SF12 (lOX) 45 ml
deionised distilled water 400 ml
non essential amino acids (lOOX) 5 ml
- 201 -
HEPES buffer (IM) 9 ml
sodium bicarbonate (7.5%) 2.5 ml
sodium hydroxide (IN) added to pH 7.2
foetal calf serum 100 ml
glutamine 5 ml
penicillin (10,000 units/ml) 2.5 ml
These media were then known as F 10/20 and SF12/20. Although the majority
of culture work was carried out in 20% fpetal calf serum, recent data 
suggest that 10% may be an adequate level,
(ii) Collection medium (FIO/PSFK or SF12/PSFK)
The working medium was made up without foetal calf serum, penicillin or 
glutamine. To this was added the following
penicillin 250 units/ml
streptomycin 250 yg/ral
kanamycin 100 yg/ml
or
gentamicin 50 yg/ml
amphotericin 3(fungizone) 2.5 yg/ml
(iii) Digestion medium (F10/20/PSK or SF12/20/PSK)
Made up as for "working medium" with the following additions
kanamycin (1000 yg/ml) 5 ml
streptomycin (10,000 yg/ml) 5 ml
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(iv) Dissection BSS
Hanks balanced salt solution (BSS) 400 ml
penicillin (10,000 units/ml) 20 ml
kanamycin (1,000 yg/ml) 8 ml
streptomycin (10,000 yg/ml) 4 ml
amphotericin 3(fungizone) 3.5 ml
2.2.2 ANTIBIOTICS
Penicillin, kanamycin and streptomycin were all prepared at the desired 
concentration in Hanks BSS.
Mitomycin C was made up in "working medium" to the required concentration.
2.2.3 ENZYMES
(i) Collagenase - made up in Hanks BSS at a concentration of 2,000 units/ml.
(ii) Trypsin - 2.5% solution diluted 1:10 in the following diluent before use:-
sodium chloride 6.0 g 
trisodium citrate 2,96 g 
tricine 1.79 g 
phenol red 0.005 g
pH of the diluent was adjusted to 7.8, and distilled water added until the 
osmolarity was equal to 290 m osmol before addition to trypsin.
r in 700 ml of distilled water
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(iii) Protease, neutral (Dispase II) - 2.5% solution made up in Hanks BSS,
2.2.4 HORMONES
All hormones were made up in Hanks BSS at an arbitrary strength and diluted 
with working medium to the required concentration.
Sterilization of solutions in sections 2.2.2 - 2.2.4 was carried out using 
either a Nalgene or Millex filtration unit, depending on the volume involved,
2.3 TISSUE CULTURE METHODS
2.3.1 PREPARATION OF PRIMARY CELL CULTURES FROM SOLID TISSUE
2.3.1.1 Tissue Collection
Tissue, whether normal or neoplastic, was collected fresh from the operating 
theatre and transported to the laboratory in a sterile container kept on ice. 
Where it was not possible to process the tissue immediately,collection medium 
was added and it was then kept refrigerated until use. Viable cells could 
be recovered from tissue stored in this way for up to 3 days,
2.3.1.2 Tissue Dissection
The tissue was transferred to a 9 cm diameter petri dish containing 25 ml of 
dissection BSS. Any obvious pieces of fatty, fibrous or necrotic material
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were removed at this stage. The remaining tissue was then transferred to a 
fresh petri dish containing dissection BSS as before. The tissue was 
chopped into pieces of about 2 mm cube using apposed scalpel blades. Care 
was necessary at this point not to damage the tissue by the use of excessive 
pressure, and, for this reason, the scalpel blades had to be kept sharp, and 
the chopping completed as quickly as possible. The pieces were then trans­
ferred by pipette to a sterile universal container. The pieces were allowed 
to settle by gravity and the supernatant aspirated off. Any remaining 
fatty tissue which floated on top of the supernatant was also removed at this 
stage. Fresh dissection BSS was added to the pieces, and again removed 
after settling out of the material had occurred. This washing procedure was 
repeated three times with dissection BSS and the pieces finally resuspended in
a medium containing high antibiotic concentrations (SF12/20/PSK or F10/20/PSK).
2
The suspension was transferred by pipette to 25 cm culture flasks and 
collagenase added at a final concentration of 200 units/ml. The flasks were 
then incubated at 37°C for a period from 1-7 days until disaggregation of the 
tissue was apparent by the formation of smaller fragments and free cells on 
shaking the flask. The timing of this incubation in collagenase was varied 
(see Results, Section 3.2.1.2), as it appeared that epithelial cells could 
survive collagenase exposure better than fibroblastic cells. The type of 
collagenase used contains some protease and peptidase activity, so it cannot 
be stated with certainty what causes the release of epithelial cells.
After incubation, the free cells and clumps of cells were spun out of 
collagenase by transferring the suspension to a sterile universal container 
and centrifuging at 200 g for 5 minutes on an MSB bench centrifuge. The 
pellet was then resuspended in SF12/20 or FlO/20 medium (10 ml) and transferred
- ZUO “
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to fresh 25 cm culture flasks. These flasks were maintained at 37 C to 
allow growth of cells and medium renewed regularly as indicated necessary 
by a change in colour of the phenol red. This methodology is summarised 
in Figure 27,
2.3,2 SUBCULTURE
2.3.2.1 Trypsinisation
Trypsin treatment was used to remove adhering cells from a flask prior to 
counting or transferring them to other flasks. This was done at regular 
intervals to prevent cells from becoming overcrowded.
The medium was removed from the cells to be trypsinised, and they were
washed with phosphate-buffered EDTA, Trypsin solution was then added to
2
cover the layer of cells (approximately 5 ml for a 25 cm flask). The 
cells were kept exposed to the enzyme for 30 seconds before its removal. The 
flask was placed at 37°C and the behaviour of the cells noted. When the 
cells were released from the surface of the flask, fresh medium was added to 
resuspend the cells and stop the action of trypsin. The suspension could 
then be counted and innoculated into different flasks as desired,
2.3.2.2 Dispase Treatment
Dispase was used as a more gentle method of subculture than trypsinisation, 
where it was desired to separate one cell type from another. Medium was 
removed from the cells to be treated. Dispase solution was added diluted 
1:9 with working medium. The flask of cells was then incubated at 37°C , 
until the desired ones were observed to have become detached from the surface
Figure 27 - Procedure for the Dissociation of Breast Tissue into Cells
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of the flask. The medium was then removed, and the cells sedimented by- 
centrifugation at 200 g for 5 minutes, followed by washing twice in medium to 
avoid any contamination by residual dispase. The desired cells could then 
be resuspended in working medium, counted and used as required,
2.3.3 INHIBITION OF CELL DIVISION
This was achieved by the action of mitomycin C, a safer and cheaper technique
than X-irradiation (MacPherson & Bryden, 1971). Cells from one flask were
trypsinised, as described in Section 2.3,2,1, and counted. This gave the
approximate number of cells in each of the other flasks set up in the same
way. Mitomycin C prepared in working medium was added to the cells at a
concentration of 2 yg/10^ cells. The volume of medium in the flasks was
2adjusted, if necessary, to the normal level (10 ml for a 25 cm flask), and 
exposure to mitomycin C was maintained at 37°C for 24 hours. At the end of 
this time, the medium containing mitomycin C was removed and fresh medium 
used to wash the cells twice. Fresh medium was again added and the flasks 
of treated cells replaced in an environment of 37^C,
2.3.4 PREPARATION OF CELLS FOR USE AS FEEDER LAYER MATERIAL
2,3.4,1 Human Foetal Intestine
Tissue was collected as in section 2.3.1,1. Several different methods were 
then used in an attempt to isolate feeder cells:-
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(i) Flushing method
A long piece of intestine (50-60 cm) was cut into smaller pieces of 7-8 cm 
for ease of handling. These were flushed out with phosphate-buffered EDTA
using a large syringe. One end of each piece was then sealed off using a
suture, and the middle of the intestine filled with either collagenase or 
trypsin solution. The other end was then also sealed, and the piece of 
intestine left at 37°C for 30 minutes in the case of trypsin digestion, or 
2 hours in the case of collagenase digestion. After incubation, the end of 
the piece of intestine was opened, and the trypsin or collagenase digest 
collected. This was then centrifuged at 200 g for 5 minutes, and the 
resulting pellet of cells resuspended in a medium containing high concentrations 
of antibiotics, (SF12/20/FSK or F10/20/PSK). These suspensions were 
innoculated into 25 cm^ culture flasks and incubated at 37°C.
(ii) Chopping method
This method was identical to that described in Section 2.3.1.2 for use with 
solid tissue. The inside of the intestine was washed out first of all with 
phosphate-buffered EDTA as described above. It was then chopped into small 
pieces in dissection BSS and the pieces suspended after washing, in medium 
containing collagenase at a concentration of 200 units/ml. This was then 
incubated at 37°C for four days to allow collagenase digestion to take place, 
after which time the cells were spun out of collagenase and resuspended in 
fresh medium before innoculation into 25 cm^ culture flasks at 37°C.
(iii) Scraping method
In this method, the intestine was washed out as previously described using 
phosphate-buffered EDTA. It was then slit longitudinally and spread out in 
a petri dish. The cells from the inside of the intestine were then gently
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scraped off using a scalpel blade. The resultant cells were suspended in
2
medium and innoculated into a 25 cm culture flask, which was then incubated 
at 37°C.
(iv) Evertion Method
A long piece of intestine was cut into pieces of approximately 5 cm in length.
Using fine forceps, the pieces were everted. The pieces were then tied off
at each end using sutures, and digested either in a concentrated collagenase
solution (2,000 units/ml) at 37°C for 30 minutes, a more dilute solution of
collagenase (1,000 units/ml) at 37°C for 2 hours, or a trypsin solution at
37°C for 30 minutes. Chopped pieces of the everted material were treated by
dilute collagenase (200 units/ml) at 37^C for 3 hours. In all cases, at the
end of the digestion period, the suspension was centrifuged at 200 g for
2
5 minutes, and the resuspended material set up in 25 cm culture flasks which 
were incubated at 37^C.
2.3.4.2 Human Umbilical Cord
Umbilical cord was collected fresh and transported to the laboratory on ice.
It was always used fresh, and so it was not necessary to attempt storage. In 
an attempt to prepare cells from the inside of the cord, the following methods 
were used:-
(i) Flushing method
The piece of cord was suspended from a hypodermic syringe needle held in a 
clamp, in a manner such that the lower end of the tissue hung into a sterile 
universal container. It was then flushed through with phosphate-buffered
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saline to clean it out, A fresh universal was placed below the cord, and
now collagenase at 2000 units/ml was flushed through, followed by some more
phosphate-buffered saline. The effluent was then centrifuged at 200 g
for 5 minutes, and a small pellet of cells resulted. This was suspended
2in medium and transferred to a 25 cm culture flask in which it was incubated 
at 37°C.
(ii) Digestion method
The cord was set up as in (i) above. It was again cleaned out using 
phosphate-buffered saline, but this time, one end was closed off using a 
suture and the cord filled with collagenase at 2000 units/ml. This was 
incubated at 37°C for 30 minutes and opened up to allow the collagenase 
digest to escape. The digest was spun at 200 g for 5 minutes and the resulting 
pellet of cells treated as in (i) above.
2.3.5 CELL STAINING
Medium was removed from cells to be stained. Hanks balanced salt solution 
(BSS) was then added to cover the cells and remove any remaining medium. This 
was poured off, and approximately half the volume of BSS reapplied, along 
with an equal volume of methanol. After this was discarded, methanol alone 
was added to cover the cells, and exposure to this maintained for 10 minutes.
The cells were now fixed. 1 ml of Giemsa’s stain was added and washed over 
the cells, followed by 9 ml of distilled water. This was left covering the 
cells for 10 minutes and then discarded. The cells were then washed with 
distilled water until no more unbound stain could be detected, and the flasks 
left to dry. This whole procedure was carried out at room temperature.
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2.3.6 CELL COUNTING
The flask of cells to be counted was trypsinised, as described in Section
2.3.2.1. The cells were suspended in an arbitrary volume of medium and 
20 ml of counting fluid added to 0.4 ml of cell suspension. This was then 
counted on a Coulter Counter at a setting best suited to the cell type 
being studied.
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3. RESULTS
3.1 FEEDER CELL CULTIVATION
A popular and successful method of selecting for epithelial, in preference 
to fibroblastic, growth is to cover the surface of the culture vessel with 
a layer of non-dividing cells. These have been found to act as a satis­
factory support for epithelial cell growth. This concept has been applied 
to the growth of mammary epithelium in this project. Initial experiments 
were carried out using as feeder layer a strain of cells (FHS 74 Int) derived 
from human foetal intestine. These cells appear to be epithelioid in nature. 
An essential feature of a feeder layer is that the cells should completely 
cover the entire growth surface of the culture vessel, in order to prevent 
attachment by stromal cells. FHS 74 Int cells achieve this by contact 
inhibition, which means that they stop growing when a complete monolayer is 
formed. Other types of cell may not exhibit this ability, and chemical 
(mitomycin G treatment) or mechanical (X-ray irradiation) means are required 
to arrest their growth at the correct time. If the cells grow beyond con­
fluence, they will "pile up" on top of each other and then become dislodged 
from the culture vessel, leaving a space for fibroblastic attachment.
FHS 74 Int cells proved very convenient as a feeder layer because of their 
property of contact inhibition and also their characteristic staining, which 
made them easily distinguishable from other cells which were growing on top of 
them. However, since the FHS strain supply was limited, and the cells did 
not remain viable beyond approximately 30 passages, it proved desirable to 
grow other cell strains which would be equally effective in the formation of 
feeder layers.
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3.1.1 UMBILICAL CORD
Before the successful establishment, of the FHI strain of cells from foetal 
intestine (see Section 3.1.2), the possibility that umbilical cord could be 
used as a substitute source of feeder cells was explored. The advantage of 
using umbilical cord instead of foetal intestine is that the former is much 
more readily available. The methods used to attempt the preparation of 
feeder cells from umbilical cord tissue were very similar to those used with 
foetal intestine (see Methods, Section 2.3.4.2).
The procedures detailed in the methods section were carried out on four 
samples of umbilical cord, but in no case were any viable cells of any kind 
produced. This may reflect the instability of umbilical cells in the 
presence of collagenase, of their increased sensitivity to handling. The 
use of umbilical cord tissue as a source of feeder cells was discarded on 
the basis of these findings.
3.1.2 FOETAL INTE STINK
Since FHS 74 Int cells were originally derived from human foetal intestinal 
tissue, the preparation of cells from this type of tissue was attempted. 
Accordingly, several techniques were applied to the process of forming viable 
feeder cells from this type of tissue. These procedures are detailed in 
Section 2.3.4.
The most successful results were produced by the enzyme collagenase and the 
evertion technique. Both incubating the everted material in collagenase 
(1000 units/ml) at 37°C for 2 hours followed by spinning down the cells at
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200 g for 5 minutes and chopping of everted tissue followed by the same 
digestion treatment used for solid tumour tissue (see Section 2,3.1.2) 
produced viable cells similar in appearance to FHS 74 Int cells. Flushing 
out the middle of the intestine with collagenase (200 units/ml), as in 
Section 2.3,4.1, also produced cells, but these were mainly fibroblastic.
Using the combination of collagenase (1000 units/ml) and the evertion 
technique, a cell strain (FHI) has been prepared, which behaves in a manner 
very similar to FHS 74 Int, except that complete contact inhibition is not 
always exhibited. This incomplete contact inhibition means that, if long­
term experiments are to be performed using the feeder layer, cell division 
may have to be arrested by mitomycin C treatment.
The new cell strain is similar in appearance to FHS 74 Int (see Plates 1 and 
2), and, more importantly, has proved successful in sustaining breast tumour 
epithelial cell growth (see Section 3.2.1,1).
3.1.3 STROMAL CELLS
The situation found in vivo is that fibroblasts and epithelial cells coexist, 
with possible exchange of material between the two cell types. For this 
reason, it was thought that they might be essential to each other for the 
maintenance of growth. Using a stromal feeder layer, therefore, conditions 
close to the natural environment of the epithelial cells could be established.
Fibroblasts were obtained from normal and neoplastic mammary tissue prepared 
as in Methods, Section 2.3.1,2, making no attempt to select for epithelial 
growth. The cells were then allowed to grow almost to confluence before
Plata 1 Feeder layer cells (FHI strain)
Cells were prepared from human foetal 
intestine, using the evertion method, 
as described in Methods, Section 2.3,4.1. 
The scale illustrated is the same for all 
plates.
Plate 2 Feeder layer cells (FHS 74 Int strain)
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treating them with mitomycin C (2 yg/10^ cells) in order to arrest their 
division. The timing of this treatment was very important as cells undergo 
one or two divisions after such treatment, and so, if carried out too late, 
the cells would still overgrow and detach from the culture vessel. Unfortunately 
neither normal nor neoplastic mammary fibroblasts proved successful in 
sustaining epithelial cell growth.
3.1.4 EMBRYONIC GLIA
Another source of feeder cells explored was glial cells from chick embryos.
Since the brain constitutes a common site of metastatic breast disease, the 
cells from this region could have specific properties in maintaining breast 
tumour epithelium in a viable state. It was thought that embryonic cells 
might also have special properties in this role after the success of FHS 74 
Int cells. Chick embryo was chosen as it was easily obtained and no evidence 
existed that it should be less capable of supporting epithelial growth than 
material of human origin. The glial cells were prepared by collagenase 
(200 units/ml) digestion of 15-day old chick embryo brain at 37°C for 3 days.
The cells were plated out and treated with mitomycin C (2 pg/10^ cells) before 
use. Unfortunately, attempts to arrest their growth were not as successful 
as with fibroblasts, and the cells became too thick to be able to distinguish 
epithelial development on top of them.
3.2 CULTIVATION OF MAMMARY TUMOUR EPITHELIAL CELLS
3.2.1 TECHNIQUES FOR EPITHELIAL SELECTION
3.2.1.1 Application of Feeder Layer
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All the forms of feeder layer described in the previous section, with the 
exception of umbilical cord cells, have been applied to the culture of 
mammary tumour epithelium. As mentioned in the course of section 3.1, 
these have met with varying degrees of success. Even the successful forms 
(FHI and FHS 74 Int) do not display consistent enhancement of epithelial 
growth.
Fibroblasts from both normal and neoplastic mammary tissue gave no enhancement 
of epithelial cell growth in any of five experiments. Nothing could be con­
cluded from the limited experience with chick embryo glial cells as feeder 
layer due to an insufficient number of studies. In fact, the only successful 
forms of feeder layer were those derived from human embryonic intestinal 
cells (FHS 74 Int or FHI strain). They support the development of epithelial- 
like colonies of the type shown in Plates 3 and 4. In both of these plates, 
it is clear how easily distinguishable is the feeder layer (in this case 
FHS 74 Int) from the other cells, Plate 4 in particular demonstrates the 
distinct border between the epithelial and feeder layer cells.
Apart from epithelial colonies with the expected characteristics, other cell 
types have been observed growing on this form of feeder layer. One of these 
was found to display proteolytic-type properties. As illustrated in Plates 
5 and 6, bare patches appear in the area of feeder layer adjacent to colonies 
of these cells, apparently due to some form of digestion of the feeder cells.
In these cases, the colonies with proteolytic properties and the customary 
epithelial colonies coexisted in the same flasks in approximately equal 
numbers and, otherwise, showed the same growth characteristics. However, 
no further characterization of the "proteolytic" colonies was made.
Plates 3 & 4 Human Mammary Tumour Epithelial-like
Colony Cultivated on Foetal Intestinal 
Feeder Layer (FHS 74.Int strain)
Breast tumour tissue was treated as 
described in Methods, Section 2*3.1.2 to 
give a cell suspension (B-MAB strain).
Some of this was innoculated on to feeder layer 
cells of the FHS 74 Int strain. Plate 3 shows 
a colony of epithelial-like cells which 
developed from this tissue.
Plate 4 shows the same cell strain but 
illustrates the border between the epithelial- 
like and the feeder layer cells.
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Plates 5 & 6 Human Mammary Tumour Cells Cultivated on
Feeder Layer (FHS 74 Int strain) and 
Displaying Proteolytic Properties
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Breast tumour tissue was treated as described 
in Methods, Section 2.3,1.2 to give a 
suspension of cells (B-DOS strain). Some of 
this was innoculated on to FHS 74 Int feeder 
layer. These plates show clumps of tissue 
which have settled on the feeder layer. From 
one side of each clump are growing out apparently 
normal cells. At the other side, however, the 
cells which are emerging appear to be different, 
which is witnessed by their proteolytic-like 
action in destroying the integrity of the feeder 
layer. This type of population existed in 
approximately equal numbers to epithelial-like 
colonies in the same flasks.
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Unfortunately, although epithelial colonies could be supported in 6 out of 
9 cases by these intestinal feeder layers, their presence could not be sus­
tained for more than 3-4 weeks. After this length of time, cultures which 
had been completely free of fibroblasts could become overgrown within the 
space of 48 hours. These stromal cells had presumably been transferred with 
the primary culture, and perhaps remained dormant until some unidentified 
change within the environment activated their development.
In contrast to the cases where foetal intestinal cells promoted mammary 
tumour epithelial cell development, feeder layer inhibition of epithelial 
cells and apparent promotion of fibroblastic growth also occurred. In one 
extreme case 5-10 times as many epithelial colonies developed in the control 
flask as in that containing the feeder layer. Stimulation of growth by 
oestradiol was seen in both control and feeder layer flasks.
In another instance, feeder layer (in this case FHI strain) failed to support 
any epithelial colony development at all, although some colonies were 
observed in the control flasks.
It appears, therefore, that although definite conclusions can be drawn about 
the inability of stromal and umbilical cord cells to act as feeder layers for 
mammary tumour epithelium, no conclusive judgement can be made in the case 
of the foetal intestinal cells. It is clear that they have potential in 
this role, but perhaps other factors could augment their actions, the most 
important one being the elimination of fibroblasts from the early stages 
in the isolation of cells from solid tissue.
- 221 -
3.2.1.2 Collagenase Digestion
In the procedure for preparing cells from solid tissue (see Methods, section 
2 .3.1.2), pieces of chopped tissue were normally incubated in whole medium 
containing collagenase (200 units/ml) for 3-5 days. During the preparation 
of cells from one mammary tumour, this time period was not sufficient to 
digest some of the chopped tissue pieces, which were allowed to digest for a 
further two days, while the pieces which had digested were removed from 
collagenase and plated out in fresh medium at day 5, During the course of
the subsequent experiment, it became evident that the portion of tissue 
which had experienced the longer collagenase digestion yielded a much higher 
ratio of epithelial cells to fibroblasts, suggesting that fibroblasts are 
much less able to withstand prolonged exposure to the enzyme. This could 
prove a very valuable finding if it were reproducible, since it would be 
advantageous to minimise the level. of fibroblasts from the earliest point 
possible.
3.2 .1.3 Dispase Action
The use of dispase as a substitute for trypsin in carrying out subculture of 
cells may be advantageous due to its gentler mode of action. When used for 
the first time on a cell strain, it was found to remove selectively epithelial 
colonies even from a feeder layer, leaving fibroblasts and feeder cells behind. 
This was not found to be the case in subsequent treatment of the same cell 
strain, however, when fibroblasts and feeder layer were released from the 
culture vessel along with the epithelial cells, this effect being noted in 
another cell strain also. This method may be of value in the selection of 
epithelial cells, but perhaps some modification is required to render it 
reproducible.
- 222 -
3.2.2 HORMONAL STIMULATION
One way to enhance further the growth of mammary epithelium in general would 
be to provide the cells with hormones additional to those already contained 
in the foetal calf serum component of the bathing medium. As described in 
the introductions to parts I and II of this thesis, the mammary gland is 
responsive to a wide range of hormones. It was of interest to establish 
whether any combination of these hormones had growth promoting effects.
3.2.2.1 Insulin
An initial experiment carried out on the effects of various concentrations 
of insulin showed that insulin was active in promoting epithelial colony 
formation. This effect was seen both in the presence and absence of feeder 
layer. An insulin concentration of 5 pg/ml was found to be more effective 
than 10 yg/ml. Insulin at 5 yg/ml was subsequently added to culture medium 
used for the growth of all mammary epithelial cells.
3.2.2.2 Oestradiol
* * 9^ "5Oestradiol-173 was added in a range of concentrations from 10 M - 10 M to
flasks containing mammary tumour cells. An initial experiment showed that
stimulation of epithelial growth was greatest when 10 ^M oestradiol was added,
regardless of the presence or absence of feeder layer. Unfortunately, the
number of colonies being compared here was very small, the maximum being 14.
Accordingly, no valuable quantitative assessment could be made, but no
further enhancement of growth appeared to occur at concentrations of hormone
-7
in excess of 10 M.
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This study was repeated using a higher concentration of mammary cells and 
a narrower range of oestradiol concentrations. Table 14 shows the findings 
of this second experiment. With no feeder layer present, increasing the 
concentration of oestradiol increased the number of epithelial colonies formed.
In combination with feeder layer, however, no such correlation could be 
drawn. These findings require more thorough investigation before any con­
clusion as to the worth of oestradiol as a stimulant of mammary epithelial 
growth can be made.
3.3 CULTIVATION■ OF NORMAL MAMMARY' TISSUE EPITHELIAL CELLS
An important step in the cultivation of any type of cell is the characterization 
of that cell strain to establish its identity beyond any doubt. In the present 
study, human mammary origin^malignancy and epithelial nature must be demonstrated, 
Consideration has been given to only one of these points - that of malignancy.
A promising method of establishing malignancy which was explored was that the 
property of establishing colonies of epithelial cells on a feeder layer might 
be restricted to cells of neoplastic origin (Aaronson & Todaro, 1968).
To examine this possibility, "normal" mammary tissue was obtained from mamma- 
plastic reduction material. This had the obvious disadvantage that the tissue 
was very fatty, but the procedure detailed in Methods, section 2,3.1.2 was 
applied to prepare cells, removing as much of the fat as possible at each 
stage. After collagenase digestion, the cells were spun down, resuspended in
medium, and innoculated on to flasks containing feeder layer as with mammary
tumour cells. The feeder layers used in these experiments were the foetal
intestinal strains (FHS 74 Int and FHI).
Table 14 Effect of Varying Concentrations of Oestradiol-
178 on Mammary Tumour Epithelial Colony 
Formation in the Presence and Absence of 
Feeder Layer
Breast tumour tissue was treated as described
in Section 2,3.1. After removal from
collagenase, equal amounts of the cells (BEH
strain) were innoculated either into empty 
2
25 cm plastic flasks, or flasks containing 
a confluent monolayer of feeder cells derived 
from human foetal intestine. Each set of
“9
flasks was fed with medium containing 0 , 10 ,
- 8 - 7
10 or 10 M oestradiol-173, which was changed 
at regular intervals for 3 weeks. The cells 
were then stained, and the epithelial colonies 
counted. The number of colonies formed in the 
absence of both feeder layer and steroid could 
not be assessed due to contamination.
Oestradiol No, of
conc. (M) Colonies
0 N/A
_Q NO FEEDER
10 9 98
LAYER
10-8 loi
10-7 181
0 13
10-9 18 GROWN ON
10-8 7 FEEDER LAYER
10-7 12
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Preliminary findings from these studies were in agreement with the concept 
that normal epithelial cells could not establish colonies on feeder layers. 
However, exceptions did occur where epithelial colonies derived from the 
"normal" mammary tissue appeared on the foetal intestinal feeder layer in 
two experiments out of the nine performed. Plates 7 and 8 show epithelial 
colonies from one of these cell strains (N-CAR) growing on FHS feeder layer. 
Colonies also grew in the absence of feeder layer, but were surrounded by 
stromal cells, as shown in Plate 9,
The yield of epithelial colonies growing on the feeder layer was great enough
to conduct an experiment to determine whether they could be cloned on fresh 
feeder layer. One flask containing a mixture of epithelial and feeder cells 
yielded 1.7 x 10^ cells, the epithelial component of which was originally 
derived from approximately 250 mg of normal mammary tissue. Aliquots of 
these cells were innoculated into flasks with and without confluent feeder 
layer. The results of this experiment are shown in Table 15. Unfortunately, 
a cloning efficiency cannot be determined in this experiment since the cells 
innoculated into the flasks represented a mixed population of epithelial 
and feeder cells. The Table shows that epithelial cells can only be passaged 
onto a feeder layer. Thus, epithelial cells will occasionally grow in the 
absence of feeder layer (Plate 9) but passage of these colonies is enhanced 
in the presence of feeder layer.
On the basis of the observations with these two normal breast samples, growth
on feeder layers could not be used to satisfy the criterion of malignancy 
in breast epithelium; The possibility remains, however, that these samples, 
although apparently normal, might have been preneoplastic. Further studies 
should be carried out to determine whether these results are reproducible, or
Plates 7 & 8 Human "Normal" Mammary Epithelial-like
i.,i iump— u i —— w —g'ws^— «■r a — ■'Hnfc»«'Wwii ni jM————
Colony Cultivated on Foetal Intestinal 
Feeder Layer (FHS 74 Int strain)
"Normal" mammary tissue from a patient 
undergoing anaplastic reduction was 
treated as described in Methods, Section
2.3.1.2, to yield a cell suspension 
(N-CAR strain). Some of this was 
innoculated on to FHS 74 Int feeder layer. 
These plates show epithelial-like colonies 
which developed in two flasks set up in 
this way. As in Plate 4, the border between 
the epithelial colony and the feeder layer 
cells is clearly illustrated.
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Plate 9 Human "Normal" Epithelial - like Colony
Cultivated in the Absence of Feeder Layer
This shows an epithelial-like colony from the 
N-CAR strain of cells as in Plates 7 and 8, 
but cultivated in the absence of feeder layer. 
Although the colony developed without the 
support of a feeder layer, it can be seen that 
it is surrounded by stromal cells, which eventually 
overgrew the entire flask.
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Table 15 Growth of "Normal" Breast Epithelial Cells
in the Presence and Absence of Feeder Layer
"Normal" breast tissue from a patient under­
going maramaplastic reduction was dissociated 
as described in Section 2.3.1. After removal 
from collagenase, the cells (N-CAR strain) were 
divided equally between flasks containing a 
confluent monolayer of feeder cells derived 
from human foetal intestine and empty flasks. 
All flasks were fed with working medium, and 
one containing both mammary and feeder cells 
trypsinized, counted and aliquots of the 
mixed cell suspension innoculated into fresh 
flasks with or without feeder layer as before. 
The medium in these flasks was changed 
regularly, and the cells stained after three 
weeks. The epithelial colonies in each flask 
were then counted,
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No, of cells 
innoculated
No, of Colonies, 
formed
108 39
5 X 10^ 52 GROWN ON
10^ 106 FEEDER LAYER
5 X lo'^ confluent epithelium
5
10 1!
10^ 1
No FEEDER
, 410 0
LAYER
10^ 1
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whether feeder layer does act as an inhibitor of growth in truly normal 
mammary epithelium.
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4. DISCUSSION
Observations in this study are limited by the fact that although tumour 
cells are of epithelial origin, any biopsy contains also a high proportion 
of stromal cells. A large tumour biopsy, therefore, yields only a small 
number of epithelial cells, A high yield of purely epithelial cells is 
required if a particular investigation is to be carried out with all tests 
and controls considered. This has not proved possible in many cases in 
this study (3 tumour samples out of 20 were too small to provide cells of 
any type). It is likely that the lack of sizeable tumour biopsies is due, in 
turn, to the increased awareness on the part of the general public that early 
action in cases of cancer can increase the chances of survival, and thus 
breast tumours go to surgery at a much earlier, and smaller, stage. This 
problem illustrates the advantages of working with pleural effusion material 
from breast cancer patients to establish optimum growth requirements of mammary 
cells. This source gives a high yield of cells (Cailleau et al., 1974), 
which appear to be easily cultivated, and strains such as the much-quoted 
MCF7 (Soule et al., 1973) have proved very useful in the elucidation of 
different aspects of both tissue culture and endocrine mechanisms (e.g.
Lippman & Bolan, 1975, Zava et al., 1977, Horwitz & McGuire, 1978, Strobl & 
Lippman, 1979). The disadvantages of using cells of this origin are that 
pleural effusions are not common and, as stated by Kirkland et al., (1979), 
may represent a highly selected class of cells. Thus, although pleural 
effusions yield material potentially useful for application to the growth 
requirements of mammary cells in general, findings must be confirmed at 
some stage with solid tumours. Studies from pleural effusion cells cannot 
readily be applied to the therapy of solid tumours. The establishment of
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the methods for routine cultivation of this more common form of malignant 
breast disease is necessary if investigations into the best therapy for each 
tumour are to be carried out.
The present findings from studies on hormonal requirements of the cells 
agree with those reported by other workers. An enhancement of epithelial 
colony formation by insulin at a concentration of 5 yg/ml was found and 
administered routinely to all cultures. This is in keeping with the findings 
of Puckett & Shingleton (1972), Heuson et al., (1972), Heuson & Legros (1972) 
and Cohen & Hilf (1974) in studies on DMBA-induced mammary tumours in rats 
and mice, Osborne et al., (1976) using MCF7 cells and Allegra & Lippman
(1978) using another mammary cell line (ZR-75-1). Campbell & Craig (1979) 
reported a general requirement for insulin by all cells in culture. The 
requirement of mammary cells in particular for this hormone is explained by 
its activation of casein and lactalbumin synthesis (Turkington & Topper,
1966, Turkington et al., 1968), RNA synthesis and general cell division 
(Voytovich & Topper, 1967, Turkington, 1970). These studies were carried 
out using mouse mammary gland explants. Since these effects are noted in 
both normal and neoplastic mammary tissue, a requirement for insulin is not 
generally a property which is lost during malignant transformation.
The other possible hormonal requirement discovered was one for oestradiol-178,
-7which appeared to be most effective at 10 M, not giving any further 
stimulation of growth at concentrations greater than this in the preliminary 
experiments performed. This was also the conclusion reached by Lippman & 
Bolan (1975), who further found that concentrations above 10 were actually 
inhibitory to mammary cell growth, a conclusion reached also by Stormshak 
et al., (1976), studying rat uterus. This was not observed, however, in
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this study. Oestrogen receptors have been detected in mammary cells of 
the MCF7 cell line (Brooks et al., 1973, Strobl & Lippman, 1979), so it 
appears that the machinery for processing steroid hormones can endure 
culture procedures, and thus responses to these hormones can be expected, 
Strobl & Lippman (1979) also report that oestrogen retention by the cells 
for over 48 hours can be taken as an indication of receptor presence, since 
this property was exhibited specifically by the oestrogen receptor-containing 
MCF7 cell line, but not by receptor-deficient control lines. This could not 
be used as conclusive evidence of receptor presence, however, as binding 
might be due to an atypical cellular protein.
The effects of other oestrogens such as oestrone, which has been reported 
to inhibit mammary cell growth when administered for only a short time 
(Jozan et al., 1979), were not studied in this project.
Feeder layer cells were originally used in the cultivation of HeLa cells 
(Puck & Marcus, 1955, Fisher & Puck, 1956). They were later found to be 
successful in the enhancement of growth in kidney, (Stoker & Sussman, 1965, 
MacPherson & Bryden, 1971), keratinizing (Rheinwald & Green, 1975a,b) and 
mammary epithelial cells (Katiyar et al., 1978, Armstrong & Rosenau, 1978, 
Kirkland et al., 1979). In the present study, feeder layers have been found 
to be of positive value in encouraging mammary tumour epithelial growth in 
approximately 65% of cases, but, in some cases, evidence of actual inhibition 
by feeder cells was found. It was thought from preliminary experiments that 
the great value of feeder layers might be that they would exclude normal 
mammary epithelial growth, thereby establishing the malignancy of cells which 
did form colonies on feeder layers. Normal mammary cells have been used 
as feeder layers,for malignant ones (Taylor-Papadimitriou e t a l . , 1977a,b),
- 233 -
but no published evidence of normal mammary growth on any type of feeder 
layer exists.
In the course of studies on the ability of feeder cells to inhibit selectively 
’’normal" mammary epithelial cell growth, on two occasions epithelial cells did 
grow well and established colonies on the feeder layer. This, therefore, 
discounts the possibility of using growth on a feeder layer as a marker of 
malignancy. The source of the normal mammary cells was tissue from patients 
undergoing mammaplastic reduction. Due to the nature of the condition 
necessitating such surgery, it could be argued that this tissue is not in 
fact normal. However, no abnormalities appeared in the histolpgy of the 
tissue, although the possibility exists that the cells which did grow on feeder 
layer may have been derived from preneoplastic tissue. Other workers 
wishing to isolate normal mammary cells used expressed milk as their source 
(Taylor-Papadimitriou et al., 1977a,b), but the advantage of using the 
surgical specimens is that they are readily available in great quantity, 
such that none of the problems arising from lack of tissue mentioned earlier 
are encountered.
One important area which was not explored in the course of this study was 
the characterization of the cells which were successfully cultivated. It is 
realised that the establishment of the human mammary, malignant and epithelial 
characteristics in the cells is essential if any conclusive results are to 
be obtained from work on a particular system. It was thought, as described 
above, that a test for malignancy was available, but this did not prove 
reliable. The epithelial nature of the cells was assumed by their growth 
pattern, being in circular rather than the parallel array displayed by 
fibroblasts. Cells of this same appearance resulted from both normal and 
neoplastic breast tissue.
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The overall conclusions from this study on the in vitro growth of mammary 
tumour epithelial cells are that the inclusion of the peptide hormone insulin 
in the growth medium gives a definite enhancement of growth, while that of 
the steroid hormone oestradiol may benefit the cells also. The use of a 
feeder layer composed of human foetal intestinal cells of epithelial nature 
will also encourage mammary epithelial cell development in a percentage of 
cases. No other types of cell used in the composition of a feeder layer had 
any success in this direction. In spite of these measures, however, it has 
not proved possible to sustain the growth of the epithelial cells in culture 
for longer than 3-4 weeks, as found also by Whitescarver et al., (1968),
Stoker et al., (1976) and Ozzello (1977), while fibroblasts seem,capable of 
growing for much greater periods than this. A longer period of growth by the
epithelial cells is necessary if the effects of various stimuli and inhibitors
are to be observed and made use of in the treatment of malignant breast disease.
Even when extended growth of epithelial cells on feeder layer is achieved, 
extensive characterization of the cells must be performed. The malignant, 
mammary and epithelial nature of the cells must be established. For example,
determination of the presence of plasminogen activating factor, as mentioned
in the Introduction, would seem to be an appropriate and readily applicable 
test for malignancy of cultured mammary epithelium. Then, before studies can 
be carried out on the effects of various growth regulators on these cells, the 
toxicity of such treatments towards feeder layer cells will first have to be 
determined. It is possible that some of the therapeutic regimes applied to 
breast tumours, especially chemotherapeutic forms, might prove more toxic 
to the feeder layer than to the breast cells. In this case, mammary epithelial 
growth would be arrested by an indirect action of the agent under study.
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Once all these unknown variables have been determined, the in vitro system 
should prove the most effective way to predict the optimal form of therapy 
for breast cancer patients. Studies on the regulation of oestrogen and 
progesterone receptor synthesis, and on the nature and functionality of 
receptor in +/o and o/+ cells would benefit also from an in vitro approach,
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